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Abstract 
Mutations in the gene encoding parkin (PARK2) result in familial early onset forms of 
Parkinson’s disease (PD) as a result of loss of E3 ubiquitin ligase function. Protein 
misfolding is a common molecular feature of most neurodegenerative diseases, including 
PD. To test whether parkin misfolding also plays a role in the more common spontaneous 
PD, we established and functionally characterized a parkin yeast model. We found that 
oxidative and protein folding stress, parkin point mutations and truncations, and parkin’s 
interaction with the PD-associated kinase PINK1 profoundly alter parkin’s subcellular 
localization and toxicity. Notably, these conditions also induce parkin fragmentation, 
degradation, and potential misfolding, all of which may contribute to PD pathogenesis. 
Future research presents great potential to establish parkin misfolding as a promising new 
therapeutic target for PD. 
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Chapter One: Introduction 
Neurodegenerative diseases are a broad spectrum of disorders with a wide variety 
of symptoms and clinical presentations that are all caused by degeneration or death of 
neuronal cells. The most common neurodegenerative disorders include Alzheimer’s 
disease (AD), which can be attributed to the majority of dementia cases, Huntington’s 
disease (HD), a heritable disease that results in loss of cognitive function and sporadic jerky 
movements, and Parkinson’s disease (PD), which is the second most common cause of 
neurodegeneration resulting in loss of motor control. In general, neuronal cell death occurs 
in the brain, but these diseases can also affect motor neurons in the periphery as seen in 
Amyotrophic Lateral Sclerosis (ALS). Unlike many other cell types, neurons are post-
mitotic during life and cannot regenerate, thus making these conditions permanent and 
mostly incurable. Neurodegenerative diseases are usually late onset, as they are often 
associated with aging that leads to the gradual accumulation of toxic molecules, for 
example, reactive oxygen species (ROS) within neurons that damage cellular components 
over time. Human cells, including neurons, contain multiple cellular pathways that act to 
prevent accumulation of cytotoxic proteins. These processes can be generally classified as 
protein quality control machinery. 
1.1 Protein Quality Control 
In order to maintain cellular homeostasis and overall cell health, protein quality 
control machinery must ensure accurate protein production, maintenance, and turnover. 
One of the main causes of cell damage is the accumulation of damaged or misfolded 
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proteins, which are often toxic to the cell. Protein damage or protein misfolding can occur 
in response to many factors, particularly oxidative stress. 
1.1.1 Oxidative Stress 
ROS play a vital role in maintaining normal cellular processes, including cell 
growth, immune response, and the synthesis of biological molecules (1,2). However, ROS 
are also associated with aging and many diseases, including cancer and neurodegenerative 
disorders. They are highly reactive and thus have the potential to cause major cellular 
damage to proteins, nucleic acids, and lipids. In healthy cells, there is a balance of pro- and 
anti-oxidants that maintain healthy levels of ROS, but an imbalance of these reagents can 
lead to excessive accumulation of ROS, which is often seen in aging. Mitochondria are one 
of the major sources of ROS because superoxide anions (O2●-) are a natural byproduct of 
cellular respiration (3). Normally, superoxide anions are reduced to hydrogen peroxide 
(H2O2) by manganese superoxide dismutase (SOD1) which can be further reduced to water 
and oxygen by catalase (4), but the failure of SOD1 or catalase can lead to the accumulation 
of O2●- or H2O2, respectively. Because of its single unpaired electron, superoxide is highly 
reactive and can generate other ROS including hydroxide radicals (OH●) and hypochlorous 
acid (HClO). The accumulation of excessive amounts of ROS can damage cellular proteins 
by causing them to lose proper function. This often leads to misfolding as a result of 
changes in the protein’s hydrophobic properties, consequently leading to protein 
aggregation (5). Due to the gradual accumulation of ROS over time, oxidative stress has 
been strongly implicated in many age related diseases, including neurodegeneration (6). 
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Oxidative damage to proteins occurs when amino acids of proteins are post-
translationally modified by ROS. There are many ways ROS can modify proteins, and the 
most common type of modification is to the thiol group of cysteine residues which are 
highly sensitive to oxidative damage (7). While they are coded for much less frequently 
than other amino acids (8), cysteines play an important role in maintaining protein structure 
and function. When the thiol groups of two cysteines are in close proximity, it is possible 
for them to form a disulfide bond whereby two free thiol groups form a covalent bond with 
one another (7). This process can occur between two cysteines within the same protein 
(intramolecular) or between cysteines of two separate proteins (intermolecular). These 
interactions are required for proper tertiary or quaternary protein structure, respectively. 
Due to their polar nature, cysteines are also capable of coordinating metal ions within 
proteins that are also required for maintaining proper three-dimensional structure, which 
involves the free thiol side chain.   
Under normal cellular conditions, cysteines can freely revert between their free 
thiol and disulfide forms, but the presence of excessive amounts of ROS can forcibly 
convert these residues from one form to another, preventing proper function. This often 
results in the formation of aberrant disulfide bonds within or between proteins, which 
disrupts their three-dimensional conformation. Additionally, ROS are capable of 
converting thiols to sulfur based acids, which are incapable of performing either of the 
normal functions of cysteines. In the presence of low amounts of ROS, free thiols (-SH) 
can be converted to sulfenic acid (-SOH), which can be reverted back to a free thiol and 
resume normal function when ROS levels are reduced (7). Alternatively, if ROS levels are 
much higher, -SOH is converted sulfinic acid (-SO2H) and subsequently, sulfonic acid         
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(-SO3H), both of which occur irreversibly. In this situation, the proteins are damaged 
beyond repair and are typically targeted for degradation (7).   
1.1.2 Protein Quality Control Machinery 
As mentioned above, protein structure and function are closely linked. When 
proteins are unable to form their native confirmation (misfold), which can occur naturally 
as a result of mutation or in response to protein damage, they often lose their ability to 
function properly and have an increased propensity to aggregate. The processing of 
damaged or misfolded proteins is essential in maintaining protein homeostasis, and the 
failure of this process can result in cellular dysfunction or cell death, which is associated 
with many diseases. Cells have two major systems for eliminating damaged and misfolded 
proteins (Figure 1-1):  
1) The molecular chaperone machinery. Most proteins require the assistance of 
molecular chaperones during and after translation to attain their accurate three-dimensional 
structure (9, 10). This process either occurs in the cytosol or proteins can be directed to the 
endoplasmic reticulum, mitochondria, or other cellular organelles, for further processing 
(11, 12). By changing the immediate local chemical and physical environment surrounding 
misfolded proteins, chaperones promote refolding, thus facilitating proper folding and 
reducing the accumulation of damaged proteins. Not surprisingly, dysfunction of the 
molecular chaperone machinery has been strongly implicated in multiple 
neurodegenerative disorders (13) and has also been identified as a target for therapeutic 
intervention (10, 15, 16).  
2) The ubiquitin proteasome system (UPS). UPS is the second system that is 
essential for protein homeostasis, which is shown in Figure 1-2. The addition of ubiquitin 
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to a substrate protein (ubiquitination) plays a large role in protein regulation by altering 
cellular localization, effecting interactions with other proteins, and with particular 
relevance to this study, targeting damaged proteins for degradation. The UPS acts to 
transfer ubiquitin successively through E1, E2, and E3 enzymes to build mono- or poly-
ubiquitin chains on substrate proteins (17). Following ubiquitination, substrate proteins are 
directed to the 26S proteasome where they are degraded. Humans contain nine genes 
encoding E1 ubiquitin activating enzymes, two of which are involved in ubiquitin 
conjugation in the UPS (18–20), about 40 genes for E2 ubiquitin conjugating enzymes, and 
over 600 genes for E3 ubiquitin ligases (21). Each class of enzyme contains structural 
similarities that are required to facilitate ubiquitin transfer, but they also have differences 
that affect their regulation and it is this diversity that differentiates substrate recognition. 
Dysregulation of the UPS is a highly studied field and research has shown its involvement 
in cancer (22, 23), cardiovascular disease (24, 25), and neurodegenerative diseases (26, 
27).  
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Figure 1-1. Cellular protein quality control. 1) Following transcription, mRNA is 
directed to the ribosome for translation which often required co-translational assistance 
from molecular chaperones like HSP40s and HSP70s. 2) Fully translated proteins mature 
and obtain their proper functional three-dimensional conformation. 3) The buildup of 
damaging molecules over time as a result of aging, environmental exposure, or cellular 
dysfunction causes protein damage leading to misfolding whereby the protein can no 
longer function properly. 4-5) Molecular chaperones can recognize damaged proteins and 
assist in their refolding which will cause them to re-attain their proper three-dimensional 
conformation and resume normal function. 6) Proteins that are damaged beyond repair are 
recognized by the UPS and ubiquitinated to target them for degradation by the 26S 
proteasome. 7) Failure of one or both of these cellular protein quality control mechanisms 
can lead to the accumulation of misfolded proteins leading to protein aggregation which 
can be toxic to the cell or even cause cell death.  
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Figure 1-2. The ubiquitin proteasome system (UPS). 
 
 
 
 
 
 
 
 
 
 
Figure 1-2. The ubiquitin proteasome system (UPS). 1) Unmodified ubiquitin is 
activated with the use of ATP and bonded to an E1, ubiquitin activating enzyme. 2) 
Activated ubiquitin is transferred from an E1 to an E2, ubiquitin conjugating enzyme. 3) 
An E2 ubiquitin conjugate interacts or docks with an E3, ubiquitin ligase. 4) The E2-E3-
ubiquitin complex comes in contact with a protein substrate which is properly oriented by 
the E3. 5) A poly-ubiquitin chain is built on the substrate protein either by direct transfer 
of ubiquitin from the E2 enzyme, or through a sequential transfer of ubiquitin from E2 to 
E3 to substrate. 6) The ubiquitinated substrate is directed to the 26S proteasome where the 
substrate protein is degraded into proteolytic fragments. 7) Ubiquitin is recycled and is 
ready for use in the UPS or other cellular pathways. 
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1.2 Neurodegenerative Disease 
Many neurodegenerative diseases are caused by genetic mutations. These genetic 
or familial forms often present a more severe phenotype and an earlier onset than sporadic 
cases. Notably, neurodegenerative-associated genes and proteins have distinct functions 
and structures, cause dysfunction and cell death in distinct sets of neurons, and cause 
distinct symptoms. That being said, there are several features that are common and central 
to many, if not all neurodegenerative diseases. 
One common feature of neurodegenerative diseases, that can also cause other 
human diseases, is loss of function (LOF) mutations, whereby an inherited mutation in a 
specific gene causes a protein to lose its proper function, leading to cell death. Examples 
of neurodegenerative diseases caused by heritable loss of function mutations include non-
sense mutations causing premature transcriptional termination of the glutamine superoxide 
dismutase (SOD1) protein causing ALS (28), and any of the several heritable mutations of 
in the PARK gene family causing PD (29).  
The second common feature of neurodegenerative diseases is toxic gain of function 
(GOF) mutations. Similar to LOF mutations, GOF mutations can be genetically inherited 
or acquired over time. Instead of losing their proper function, GOF mutations often cause 
proteins to misfold and aggregate, dragging other essential proteins into large insoluble 
protein aggregates that can be cytotoxic (30). The accumulation of protein aggregates 
overloads the protein quality control machinery, causing further stress to the cell by 
disrupting normal cellular processes. An example of neurodegeneration caused by toxic 
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GOF mutations is α-synuclein mutations causing the formation of Lewy Bodies leading to 
PD (31, 32). 
Another hallmark of neurodegenerative disorders is the accumulation of damaged 
or misfolded proteins into insoluble plaques or aggregates. The accumulation of aggregated 
of misfolded proteins has been proposed to be cytotoxic. Recent studies have suggested, 
however, that protein aggregation can indeed play a protective role in cells by sequestering 
potentially toxic protein species, thereby reducing their potential to damage the cell (33). 
Some well-established examples of disease-associated protein aggregates include 
neurofibrillary tangles made of  the protein tau and plaques made of amyloid fibrils of the 
Aβ peptide in AD (34), nuclear and cytosolic aggregates made of polyglutamine repeat 
proteins in HD and Spinocerebellar Ataxia Type 1 (36), and Lewy Bodies made  primarily 
of α-synuclein in PD (37). As stated above, the major cellular systems that neutralize or 
eliminate misfolded proteins are 1) refolding via molecular chaperones and 2) degradation 
via the UPS or autophagy.  
 Although research over the past decades has discovered the genetic cause of many 
of these diseases, the underlying mechanisms of how they cause neuronal damage and cell 
death are still widely unknown. Furthermore, there is even less understanding of what 
causes the much more common sporadic cases of neurodegenerative diseases and their 
underlying mechanisms. 
1.2.1 Alzheimer’s Disease 
AD is the most common neurodegenerative disorder and the most common cause 
of dementia, accounting for 60-70% of all cases of dementia (38). Like most 
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neurodegenerative disorders, this disease generally has a late age of onset, usually 
presenting after 65 years of age. Patients experience progressive neurological deterioration 
with the most common symptom being memory loss. There are cases of early onset AD 
which are more frequently seen in cases of familial inheritance. Pathology of Alzheimer’s 
patients presents with the classical protein aggregates, referred to as plaques, which 
overload the protein quality control machinery. Alzheimer’s plaques are predominantly 
made of Aβ, a short amino acid peptide made of fragments of the amyloid precursor protein 
(APP). The tau protein, whose normal function is to stabilize microtubules, can also been 
found in Alzheimer’s protein aggregates, but this is likely due to mis-sorting of the protein 
caused by Aβ. Although environmental exposure and lifestyle choices, such as smoking, 
can increase the risk of developing Alzheimer’s disease, there is no evidence that there is 
any way to prevent disease development (38,39). There is currently no cure for Alzheimer’s 
disease and no available treatment to slow or prevent disease progression. Treatment 
options, which consist of five different compounds, are only intended to manage 
neurological symptoms (41). 
1.2.2 Huntington’s Disease  
Unlike most other neurodegenerative diseases, HD is solely caused by one protein 
known as huntingtin (Htt). HD occurs as a result of the expansion of a polyglutamine 
(polyQ) region within Htt, which causes the protein to misfold and form aggregates, again 
stressing the protein quality control machinery. The regular function of the Htt protein is 
still unknown, but it is expressed at the highest levels in the brain and testes (42). HD 
generally presents between 35 and 45 years of age, but symptoms can begin during infancy 
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or late in life depending on the size of the polyQ expansion. The wild-type Htt protein 
contains less than 36 glutamine repeats and expansion of the polyQ track causes increased 
disease severity and leads to an earlier age of onset which is directly correlated to the length 
of the polyQ expansion. HD heritability is dominant, where one mutant copy of the gene 
can drag normal copies of the protein into Htt aggregates. There are currently no treatments 
available to prevent or eliminate Htt aggregates, but several treatments have been used to 
manage symptoms which include jerky, random, and uncontrollable movements known 
as chorea.  
1.2.3 Amyotrophic Lateral Sclerosis  
ALS, made famous by the baseball player Lou Gehrig, is different than most other 
neurodegenerative diseases as it affects motor neurons in the periphery rather than in the 
brain. ALS is progressive, with neurons in the extremities being affected first which leads 
to movement difficulties that gradually causes paralysis of the arms and legs. Patients 
generally do not experience any cognitive symptoms but they eventually lose the ability to 
speak, chew, or swallow, and typically succumb to respiratory failure after cell death 
occurs to motor neurons controlling the diaphragm. This condition is also different from 
most other neurodegenerative diseases because of its rapid progression. After onset, 
patients typically survive for only three to four years. ALS can be heritable, whereby 
mutations in the genes encoding SOD1 (43), FUS, TDP-43 (44), C9Orf72 (45), the recently 
discovered RGNEF (46, 47), and more can cause ALS, but these only account for a small 
proportion of all ALS cases. Pathology of ALS patients is a proteinopathy where proteins 
form potentially toxic aggregate as seen in other neurodegenerative diseases. There is 
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currently no cure for the disease and the only available treatment is a drug called riluzole, 
which only extends patients’ lifespan by approximately three months. 
1.3 Parkinson’s Disease 
PD is the second most common neurodegenerative disease affecting more than 100 
000 Canadians and typically has a late age of onset, which occurs around 70 years of age 
(48). Patients experience progressive neurodegeneration that results in a variety of physical 
manifestations including resting tremors, rigidity, postural instabilities, and staggered gait. 
PD cases can be classified into two categories: familial and non-familial, also referred to 
as sporadic or idiopathic PD; in both cases, patients experience loss of dopaminergic 
neurons in the substantia nigra resulting in decreased dopamine uptake at neural synapses 
(49). Inherited forms of PD have been linked to seven genes with various functions (Table 
1-1). One of the most common pathologies seen in PD patients is the formation of Lewy 
Bodies composed primarily of -synuclein which can be inherited in an autosomal 
dominant manner (50). Although inherited PD is associated with one or more mutations in 
the PARK family of genes, these only account for approximately 10% of all cases of PD. 
In cases of idiopathic PD, which account for the remaining 90% of PD cases, the 
relationships between these proteins is extremely complex. Although pathogenic mutations 
in single genes have been identified in familial PD (51), it is plausible to speculate that 
there is an intricate interplay between these genes that cause cases of sporadic PD (52–54). 
This study focuses predominantly on the role of parkin (PARK2) in idiopathic PD and how 
dysregulation of the protein quality control machinery may also be involved. 
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Table 1-1. PARK family of genes involved in inherited Parkinson’s disease. 
Gene Protein Inheritance Function 
PARK1 -synuclein Dominant Presynaptic protein 
PARK2 parkin  Recessive Ubiquitin E3 ligase 
PARK5 UCH-L1 Dominant  Ubiquitin hydrolase 
PARK6 PINK1  Recessive Mitochondrial kinase 
PARK7 DJ-1 Recessive Chaperone 
PARK8 LRRK2 Dominant Kinase 
PARK13 HTRA2 Unknown Serine proteinase 
1.3.1 Parkin – An E3 Ubiquitin Ligase 
Research on parkin began in 1998 with the discovery of a mutation in the PARK2 
gene, which is located on the long arm of chromosome 6, by Tohru Kitada et al. in a 
Japanese family (55). This study showed that parkin contains amino acid similarity to 
ubiquitin from residues 1-76 and high cysteine content in the remainder of the protein. 
They also established, based on exon deletions found in five patients, that parkin is linked 
to Autosomal Recessive Juvenile Parkinsonism (AR-JP), an early onset form of PD that 
affects individuals less than 40 years of age. AR-JP is pathologically very similar to PD, 
as patients exhibit the same decreased sensitivity to dopamine in the substantia nigra and 
experience the same progressive neurodegeneration and loss of motor control at a much 
younger age. Also similar to PD, AR-JP mutations are often inherited in an autosomal 
recessive manner, many of which map to the PARK2 gene encoding parkin (Figure 1-3).  
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Figure 1-3. Mutations and deletions in the PARK2 gene causing Parkinson’s disease. 
(56, 57)  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-3. Mutations and deletions in the PARK2 gene causing Parkinson’s disease. 
A) Schematic representation of the PARK2 gene showing known exon deletions, frameshift 
mutations, non-sense mutations, and splicing mutations causing Parkinson’s disease. B) 
Schematic representation of the parkin protein encoded by the PARK2 gene and its 
functional domains showing known nonsense mutations causing Parkinson’s disease. The 
highlighted red missense mutations in B) were used in this study to assess parkin 
misfolding. Modified from (55, 56).    
16 
 
 
 
Figure 1-4. Parkin is an E3 ubiquitin ligase involved in the UPS.  
 
 
 
 
 
 
Figure 1-4. Parkin is an E3 ubiquitin ligase involved in the UPS. (A) Schematic 
representation of parkin domains based on structural determination by NMR containing an 
N-terminal Ubl domain, which acts to auto-inhibit parkin activity, and a C-terminal 
Rcat/RING2 domain required for catalytic transfer of ubiquitin. (B) The role of parkin as 
an E3 ligase in UPS which acts to transfer ubiquitin from E2 to target substrate. 
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Following its initial discovery in the context of AR-JP, work by several groups 
focused on deciphering parkin’s regular function and its altered function that causes PD 
development. Initially, sequence homology was used to define the functional domains 
within parkin where, in addition to the N-terminal ubiquitin-like domain, three additional 
domains were proposed based on sequence homology, which included two Really 
Interesting New Gene (RING) domains (58). Since its discovery, a fifth domain (RING0) 
has also been described within parkin, and our understanding of its function has vastly 
increased (59).  
We now know that human parkin is a 465 residue protein made up of five domains 
and functions as an E3 ubiquitin ligase in the UPS (Figure 1-4). Parkin is classified as an 
RBR (RING1-BRcat-Rcat, formerly known as RING1-inBetweenRING-RING2) E3 ligase 
(60). Its functions are twofold during the process of ubiquitin transfer: 1) it acts as a 
scaffold to orient the E2 enzyme for the transfer of ubiquitin to substrate proteins, and 2) 
parkin accepts ubiquitin onto a catalytic cysteine located in the Rcat/RING2 domain before 
transferring it to the substrate protein. This action differs from the RING class E3 enzymes 
that only act as a scaffold between the E2 and protein substrate (61) and from homologous 
to the E6-AP carboxyl terminus (HECT) E3 ligases that accept activated ubiquitin onto a 
catalytic site before interacting with and subsequently ubiquitinating substrate proteins 
(62). Parkin can therefore be classified as a RING/HECT hybrid. Previous work in our lab, 
in addition to work by several other groups, has studied parkin structure, exploring its 
regulation and the dynamics involved in ubiquitin transfer using nuclear magnetic 
resonance (NMR) spectroscopy and other methods (63–65). These studies have shown that 
the N-terminal Ubl domain of parkin acts to inhibit parkin ubiquitination by folding back 
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on itself, blocking surfaces of the protein required for ubiquitin transfer and E2 docking. 
They have also shown that this inhibition can be regulated through phosphorylation of the 
Ubl domain and ubiquitin, both at Serine 65 by PTEN-induced putative kinase 1 (PINK1), 
a PD-associated kinase. Structural studies have also established that the four C-terminal 
domains of parkin each coordinate two Zn2+ ions that are essential for structural stability 
of the protein (59).  
In addition to the extensive research aimed at understanding parkin at a structural 
level, there have also been significant efforts made to understand parkin function at a 
cellular level. Prior to the recent discovery of the connection between parkin and PINK1, 
which will be discussed below, the majority of parkin related research was focused on its 
role as an E3 ligase. AR-JP causing loss-of-function mutations are found across the entire 
length of the PARK2 gene. These mutations are comprised of point mutations (missense, 
nonsense or frame shift) and deletions across one or more exons, resulting in early 
termination or truncation (66, 67). Functional studies have implied the ubiquitination and 
subsequent degradation of many different proteins by parkin, including CDrel-1, a GTPase 
expressed in the nervous system, and Pael-R, a G-protein coupled transmembrane protein 
expressed in dopaminergic neurons. The literature also describes hundreds of potential 
parkin substrates that have been detected by high throughput screens (68) and in vitro 
testing (69). Most of these substrates have not been confirmed independently and it remains 
to be determined whether there are changes in the levels of these proteins upon 
dysregulation of parkin.  
Although many studies associate parkin to PD through its inability to prevent the 
accumulation of damaged protein, work by several groups suggest that pathogenic parkin 
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mutants induce parkin misfolding and aggregation. Schlehe et. al have shown that the AR-
JP causing R42P is actively degraded by the proteasome upon expression (70). Similar 
aggregation patterns have been shown by Wen-Jie et. al using mutations of two cysteine 
residues that normally co-ordinate binding of structural zinc ions. They show that these 
mutants not only form perinuclear aggregates, but also disrupt the co-localization of parkin 
with two different E2 enzymes, UbcH7 and UbcH8 (71). 1-methyl-4-phenylpyridinium 
(MPP+) is a positively charged molecule that induces ROS accumulation by inhibiting 
complex I, interfering with oxidative respiration. Parkin has been found in insoluble 
fractions of SH-SY5Y cells experiencing excess accumulation of MMP+ induced ROS and 
in non-familial PD patient brain samples (72). In addition to these results, the proposed 
association of parkin with alpha-synuclein within Lewy bodies (73, 74) gives additional 
support to the claim that aggregation of insoluble mutants or oxidatively damaged parkin 
plays an important role in the pathogenesis of idiopathic PD. Overall, it remains mostly 
unclear how parkin is oxidized under stress conditions and how missense mutations cause 
misfolding and subsequent PD.  
1.3.2 Parkin’s Role in Mitophagy 
Parkin has been implicated in the degradation and turnover of damaged 
mitochondrial proteins and entire mitochondria (mitophagy, (75, 76)), and it is suggested 
that this activity is induced by PINK1 mediated phosphorylation (77, 78). PINK1 is a 
serine/threonine kinase that contains an N-terminal mitochondrial targeting sequence 
(MTS) that is used to direct and anchor PINK1 to the mitochondria and a C-terminal kinase 
domain (79). Currently there is not a clear consensus on where PINK1 is anchored to the 
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mitochondria as some studies suggest that it undergoes processing and cleavage at the inner 
mitochondrial membrane (80), while others propose that PINK1 is directed to and interacts 
with the outer membrane in response to loss of membrane potential, leaving the C-terminal 
kinase lobe facing the cytosol to interact with ubiquitin, parkin, or other proteins (77, 81). 
There are over 50 recessive mutations to PINK1 that can cause PD and studies suggest that 
these mutations inhibit parkin meditated protein degradation by inhibiting PINK1 
phosphorylation and recruitment of parkin, or by preventing PINK1 translocation to the 
mitochondria, also preventing parkin activation (82).     
 Narendra et. al have shown that PINK1 is normally degraded in the cytosol in 
HeLa cells, but upon mitochondrial damage following carbonyl cyanide m-chlorophenyl 
hydrazone (CCCP) treatment, damaged mitochondria lose their membrane potential. 
CCCP damages mitochondria by uncoupling the proton gradient established by the electron 
transport chain during oxidative respiration (83). This study showed that the loss 
mitochondrial membrane potential causes PINK1 to be selectively recruited and anchored 
to the outer mitochondrial membrane. They further showed that parkin only localizes to 
mitochondria of CCCP treated cells when PINK1 is present (84). Although this study 
provides strong evidence that PINK1 is required for parkin recruitment, this does not 
explain the mechanism by which this recruitment of parkin to mitochondria and the ensuing 
mitophagy occurs. Figure 1-5 shows one potential model of how PINK1 recruits and 
activates parkin. Previous studies suggest that parkin recruitment is activated by: 1) 
phosphorylation of free ubiquitin to activate parkin (85),  2) by phosphorylation of one of 
several mitochondrial proteins, such as TOM20 or mitofusin 2, to recruit parkin 
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Figure 1-5. Activation of parkin mediated mitophagy of damaged mitochondria by 
PINK1.  
 
 
 
 
 
 
 
 
 
 
Figure 1-5. Activation of parkin mediated mitophagy of damaged mitochondria by 
PINK1. 1) Following its transport to damaged mitochondria, 2) PINK1 phosphorylates 
parkin and ubiquitin. 3) Phospho-parkin undergoes a closed-to-open conformational 
change and becomes more active, 4) directing it to damaged mitochondria, while PINK1 
phosphorylation of ubiquitin is required to activate parkin. 5) While at the mitochondrial 
membrane, activated phospho-parkin ubiquitinates damaged mitochondrial proteins 
leading to 6) their degradation by the 26S proteasome or lysosomal degradation of damaged 
mitochondria (mitophagy).   
22 
 
 
 
for ubiquitination (86, 87), or 3) direct phosphorylation of S65 in the ubiquitin-like domain 
of parkin by PINK1, which converts parkin to an open or “active” conformation, priming 
it for ubiquitination (88). Ultimately, the recruitment of parkin to damaged mitochondria 
causes ubiquitination of damaged mitochondrial proteins, and subsequently, lysosomal 
degradation. Notably, these models are highly controversial because the published 
experimental data has not allowed researchers to draw a definite conclusion regarding the 
mechanism of parkin activation by PINK1. Additionally, a direct interaction between 
PINK1 and parkin has yet to be demonstrated.  
1.4 Yeast Models 
Saccharomyces cerevisiae, commonly known as baker’s or brewer’s yeast, is a 
model organism that has many advantages that make that it an excellent model system to 
study human diseases. Yeast is a single celled eukaryote that contains membrane bound 
organelles found in higher order eukaryotes and as a result, many key cellular pathways 
and processes relevant to human disease are conserved. As a unicellular organism, yeast 
can be grown in isolation as they do not require the release of growth factors from 
neighboring cells, which is often required for mammalian systems. In the laboratory, yeast 
is relatively easy to handle and has extremely short generation times, but the greatest power 
of the system comes from the ease of genetic manipulation. The yeast genome is 
considerably smaller than that of humans, with about 25% of the total number of genes 
found in humans (89). This smaller size has enabled the identification and characterization 
of each and every yeast gene to test whether they are essential and identify any phenotypes 
associated with deletion or over-expression. To this end, comprehensive deletion and over-
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expression libraries have been generated that allow for high-throughput screening for 
genetic interactions, which is not possible in any model other organism. Furthermore, yeast 
can exist in both a diploid and haploid state, so it can be used to study the effects of 
heterozygous deletions or mutations. 
1.4.1 Yeast Models of Neurodegeneration 
Many established yeast models have been and are currently used to study human 
disease and one prominent class of human diseases studied in yeast are neurodegenerative 
disorders. One of the best-established yeast models of neurodegeneration is the poly-
glutamine expansion causing HD. Yeast HD models have established that polyQ expanded 
Htt exhibits tendencies to aggregate that are reminiscent of those found in human cells and 
have also shown the same toxicity associated with polyQ expansion (90, 91). Since its 
establishment, this model has been used to study how protein misfolding and aggregation 
can be modulated by molecular chaperones like heat shock protein (HSP) 70 and has 
identified this class of proteins as a potential for therapeutic intervention (92, 93). Other 
established yeast models for neurodegenerative diseases include Aβ models of Alzheimer’s 
disease (94–96), and ALS models investigating SOD1, FUS, and TDP-43 aggregation and 
toxicity (97, 98).  
1.4.1.1 Parkinson’s Disease Yeast Models 
There are also several established yeast models for PD associated genes and 
mutations. Of these genes, α-synuclein is the most well characterized model (99–101). 
Yeast models of α-synuclein, like yeast Htt models, closely mimic α-synuclein behavior in 
mammalian cells, showing transport of α-synuclein to the cell membrane under normal 
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levels of expression (102) and following accumulation (mimicked by overexpression), α-
synuclein forms cytoplasmic inclusion that are similar to Lewy Bodies in human patients 
(103). With this established model, researchers have been able to further characterize the 
effects of specific point mutants (100), clearance of α-synuclein aggregates (104), and the 
effects of the ribosomal chaperone RPS3A (105). Yeast models have also been used to 
characterize the PD associated chaperone DJ-1. Under normal conditions in human cells, 
DJ-1 is a redox sensitive chaperone that acts to prevent α-synuclein aggregation (106, 107). 
Yeast models frequently use the Saccharomyces cerevisiae protein HSP31, which is a 
member of the DJ-1 superfamily of chaperones. Although HSP31 deletion strains do not 
exhibit a phenotype compared to wild-type yeast under normal conditions, they do have an 
increased sensitivity to oxidative stress (108). There has also been one recent parkin yeast 
model published in 2015 (109).  
It must be noted that because yeast is a simple model system, results obtaining using 
this model may not always directly translate into human cells, therefore, they must be 
carefully interpreted and validated in other system. Nevertheless, yeast models can give 
new insight into protein function and potential therapeutics by focusing on conserved 
pathways including protein quality control, UPS, and protein misfolding, making it a highly 
versatile and capable model system. 
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Figure 1-6. Parkin truncation variants and point mutants. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-6. Parkin truncation variants and point mutants. Schematic representation of 
generated parkin (A) truncation variants and (B) point mutants used in this study. 
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1.5 Rationale, Hypothesis, Objectives, and Significance 
1.5.1 Rationale 
Parkin dysfunction can cause PD, but the underlying mechanisms causing disease 
development and progression remain unresolved. Independent evidence suggests that 
regulation by PINK1, loss of function caused by mutations, and misfolding can all 
contribute to PD development. Additionally, there currently is not an effective animal 
model that has clarified the role of parkin misfolding and ensuing cellular outcomes that 
lead to PD.  
1.5.2 Hypotheses 
1) Parkin truncations and point mutations alter cell growth and disrupt normal 
parkin localization. 
2) Parkin is involved in genetic interactions with genes required for oxidative stress 
management and preventing protein misfolding. 
3) Oxidative stress damages parkin resulting in misfolding and altered cellular 
localization. 
4) PINK1 interacts with parkin to disrupt parkin localization and stability 
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1.5.3 Objectives 
1) Establish a functional parkin yeast model 
A yeast model expressing parkin and several parkin mutants (Figure 1-6) was established. 
The system was used to identify how dysregulation of parkin affected growth, and altered 
localization with the use of growth assays and fluorescence microscopy, respectively. 
Parkin variants bearing N- and C-terminal truncations allowed mapping and 
characterization of results based on functional knowledge of each domain. Additionally, 
two parkin point mutants were selected that have an increased propensity to misfold. These 
mutants were used to compare oxidative stress induced misfolding to aggregation caused 
by pathogenic AR-JP mutants. Two additional mutations to S65, the serine residue 
phosphorylated by PINK1 (88), were used to monitor how parkin aggregation and toxicity 
changed in the absence of PINK1-mediated phosphorylation.  
2) Identify genetic interactions that alter parkin misfolding and toxicity 
We tested how parkin localization is affected by the deletion of key genes involved in 
managing oxidative stress and protein misfolding by performing a pilot screen using yeast 
deletion libraries. Changes in growth and parkin localization were examined by spotting 
assays and fluorescence microscopy, respectively.  
3) Assess how oxidative stress alters folding and localization of parkin 
The effects of oxidative stress treatment towards parkin localization, toxicity and stability 
were examined in yeast by fluorescent microscopy, growth assays, and Western blot 
analysis following treatment with stress inducing chemicals.  
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4)  Identify how PINK1 modifies parkin stability and cell toxicity 
We tested how parkin toxicity, localization, and stability were altered by co-expression of 
PINK1 in yeast using growth assays, fluorescent microscopy, and Western blot analysis.  
1.5.4 Significance 
The use of genetic screens gave insight into alternate cellular pathways that parkin may be 
involved in that contribute to PD. This built a strong rational to conduct a high throughput 
screen using the entire deletion and over-expression yeast libraries, which may uncover 
previously unidentified genetic interactions with parkin and elucidate previously 
undescribed pathways that may modulate parkin localization and function. By assessing 
how mutations, truncations, oxidative stress, and PINK1 co-expression, altered parkin 
localization, toxicity, and stability, we also established that parkin misfolding and 
regulation contribute to its dysfunction. Continuing research on these aspects of parkin 
dysregulation will certainly provide a better understanding of how parkin contributes to 
PD.  
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Chapter Two: Materials and Methods 
2.1 Materials 
2.1.1 Escherichia coli Strains - DH5α Genotype F–Φ80lacZΔM15 Δ(lacZYA-argF) 169 
recA1 endA1 hsdR17 (rK–, mK+) phoA supE44 λ– thi-1 gyrA96 relA1 
2.1.2 Bacterial Media 
2.1.2.1 Luria-Bertani (LB) - 10 g/L NaCl (Sigma Aldrich), 10 g/L tryptone (Sigma 
Aldrich) and 5 g/L yeast extract (Sigma Aldrich), supplemented with antibiotics: 100 
g/mL ampicillin (Amresco) or 50 g/mL kanamycin (Amreseco).   
2.1.2.2 2xYT - Full nutrient media for non-selective bacterial growth in liquid culture. 
16 g/L tryptone, 10 g/L yeast extract (Sigma Aldrich) and 5 g/L NaCl. 
2.1.3 Saccharomyces cerevisiae Strains - W303 MAT a (genotype: leu2-3,112 trp1-1 
can1-100 ura3-1 ade2-1 his3-11,15) were used in all growth assays and protein work. 
BY4742 MAT a (Genotype his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0) were used in all fluorescence 
microscopy experiments. BY4741 MATα (Genotype his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0) were 
used for screening genetic deletion strains. 
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2.1.4 Yeast Media 
2.1.4.1 Yeast Peptone Dextrose (YPD) - Full nutrient media for non-selective yeast 
growth in either liquid or agar plates. 10 g/L yeast extract (Amresco), 20 g/L peptone 
(Sigma-Aldrich), and 20 g/L dextrose (Sigma-Aldrich). 
2.1.4.2 Selective Dextrose (SD) - Media lacking essential amino acids required for growth 
of yeast deficient in amino acid biosynthesis in liquid media or on agar plates. 2% Glucose, 
YNB (Sigma-Aldrich) as nitrogen source, and amino acid powder as required for selection. 
100X general amino acid solutions (6 g/L l-isoleucine, 2 g/L L-arginine, 4g/L L-lysine 
HCl, 6 g/L L phenylalanine, 1 g/L L-threonine, and 1g/L L-methionine); 100X selective 
amino acids (4g/L L-tryptophan, 6g/L L-leucine, 2 g/L L-histidine-monohydrate);  0.2% 
(w/v) adenine hemisulfate in 0.1 M NaOH; 0.4% (w/v) uracil in 0.1M NaOH.  
2.1.4.3 Selective Galactose/Raffinose (SGal/Raff) - Media lacking essential amino acids 
required for growth of yeast deficient in amino acids biosynthesis; used to induce genes 
carried on vectors under control of Gal promoter. 2% Galactose (Sigma-Aldrich), 2% 
Raffinose (Sigma Aldrich), YNB as nitrogen source, and amino acid powder as required 
for selection. 
2.1.5 Mammalian Cell Lines – Cervical cancer derived HeLa cells, human embryonic 
kidney (HEK) 293 cells stably expressing transfected FLAG-Parkin, and neuroblastoma 
derived SH-SY5Y cells were used in this study. 
2.1.6 Cell Culture Media - Dulbecco's Modified Eagle Medium (DMEM, Corning) with 
4.5 g/L or 1 g/L glucose was supplemented with 10% fetal bovine serum (FBS, Gibco), 
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100 I.U./mL penicillin (Corning Cellgro), 100 µg/mL streptomycin (Corning) and 1x 
glutamine (Sigma Aldrich). 
2.1.7 Sources of DNA used for Cloning - Human parkin DNA used to clone parkin and 
parkin truncation variants was acquired from Dr. Shaw (Western). Yeast specific PINK1 
DNA used in cloning and human PINK1 and kinase dead PINK1 DNA used for expression 
in mammalian was provided by was generously provided by Dr. Endo (Kyoto Sangyo 
University)  
2.1.8 Chemicals  
2.1.8.1 General Chemicals  
All chemicals were purchased from Sigma Aldrich unless stated otherwise. 
2.1.8.2 Protease Inhibitors  
Protease and Phosphatase Inhibitor Cocktail (Thermo Scientific) 
SIGMAFAST™ Protease Inhibitor Tablets (Sigma Aldrich) 
N-Ethylmaleimide (NEM, Sigma Aldrich) 
Phenylmethanesulfonyl fluoride (PMSF, Sigma Aldrich) 
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2.1.9 Antibodies 
 
Table 2-1. Antibodies used in this study. 
Antigen Epitope Supplier Use Concentration 
Parkin Ubl Novus WB 1-1000 
   IF 1-200 
Parkin RING1 Abcam WB 1-1000 
   IF 1-500 
Parkin RING2 Cell Signaling WB 
WB 
1-10000 (Yeast) 
1-2000 (Mam) 
   IF 1-200 
Parkin Unknown Santa Cruz IF 1-200 
PGK1 N/A Antibodies-online WB 1-10000 – 1-20000 
Tubulin N/A Abcam WB 1-5000 
FLAG N/A Sigma Aldrich WB 1-1000 – 1-2000 
Polyubiquitin N/A Enzo WB 1-2000 
PS65-Ubiquitin N/A Boston Biochem WB 1-500 
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2.2 Methods 
2.2.1 Cloning 
2.2.1.1 Polymerase Chain Reaction (PCR) – PCR is a technique used to create parkin 
variant templates to be used in Gateway® recombination cloning. Reaction mixtures 
included: 10 mM dNTPs (2 μL), variable concentration template (1 μL), 100 mM forward 
primer (2 μL), 100 mM reverse primer (2 μL), Q5 polymerase (1μL) (New England 
Biolabs), 5x buffer (20 μL) (New England Biolabs), and ddH2O (72 μL). Samples were run 
for 25 cycles with denaturing, annealing, and extension temperatures of 95°C, 58°C, and 
72°C respectively. DNA products were resolved by agarose gel electrophoresis (See Table 
2-2 for primer design).  
2.2.1.2 Agarose Gel Electrophoresis - 1% agarose powder was dissolved in TAE (40 mM 
Tris, 20 mM acetic acid and 1 mM ethylenediaminetetraacetic acid (EDTA)) buffer with 
1ug/mL ethidium bromide (Sigma Aldrich) and allowed to solidify at room temperature. 
2.2.1.3 Gel Purification of DNA - AccuPrep® Gel Purification Kit (Bioneer) was used to 
purify DNA products from agarose gel. DNA bands were excised from the agarose gel and 
purified as described in the supplier instruction manual. 
2.2.1.4 Mini Prep - High Speed Plasmid Mini Kit (Geneaid) uses standard alkaline lysis 
followed by neutralization and ethanol wash on DNA binding columns to extract dsDNA 
plasmids from E. coli. E. coli were grown in 3 mL cultures of LB supplemented with 
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ampicillin or kanamycin. Cells were lysed and DNA was extracted following the protocol 
described in the supplier instruction manual.  
2.2.1.5 Midi/Maxi Prep - PureLink® HiPure Plasmid Midi/Maxiprep Kits provided by 
Invitrogen were used to prepare DNA for transfection of HeLa cells. 250-500 mL LB Amp 
cultures of E. coli were grown and isolated as per the instruction manual.  
 
Table 2-2. Custom designed primers used to generate constructs for use in 
Gateway® cloning. 
Clone and Orientation Sequence (5’ to 3’) 
Parkin/Ubl Fw  ggggacaagtttgtacaaaaaagcaggctatgatagtgtttgtcaggttcaact 
141C/141-409 Fw  ggggacaagtttgtacaaaaaagcaggctatgtcaatctacaacagcttttatgtgt 
321-465 Fw ggggacaagtttgtacaaaaaagcaggctatggaggagtgtgtcctgcagatggggg 
Parkin/141C/321-465 
Rv w/ Stop  
ggggaccactttgtacaagaaagctgggtctacacgtcgaaccagtggtccccc 
Parkin/141C/321-465 
Rv No Stop 
ggggaccactttgtacaagaaagctgggtccacgtcgaaccagtggtcccccatg 
141-409 Rv w/ Stop  ggggaccactttgtacaagaaagctgggtctaaaatacggcactgcactccccttca 
141-409 RV No Stop ggggaccactttgtacaagaaagctgggtcaaatacggcactgcactccccttca 
Ubl Rv w/ Stop  ggggaccactttgtacaagaaagctgggtctaaccttttctccacggtctctgcaca 
Ubl Rv No Stop  ggggaccactttgtacaagaaagctgggtcaccttttctccacggtctctgcaca 
PINK1 Fw ggggacaagtttgtacaaaaaagcaggctatggtcagagaacagaaggccaag 
PINK1 Rv w/ Stop ggggaccactttgtacaagaaagctgggttcacttatcatcatcatccttata 
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2.2.1.6 Preparation of Competent DH5 Cells – Two mL 2xYT culture of DH5 were 
inoculated and incubated for six hours at 37°C during the day. Ten μl of culture was 
transferred into 2 mL fresh 2xYT and incubated overnight at 37°C. The culture was diluted 
1:100 in 1xYT media and incubated at 37°C. During this time, the culture OD600 was 
checked 30 minutes after the first 2 hours and every 15 minutes after that. Cultures were 
grown to OD600 0.4-0.5. All the following steps occurred on ice. Cultures were chilled on 
ice 10 minutes by pouring equal volumes into two 50 mL conical PP centrifuge tubes. 
Samples were spun at 2,000xg for 15 minutes at 4°C in RT6000 Sorvall centrifuge with 
Swinging Bucket Rotor and resuspended with a 10mL pipet in 10 mL of CaCl2 solution 
(60 mM CaCl2.2H2O, 10 mM PIPES pH 7.0 and 15% glycerol) per 50 mL tube with a 10 
mL disposable pipet. Samples were spun again at 2,000xg for 10 minutes at 4°C in RT6000 
Sorvall centrifuge with Swinging Bucket Rotor and resuspended with 10 mL pipet in 10 
mL total volume of CaCl2 solution before incubating on ice for 30 minutes. Following the 
incubation on ice, samples were spun at <2,000xg for 10 minutes at 4°C in RT6000 Sorvall 
centrifuge with Swinging Bucket Rotor and resuspended with 5 mL pipet into 1 mL volume 
of CaCl2 Solution per 50 mL volume starting culture. Using P1000 pipet solutions were 
aliquoted in 100 µL volumes into chilled tubes and quickly frozen to -80°C. 
2.2.1.7 Gateway® Cloning – Gateway® Cloning is technique that utilizes homologous 
recombination to selectively insert the desired gene product into one of several destination 
vectors (110). After isolating PCR generated dsDNA constructs, the BP recombination 
reaction was first used transfer PCR template DNA into an intermediate cloning vector. 
Reaction mixtures included BP Clonase (1μL) (Invitrogen), pDONR vector (1μL) 
(Invitrogen), gel purified PCR DNA (3 μL). The reaction was incubated at 37°C overnight. 
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Following the overnight incubation, the reaction was quenched with 1 μL Proteinase K 
(Invitrogen) and incubated for 10 minutes at 37°C. Three μL of reaction mixture was 
transformed into competent DH5α cells via E. coli transformation protocol (see below) and 
plated on LB agar plates containing 50 µg/ml Kan. Single colonies were isolated and grown 
in liquid LB Kan media overnight at 37°C. DNA was isolated from the E. coli using the 
High Speed Plasmid Mini Kit (Geneaid) and sequenced using the sequencing services 
provided by Robarts Research Institute at Western University to verify successful 
incorporation of the DNA into the pDONR201 vector. 
 After successfully isolating the desired construct in the pDONR backbone, the LR 
recombination reaction was used to transfer from the intermediate vector to one of several 
possible destination vectors. Reaction mixtures included: LR Clonase (4 μL) (Invitrogen), 
destination vector (2 μL), pDONR vector as source of recombinant DNA (2 μL), and TE 
(10mM Tris pH 8.0, and 1 mM EDTA) buffer (12 μL). The reaction was incubated at 37°C 
overnight followed by quenching with 2 μL Proteinase K, which was incubated for 10 
minutes at 37°C. Ten μL of the reaction was transformed into competent DH5α cells via 
E. coli transformation protocol and plated on LB agar plates containing 100 µg/mL 
ampicillin (Amp). Again, single colonies were isolated, grown in LB AMP overnight at 
37°C and the DNA was extracted and sequenced to verify successful recombination into 
the destination vector. A list of constructs and destination vectors used in this study can be 
found in Table 2-3. 
2.2.1.8 Bacterial Transformation – Transformation is a protocol for introducing double 
stranded plasmid DNA into E. coli cells for replication/expression. One hundred μL 
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aliquots of competent DH5 cells were removed from -80°C and allowed to thaw on ice 
for five minutes. 1-5 μL of plasmid DNA was added and samples were left to incubate on 
ice for 30 minutes. Samples were heat shocked at 42°C for 100 seconds followed by a two 
minutes incubation on ice. 900 μL of 2xYT was added to each sample to make to total 
volume of 1mL.  Samples were then incubated at 37°C shaking for at least one hour. After 
recover, cells were pelleted at 15 000xg for one minute and the supernatant was removed. 
The pellet was resuspended in 100 μL LB or 2xYT and plated on LB agar plates with 
antibiotic.  
 
Table 2-3. List of constructs and expression vectors used in this study. 
Construct Vector Expression Control Expression System 
Parkin (WT) pRS423 Galactose Induced Yeast 
Parkin (WT) pRS423-YFP Galactose Induced Yeast 
Parkin (WT) pcDNA3.1 Constitutive Mammalian 
Parkin S65A pRS423 Galactose Induced Yeast 
Parkin S65A pRS423-YFP Galactose Induced Yeast 
Parkin S65A pcDNA3.1 Constitutive Mammalian 
Parkin S65E pRS423 Galactose Induced Yeast 
Parkin S65E pRS423-YFP Galactose Induced Yeast 
Parkin S65E pcDNA3.1 Constitutive Mammalian 
Parkin C289G pRS423 Galactose Induced Yeast 
Parkin C289G pRS423-YFP Galactose Induced Yeast 
Parkin C289G pcDNA3.1 Constitutive Mammalian 
Parkin C418R pRS423 Galactose Induced Yeast 
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Parkin C418R pRS423-YFP Galactose Induced Yeast 
Parkin C418R pcDNA3.1 Constitutive Mammalian 
141C  pRS423 Galactose Induced Yeast 
141C  pRS423-YFP Galactose Induced Yeast 
141C  pcDNA3.1 Constitutive Mammalian 
141-409 pRS423 Galactose Induced Yeast 
141-409 pRS423-YFP Galactose Induced Yeast 
141-409 pcDNA3.1 Constitutive Mammalian 
321C pRS423 Galactose Induced Yeast 
321C pRS423-YFP Galactose Induced Yeast 
321C pcDNA3.1 Constitutive Mammalian 
Ubl pRS423 Galactose Induced Yeast 
Ubl pRS423-YFP Galactose Induced Yeast 
Ubl pcDNA3.1 Constitutive Mammalian 
PINK1 (WT) pRS416 Galactose Induced Yeast 
PINK1 (WT) pDENTIG Constitutive Mammalian 
Kinase Dead PINK1 pRS416 Galactose Induced Yeast 
Kinase Dead PINK1 pDENTIG Constitutive Mammalian 
 
2.2.2 Yeast Culturing Techniques 
2.2.2.1 Yeast Transformation - Yeast cells were inoculated in 3 mL YPD or SD media 
and grown overnight at 30°C. Starter cultures were used to inoculate a 30ml culture in YPD 
or SD to an OD600 = 0.200. Cells were grown for 4-5 hours at 30°C to OD600 = 0.500. Equal 
volumes of the culture were poured into two 50mL sterile centrifuge tubes and centrifuge 
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for 5 minutes at 2000xg at 4°C. Supernatant was discarded and cell pellets were 
resuspended in 5 mL sterile H2O per 50 mL tube. Samples were centrifuged again for 5 
minutes at 2000xg at 4°C after which the supernatant was aspirated and cell pellets were 
resuspended in 2 mL of 100 mM Li-Acetate/TE and incubate for 10 minutes at 30°C. 
Samples were once again centrifuged for 5 minutes at 2000xg at 4°C and the supernatant 
was removed. One hundred mM Li-Acetate/TE was used to resuspend cells in the 
necessary volume for the number of transformations + 1 (100 μl/transformation). One 
hundred μl of yeast cell suspension was aliquoted into labeled tubes and to each tube add 
in order: 250 μl transformation buffer (1 X TE, 40% polyethylene glycol and 100 mM Li-
Acetate), 12 μl salmon sperm DNA, 1 μl mini-prep cDNA and 25 μl DMSO (Sigma-
Aldrich). After resuspension, samples were heat shocked for 20 minutes at 42°C shaking. 
Samples were chilled on ice for 5 minutes before centrifuging for 1 minute at 1000xg, after 
which the supernatant was aspirated. Cells were then resuspended in 50 μl TE. The entire 
suspension was plated onto selective agar plates.  
2.2.2.2 Protein Induction – Yeast cells maintained on selective agar plates were used to 
inoculate liquid cultures in SD media. Cultures were incubated overnight at 30°C with 
constant shaking. After approximately 16 hours of growth, cultures were spun at 3000xg 
to pellet cells. The supernatant was aspirated and the cells were resuspended in sterile 
ddH2O. This process was repeated and cells were washed a second time with ddH2O before 
spinning one more time at 3000xg and aspirating the supernatant. The cells were then 
resuspended in SGal/Raff media to induce expression of constructs under control of the 
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Gal promoter. Cells were allowed to incubate in inducing media for 8-10 hours at 30°C 
before analysis or preparation for protein extraction.  
2.2.3 Growth Assays 
2.2.3.1 Spotting Assays - Yeast cells were inoculated into 3 mL liquid cultures of SD 
media and incubated with constant shaking overnight at 30°C. These cultures were diluted 
1:10 in water and the OD600 was measured as a proxy for cell density. In 96 well plates, 
yeast cultures were diluted in sterile ddH2O to 200 μl with an OD600 = 1.0. The subsequent 
five wells were filled with 120 μl of ddH2O. Serial dilution of 1:4 volume from top well 
into subsequent 5 wells were prepared by transferring 30 μl from well to well. Equal 
volumes of each well were transferred onto agar plates using a 48 prong spotting tool 
(“frogger”). Samples were plated on YPD media to ensure equal cell concentrations as well 
as SGal/Raff plates to detect affects caused by protein induction. Plates were dried for 10-
15 minutes prior to spotting to prevent samples from running. After spotting the plates were 
incubated at 30°C for 2-5 days. Pictures were taken to document growth differences 
between samples at the indicated incubation times. 
2.2.3.2 Growth Curves – Yeast cultures were inoculated in SD media and grown 
overnight at 30° C with constant shaking. After approximately 12-16 hours, cultures were 
spun at 3000xg for 5 minutes and washed twice with sterile ddH2O after removing the 
supernatant. Following the wash step, protein expression was induced by resuspending the 
cells in SGal/Raff media. Culture density was measured at a 600nm wavelength using a 
spectrophotometer. After measuring the OD600, cultures were diluted to an OD600 = 0.2 in 
SGal/Raff media and 300 μL of the culture was added to each well of a honeycomb plate. 
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Plates were incubated for 2-3 days in a Bioscreen C instrument (Oy Growth Curves Ab 
Ltd) at 30°C. OD600 measurements were taken every 15 minutes after the plates were 
agitated for 15 seconds prior to reading.   
2.2.3.2.1   Quantification of Growth Curves – Means of OD600 measurements at mid-log 
growth were compared using GraphPad Prism 6 software to calculate statistical 
significances. Means and standard deviations were compared using either an unpaired T-
test for experiments with two samples or a One-way ANOVA for experiments containing 
three or more samples. All sample means were compared to a vector control at an 
equivalent time point to assess growth inhibition. 
2.2.4 Fluorescent Microscopy - Imaging of YFP (yellow fluorescent protein) tagged 
parkin variants expressed in BY 4742 MAT a following 10 hours of galactose induction 
were performed on a Leica TCS SP5 II Confocal microscope using a HCX PL APO 63x 
oil objective. Images were captured using an equipped CCD camera using Leica 
Application Suite Advance Fluorescence Life V2.6.0 software.  
2.2.5 Cell Lysis  
2.2.5.1 Yeast - Following 10 hours of induction in SGal/Raff media at 30°C, yeast cultures 
were spun at 3000xg for 5 minutes to pellet cells. After aspirating the supernatant, the 
pellets were washed with sterile ddH2O. These steps were repeated to wash the cells a 
second time, after which, the cells were spun one more time. Again the supernatant was 
aspirated and cell pellets were put through one freeze thaw cycle at -20°C to assist with 
lysis. Cells were resuspended in equal volumes cold lysis buffer (50 mM Hepes pH 7.5, 
150 mM NaCl, 5 mM EDTA, 1% Triton X-100, SIGMAFAST™ Protease Inhibitor 
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(Sigma), and 50 mM NEM or 2 mM PMSF) and glass beads. Yeast cells were lysed by 
vortexing in a Disruptor Genie (Scientific Industries) 6 times for 30 seconds with 1 minute 
incubations on ice between vortexes. After lysis, samples were spun at 20000xg for 10 
minutes at 4°C. The supernatant was collected and the protein concentration of each sample 
was determined and normalized using the bicinchoninic acid (BCA) kit (Promega) using 
bovine serum albumin (BSA) as a standard.  
2.2.5.2 Mammalian - Cells were washed with cold PBS which was then aspirated off. A 
cell scraper was used to detach cells into cold lysis buffer (50 mM Hepes pH 7.5, 150 mM 
NaCl, 5 mM EDTA, 1% (v/v) Triton X-100, and SIGMAFAST™ Protease Inhibitor) after 
which, extracts were frozen at -20°C. After thawing on ice, extracted were lysed using a 
Branson Sonifier® ultrasonic cell disruptor for two 3-5 second pluses. Lysed samples were 
centrifuged at 20000xg for 10 minutes at 4°C. The supernatant was collected and protein 
concentrations were determined using the BCA kit (Promega) using BSA as a standard.  
2.2.5.3 NaOH Based Yeast Lysis – NaOH based lysis is an alternative method of yeast 
lysis used to address post lysis protease dependent protein degradation. The protocol was 
followed as described by Von der Haar T. (111) with adaptions made using 5ml cultures 
and adapting total volumes accordingly. 
2.2.6 Western Blotting – Thirty µg of  normalized protein samples in 1x sample buffer 
(2% sodium dodecyl sulphate (SDS), 5% glycerol, 50 mM EDTA, 200mM Tris-HCl pH 
6.8) with or without reducing agents (1% β-mercaptoethanol (BME) and 100 mM 
dithiolthreitol (DTT)) were loaded onto 12% or 15% acrylamide gels. Once resolved, the 
protein samples were transferred to nitrocellulose membranes (Bio Rad) using the Trans 
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Blot Turbo Transfer System (Bio Rad) following the manufacturer’s instructions. 
Membranes were blocked with blocking buffer (PBST 0.01% Tween-20, 2% BSA (Sigma 
Aldrich), and 2% goat serum) for 1 hour at room temperature and then incubated with 
primary antibodies (concentrations can be found in Table 2-1) in PBST with 2% BSA 
overnight at 4°C. Primary antibodies solutions were removed and membranes were washed 
with PSBT for 10 minutes 6 times before adding secondary antibody solutions and 
incubating at room temperature for 1 hour. After removing secondary antibody solutions, 
the membranes were again washed 6 times with PBST. Samples were imaged at infrared 
wavelengths using the LiCor system (Odyssey) using Odyssey V3.0 software.  
2.2.7 SYTOX® Green Cell Death Assay - Yeast cells maintained on selective agar plates 
were used to inoculate liquid cultures in SD media. Cultures were incubated overnight at 
30°C with constant shaking. After approximately 16 hours of growth, cultures were spun 
at 3000xg to pellet cells. The supernatant was aspirated and the cells were resuspended in 
ddH2O. This process was repeated and cells were washed a second time with ddH2O before 
spinning one more time at 3000xg and aspirating the supernatant. The cells were then 
resuspended in SGal/Raff media to induce expression of constructs under control of the 
Gal promoter. Cells were allowed to incubate in inducing media for 8-10 hours at 30°C 
before adding 5 µL of SYTOX® Green Nucleic Acid Stain (Thermo-Fisher) to 1 mL of 
culture to a final concentration of 25 µM. The cultures were vortexed and allowed to 
incubate at room temperature for ten minutes. Three 200 µL aliquots of the SYTOX® 
treated culture were added to 96 well plates followed by analysis using the Victor3V Plate 
Reader using the Perkin Elmer 2030 Manager Software. SYTOX® emission were read at 
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535nm and culture density was measured at 595nm. STYOX® measurements were 
corrected to culture density and values used for analysis.  
 
2.2.8 Semi Denaturing Detergent Agarose Gel Electrophoresis (SDD AGE) – SDD AGE 
is a technique used to resolve amyloid-like protein aggregates using mild detergents. 
Protein expression in yeast was performed, as described above. After 10 hours of protein 
induction, cells were washed twice in ddH2O before resuspending in equal volumes of cold 
SDD PAGE lysis buffer (100 mM Tris pH 7.5, 200 mM NaCl, 1mM EDTA, 5% glycerol, 
1 mM PMSF, 50mM NEM, Phosphatase and Protease Inhibitor Cocktail (Sigma Aldrich), 
and SIGMAFAST™ Protease Inhibitor) and glass beads. Yeast cells were lysed by 
vortexing in a Disruptor Genie (Scientific Industries) 6 times for 30 seconds with 30 second 
incubations on ice between vortexes. After lysis, samples were spun at 1000xG for 10 
minutes to pellet insoluble debris. The supernatant was collected and protein extracts were 
normalized by BCA assay (Pierce) using BSA as a standard. Sample buffer (1x TAE, 5% 
glycerol, and 0.2% SDS) was added to protein extracts and 30 µg total protein was loaded 
into each lane. Sampled were resolved by electrophoresis through a 1.8% agarose gel 
containing 0.1% SDS. After rinsing the gel in TBS (10 mM Tris pH 7.5, and 150 mM 
NaCl) samples were transferred to a nitrocellulose membrane (Bio Rad) through capillary 
force using pre-assembled TurboBlotter™ Rapid Downward Transfer System packs (GE 
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Healthcare). Once samples were transferred to the nitrocellulose membrane, samples were 
treated and imaged in the same way as standard Western blots (described above).  
2.2.9 Cell Culture 
2.2.9.1 Cell Maintenance and Passaging - Cervical cancer derived HeLa, human 
embryonic kidney (HEK 293) stably expressing FLAG-Parkin, and neuroblastoma derived 
SH-SY5Y cell lines were used in this study. Cells were continually passaged on culturing 
plastics (Starsted) in Dulbecco's Modified Eagle Medium (DMEM) containing 4.5g\L 
glucose supplemented with 10% fetal bovine serum (FBS), 100 I.U./mL penicillin 
(Corning Cellgro), 100 µg/mL streptomycin (Corning Cellgro), and 1x glutamine (Sigma 
Aldrich) at 37°C with ~5% CO2. Cell lines were passaged using standard 0.25% trypsin 
with 2.21 mM EDTA incubation followed by washing with fresh DMEM and re-seeding 
to new sterile culture plastics.     
2.2.9.2 Transfection - Cells were grown to approximately 90% confluency in DMEM 
before transfecting cells using Lipofectamine® 2000 (Thermo Fisher) following the 
supplier recommended concentrations in Opti-MEM® low serum media. Transfections 
were incubated for 16-20 hours at 37°C before washing with PBS. Cells were returned to 
DMEM media to recover for 24 hours before passaging into 6 well plates or 8 chamber 
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microscopy slides. Cells were allowed to recover for 24 hours after passaging before 
further treatment or analysis.  
2.2.10 Chemical Stress Treatment 
2.2.10.1.1  Yeast - Spotting assays and Bioscreen growth curve experiments were 
performed with selective agar or liquid media, respectively, containing 50 µM H2O2, 100 
µM H2O2, 1 mM H2O2, 500 µM azetidine-2-carboxylic acid (AZC, Sigma-Aldrich), 10 µM 
peroxynitrite (Enzo), 2 mM DTT, 25 µM radicicol (Sigma-Aldrich), or 50 µM antimycin 
A (Sigma Aldrich). Spotting assays were grown for 3-5 days at 30°C under stress 
conditions where as Bioscreen growth experiments were incubated for 2-3 days at 30°C 
with agitation every 15 minutes  
2.2.10.1.2  Mammalian - Mammalian cells were treated with either 75 µM H2O2, 10 µM 
MG132, 1 mM LAZC, 50 µM antimycin-A, or 10 µM peroxynitrite for either 8 hours or 
16 hours in DMEM at 37°C with 5% CO2. Following treatment, cells were washed with 
PBS and used for Western Blotting or Immunofluorescence microscopy (IF). 
2.2.11 Viability Assay – SH-SY5Y cells expressing endogenous parkin and PINK1, HEK 
293 cells stably expressing FLAG-parkin but no PINK1, or HeLa cells transiently 
transfected with parkin, various parkin mutants, wild-type (WT) PINK1, and/or a kinase 
dead (KD) mutant PINK1 were used to perform viability assays. Following transfection or 
standard passaging, cells were given either 1 or 4 days to recover in rich media (DMEM 
with 10% FBS and 4.5 g/L glucose) or minimal media (DMEM with 1% FBS and 1 g/L 
glucose) before performing the luminescence based Cell Titer-Glo® Luminescent Cell 
Viability Assay (Promega). Samples were prepared as recommended by the supplier and 
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loaded into 96 well plates. Plates were then measured using the Victor3V Plate Reader 
(Perkin Elmer) using the Perkin Elmer 2030 Manager Software. 
2.2.12 Immunofluorescence Microscopy  - 8 well chamber slides (Lab-Tex) were coated 
with Poly-L-Lysine (Sigma Aldrich) before passaging cells into wells. Culturing media 
was removed after a 24 hour recovery period and cells were fixed with 4% 
paraformaldehyde in PBS pH 7.4 for 20 minutes at room temperature. Cell were rinsed 
with PBS every 5 minutes for 30 minutes followed by permeabilization with 0.1% Triton 
X-100 (Sigma Aldrich) in PBS for 10 minutes. The Triton X-100 solution was removed 
and cells were washed 6 times with PBS before blocking in PBST (PBS + 0.01% Tween 
20) with 6% BSA and 2% goat serum for 1.5 hours at room temperature. Following 
blocking, cells were incubated in primary antibody solution for 1 hour at room temperature 
with antibody titers corresponding to Table 2-1 in section 2.1.9. Cells were then washed 
with PSBT every 5 minutes for 30 minutes. This was followed by incubation with 
secondary antibody solution for 1 hour at room temperature. Cells were washed again for 
30 minutes at 5 minutes intervals with PBST before mounting with SlowFade® Gold anti-
fade reagent with DAPI (Life Technologies) mounting media. Samples were then 
visualized using a Zeiss Axio Vert A1 Inverted fluorescent microscope using a 40x 
objective. Images were captured using an Axiocam Icc5 camera operating on the Zen 2 
Lite software.  
2.2.13 Shutoff 
2.2.13.1 Yeast – After ten hours of protein induction, glucose was added to the cultures to 
a final concentration of 2% to quench expression under control of the gal promoter. At the 
point of glucose addition, 50µM MG132 or an equivalent volume of DMSO were added to 
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cultures. Δerg1, Δerg3 W303 MAT a yeast strains were used in these experiments to inhibit 
export of MG132 from the cells.  Aliquots of the culture were taken at various time points 
following expression inhibition, and frozen at -80°C until all time points were collected. 
All time points were then lysed as described above, used to perform western blots, and 
band intensities were quantified using Odyssey V3.0 software.  
2.2.13.2 Mammalian – Following transfection or normal passaging, mammalian cells were 
treated with 200 µg/mL cycloheximide (Sigma Aldrich) and 10 µM MG132 or an 
equivalent volume of DMSO in fresh culturing media (DMEM with 10% FBS and 4.5 g/L 
glucose). Cells were harvest as described above at various time points and kept at -20°C 
until all time points were collected. Samples were then lysed as previously described, used 
for western blotting, and band intensities were quantified using Odyssey V3.0 software.  
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Chapter Three: Results 
3.1 Parkin Sequence Analysis 
To gain a better understanding how the amino acid composition of parkin affects 
its sensitivity to damage by oxidation, which can lead to altered parkin function, we 
performed an amino acid sequence analysis. Using sequence files obtained from 
Uniprot.org, we conducted a comprehensive analysis, aligning the parkin sequences of 38 
difference species (Appendix 2). For clarity, a representative alignment of four species 
(Homo sapiens, Mus musculus, Drosophila melanogaster, and Caenorhabditis elegans) is 
shown in Figure 3-1. These four species cover a wide spectrum of species divergence from 
roundworm to insects and mammals. Amino acids C431, H433, and E444, which make up 
the catalytic triad involved in human parkin’s E3 ubiquitin conjugation activity (112), are 
highly conserved in these species. C431 and H433 are completely conserved across all four 
species, and E444 is substituted for an acidic aspartate residue in C. elegans.  
Analysis of the human parkin amino acid sequence revealed that 35 of the 465 
residues are cysteines, equating to 7.52% of the total protein. This proportion of cysteines 
is approximately two times higher than the calculated random incorporation of 3.28% 
based on the two of 61 possible sense codons encoding cysteine residues and, more 
importantly, nearly three times higher than the average for all analyzed human proteins, 
which is 2.26% (8). Twenty-nine of parkin’s 35 cysteines (82.8%) are conserved between 
all four species and all of these residues are located within the boundaries of structurally 
determined functional domains. When C. elegans is excluded from this analysis, this 
number increases to 32 of the possible 35 cysteines (91.4%).   
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Figure 3-1. Parkin sequence alignment. (A) Schematic representation of parkin domains 
based on structural determination by NMR. (B) Amino acid sequences acquired from 
UniProt were aligned using Clustal Omega software. Cysteine residues are in red and 
amino acid residues of the functional domains in the human sequence are highlighted in 
the corresponding colour as shown in panel A. Asterisks (*) indicate positions with fully-
conserved residues;  colons (:) indicate conservation between groups of strongly similar 
properties, and periods (.) indicate conservation between groups of weakly similar 
properties. 
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Figure 3-1 
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Many of these cysteines are known to be involved in coordinating Zn2+ ions, which is 
required for proper folding and stability of parkin (59). However, this unusually high 
cysteine content also suggests a high susceptibility to oxidative damage and disulfide 
formation caused by exposure to reactive oxygen species (ROS) in vivo. 
3.2 The Parkin Yeast Model 
The yeast genome does not contain a PARK2 orthologue. We therefore used human 
parkin to establish a yeast model to study how parkin is affected by truncations, point 
mutations, PINK1 meditated phosphorylation, or various types of chemical stress including 
oxidative, nitrogenous, or membrane stress. Recombination-based cloning (Gateway) was 
used to generate yeast expression vectors for human parkin: one expressing the unmodified 
wild-type protein, and one containing a carboxy-terminal (C-terminal) yellow fluorescent 
protein (YFP) fusion protein (parkin-YFP) to visualize cellular localization by fluorescence 
microscopy. These parkin expression vectors contain a galactose inducible promoter 
(GAL1) to allow controlled expression of parkin. Unlike many constitutive promoters used 
in many mammalian systems, yeast enables the use of various promoters that can be 
selectively induced. This allows yeast to be grown on media containing glucose as a 
primary carbon source which causes them to grow and divide like wild-type yeast, but 
switching to a galactose based media induces parkin translation, allowing for controlled 
expression. Additionally, yeast expressing parkin can be switched back to glucose based 
media to selectively inhibit parkin expression without altering transcription of all other 
cellular proteins. Both the YFP-tagged and untagged parkin expression vectors were 
transformed into yeast. We first assessed whether the expression of human parkin has an 
53 
 
 
 
effect on the growth of yeast cultures under normal conditions. Spotting assays on agar 
plates and growth curves in liquid media showed an extremely mild growth defect 
associated with the over expression of untagged human parkin (Figure 3-2 A and B). 
Notably, control yeast (transformed with empty vector) and those over-expressing parkin 
had a similar growth rate during exponential growth phase as documented by a similar 
maximum slope of the curve during the first 12-18 hours of growth (Figure 3-2 B). Cells 
expressing parkin took two to three hours longer to enter logarithmic growth, indicating a 
prolonged lag phase.  
We next assessed parkin localization of parkin-YFP by fluorescent microscopy. 
After ten hours of inducing parkin-YFP expression, parkin-YFP was diffusely localized 
throughout the yeast cytosol (Figure 3-2 C) as previously reported in mammalian systems 
(113, 114). A minor proportion of yeast cells showed small cytosolic foci of increased 
signal intensity which could indicate subcellular accumulation of parkin (data not shown). 
Western blots showed that after ten hours of galactose induction, parkin was stably 
expressed in the transformed yeast (Figure 3-2 D). These data established our yeast parkin 
model and set the baseline to determine how cellular stress conditions and genetic 
modifications alter parkin toxicity, localization, stability, and degradation.  
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Figure 3-2. Establishing a parkin yeast model. (A) Liquid cultures of W303 were grown 
to stationary phase in non-inducing selective media and diluted to OD600 = 1.0 and serial 
diluted 1:5 before spotting on selective inducing agar media and incubated at 30°C for 2-4 
days before imaging to assess the effects of parkin expression on wild type W303. (B) 
Liquid cultures grown to stationary phase in non-inducing selective media were washed 
twice with sterile H2O and resuspended in inducing selective media before diluting to 
OD600 = 0.2 and incubating at 30°C. OD600 measurements were taken every 15 minutes and 
plotted to generate a growth curve. Standard deviations did not exceed a maximum OD600 
= 0.02. At mid-log growth parkin growth was statistically different from the control with a 
P value ≤ 0.001 as determined from an unpaired T-test. ● (Black) - Vector; ● (Green) - 
parkin (C) BY cells expressing parkin-YFP were grown in inducing liquid media for 8 
hours and fluorescent images were captured using a Leica TCS SP5 II confocal microscope 
at 63x magnification. The scale bar represents 5µm. (D) Thirty µg total protein of cell 
extracts from wild type W303 and W303 expressing parkin were resolved by SDS-PAGE, 
transferred to nitrocellulose membranes and expression of parkin was detected using 
immunodetection and imaged using infrared conjugated secondary antibodies. PGK1 was 
used to assess equal loading.  
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Figure 3-2. Establishment of the parkin yeast model.  
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3.3 Genetic Modulators of Parkin Toxicity and Localization 
Yeast can be used to perform extremely powerful genetic screens that cannot be 
carried out in any other model systems. These screens make use of the exhaustive over-
expression and deletion libraries that have been generated in yeast. Based on previous 
descriptions of parkin’s involvement in degradation of damaged proteins and turnover of 
damaged mitochondria (mitophagy), we decided to perform a genetic screen with parkin 
in a select library of 17 yeast deletions strains of genes involved in managing oxidative 
stress and protein misfolding which are described in Table 3-1.  
Parkin and parkin-YFP expressing yeast plasmids were transformed into the 
selected yeast strains. Deletion strains expressing untagged parkin were spotted onto 
inducing media and growth was assessed against a wild-type control strain expressing 
parkin (Figure 3-3 A). This screen revealed three deletion strains that show reduced growth 
due to the over-expression of human parkin: 1) deletion of SOD2, encoding a 
mitochondrial superoxide dismutase that protects against toxicity caused by superoxide 
radicals (115, 116); 2) deletion of YAP1, encoding a transcription factor required for 
oxidative stress tolerance that is activated by H2O2 (117); and 3) deletion of BTN2, 
encoding a v-SNARE binding protein that facilities protein retrieval from a late endosome 
to the Golgi and contributes to prion curling (118). Deletion strains expressing parkin-YFP 
were used for fluorescent microscopy to assess changes in parkin localization. Only two 
strains, deletion of SOD2 and SGT2, showed changes in parkin localization, showing 
subcellular accumulation of parkin into bright puncta; all other strains showed diffuse 
parkin localization as seen in wild-type yeast cells. SGT2 is a cytoplasmic co-chaperone 
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that is part of a protein complex required to mediate post-translational insertion of tail-
anchored proteins into the endoplasmic reticulum (ER) membrane (119), suggesting that 
altered capability of cells to undergo proper protein trafficking and folding affects parkin 
localization. These results indicate that genetic interactions can cause growth retardation 
and parkin accumulation, but these phenotypes are not necessarily dependent on one 
another. The results from this limited pilot screen built a strong rational to conduct a high-
throughput screen using the entire deletion and over-expression yeast libraries. A high-
throughput screen may uncover novel genetic interactions with parkin and elucidate 
pathways that modulate parkin localization and parkin function that have not been 
described previously. 
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Figure 3-3. Pilot screen for genetic modulators of parkin toxicity and localization. 
Parkin or parkin-YFP was transformed into a selected set of BY deletion strains of genes 
involved in managing oxidative stress and protein misfolding. (A) BY deletion strains 
expressing parkin were spotted to assess the effects of parkin expression on BY deletion 
strains. (B) BY deletion strains expressing parkin-YFP were grown in inducing liquid 
media for 8 hours and fluorescent images were captured using a Leica TCS SP5 II confocal 
microscope at 63x magnification to detect changes in parkin localization. The scale bar 
represents 5 µm. 
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Figure 3-3 
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Table 3-1. List of yeast deletions and corresponding gene function used to screen for 
parkin genetic interactions. Cellular functions and phenotypes associated with gene 
deletions. Modified from the Saccharomyces Genome Database. 
Gene Function Null Phenotype Reference(s) 
HSP12 Plasma membrane protein involved in 
maintaining membrane organization; 
involved in maintaining organization during 
stress conditions; induced by heat shock, 
oxidative stress, osmostress, stationary phase, 
glucose depletion, oleate and alcohol. 
Slow growth phenotype, 
increased sensitivity to cell-
wall affecting drugs, and 
increased flocculation. 
(120, 121) 
HSP30 Negative regulator of the H(+)-ATPase 
Pma1p; stress-responsive protein. 
No growth phenotype. (122) 
HSP31 Methylglyoxalase that converts 
methylglyoxal to D-lactate; involved in 
oxidative stress resistance. 
No growth phenotype; 
increased sensitivity to 
oxidative stress and 
accumulation of ROS. 
(121) 
TRX2 Cytoplasmic thioredoxin isoenzyme; part of 
thioredoxin system which protects cells 
against oxidative and reductive stress. 
Increased heat sensitivity 
and decreased resistance to 
hydrogen peroxide. 
(123, 124) 
UBI4 Ubiquitin; becomes conjugated to proteins, 
marking them for selective degradation via the 
ubiquitin-26S proteasome system; essential 
for the cellular stress response. 
Increased sensitivity to 
elevated temperature, zinc 
deficiency, nitrogen 
starvation, and oxidative 
stress. 
(125, 126) 
YAP1 Basic leucine zipper (bZIP) transcription 
factor; required for oxidative stress tolerance; 
activated by H2O2 through the multistep 
formation of disulfide bonds. 
Increased mutation 
frequency, decreased 
resistance to oxidizing and 
reducing agents. 
(117) 
TRX1 Cytoplasmic thioredoxin isoenzyme; part of 
thioredoxin system which protects cells 
against oxidative and reductive stress. 
Decreased chromosome and 
plasmid maintenance.  
(123, 124) 
TSA1 Thioredoxin peroxidase; acts as both 
ribosome-associated and free cytoplasmic 
antioxidant; self-associates to form high-
molecular weight chaperone complex under 
oxidative stress. 
Hypersensitive to oxidative 
stress and shows decreased 
anaerobic growth rate. 
(127, 128) 
TSA2 Stress inducible cytoplasmic thioredoxin 
peroxidase; cooperates with Tsa1p in the 
removal of reactive oxygen, nitrogen and 
sulfur species using thioredoxin as hydrogen 
donor. 
Decreased growth rate in 
exponential phase. 
(129, 130) 
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BTN2 v-SNARE binding protein; facilitates specific 
protein retrieval from a late endosome to the 
Golgi; modulates arginine uptake, possible 
role in mediating pH homeostasis between the 
vacuole and plasma membrane H(+)-ATPase. 
Decreased resistance to 
acidic pH. 
(118, 131) 
CTA1 Catalase A; breaks down hydrogen peroxide 
in the peroxisomal matrix formed by acyl-
CoA oxidase (Pox1p) during fatty acid beta-
oxidation. 
Decreased resistance to 
oxidative stress and 
decreased superoxide 
accumulation. 
(132, 133) 
CUR1 Sorting factor, central regulator of spatial 
protein quality control; physically and 
functionally interacts with chaperones to 
promote sorting and deposition of misfolded 
proteins into cytosolic compartments. 
Increased prion formation 
and abnormal protein 
distribution. 
(11, 131) 
SRX1 Sulfiredoxin; contributes to oxidative stress 
resistance by reducing cysteine-sulfinic acid 
groups in the peroxiredoxin Tsa1p, which is 
formed upon exposure to oxidants. 
Decreased oxidative stress 
resistance and increased 
sensitivity to hydrogen 
peroxide.  
(134) 
SGT2 Glutamine-rich cytoplasmic co-chaperone; 
serves as a scaffold bringing together TRC 
complex members required to mediate 
posttranslational insertion of tail-anchored 
proteins into the ER membrane; plays a role in 
targeting chaperones to prion aggregates. 
Increased heat sensitivity 
and decreased resistance to 
hygromycin B.  
(119) 
PRX1 Mitochondrial peroxiredoxin with thioredoxin 
peroxidase activity; has a role in reduction of 
hydroperoxides. 
Decreased resistance to 
oxidative stress. 
(135) 
SOD2 Mitochondrial manganese superoxide 
dismutase; protects cells against oxygen 
toxicity.  
Increased apoptosis, and 
decreased chronological and 
replicative lifespan. 
Increased sensitivity to 
oxidative stress, heat, and 
ionic stress 
(115, 116) 
SNO4 Possible chaperone and cysteine protease; 
required for transcriptional reprogramming 
during the diauxic shift and for survival in 
stationary phase 
Decreased oxidative stress 
resistance and increased 
accumulation of ROS. 
(136) 
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3.4 Oxidative Stress and Parkin Accumulation 
Before testing the effects of stress inducing treatments on parkin expressing cells, 
we tested to see if parkin is modified from naturally occurring stress inducing chemicals, 
such as reactive oxygen or nitrogen species that can be by-products of normal cellular 
processes (137, 138).  Based on the high cysteine content of parkin, we hypothesized that 
parkin would be highly susceptible to oxidative modification in vivo. Western blots were 
performed with protein lysates from yeast cells expressing parkin (Figure 3-4 A). Before 
resolving by SDS-PAGE, samples were prepared in loading buffer either with or without 
reducing agents (βME/DTT). In the absence of reducing agents, parkin migrated through 
the gel at a faster pace than parkin treated with reducing agents. N-Ethylmaleimide (NEM) 
irreversibly modifies cysteine residues by adding an alkyl group to the sulphur atom on 
their side chains. When protein lysates from yeast cells expressing parkin were treated with 
50 mM NEM, the molecular weight shift of parkin observed by Western blot with non-
reducing buffer was eliminated (data not shown). A closer analysis of the parkin signal of 
under non-reducing conditions (Figure 3-4 A lane 2) revealed a predominant species 
around 50kDa with a smeared signal above and below the predominant band. These results 
suggest that parkin is modified by oxidative damage under normal growth conditions in 
yeast. 
To test if this result was an artefact caused by the non-native environment of a yeast 
cell, similar experiments were performed with three human cell lines expressing different 
forms of parkin. HeLa and HEK 293 cells were chosen as simple model mammalian           
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Figure 3-4. Parkin is oxidatively modified in vivo. 
 
 
 
 
 
 
 
 
 
 
Figure 3-4. Parkin is oxidatively modified in vivo. Cell lysate from W303 (A) or various 
mammalian cells (B) expressing parkin (W303), transiently transfected parkin (HeLa), 
endogenous parkin (SH-SY5Y), or stably transfected FLAG-parkin (HEK 293) were used 
to perform western blots and probe for parkin. 30µg (A) or 80µg (B) of total protein from 
cell extracts were prepared in loading buffer with or without reducing agents (1% BME 
and 100mM DTT). Samples were resolved by SDS-PAGE, transferred to nitrocellulose 
membranes and expression of parkin was detected using immunodetection and imaged 
using infrared conjugated secondary antibodies. PGK1 and tubulin were used to assess 
equal loading for yeast or mammalian extracts respectively.  
  
64 
 
 
 
systems, and SH-SY5Y cells were selected based on their neuron-like characteristics. HeLa 
cells used were transiently transfected with human parkin. HEK 293 cells stably expressing 
parkin tagged amino (N)-terminally with the FLAG epitope (FLAG-parkin) were provided 
by Dr. Rylett (Robarts, Western University) and SH-SY5Y cells used express endogenous 
parkin. Western blots were performed with protein lysates from these three cell lines 
(Figure 3-4 B) which showed that there is a similar molecular weight shift for parkin in 
mammalian cells in the absence of reducing agents. This trend occurred with varying 
degrees of intensity, which is likely due to the various levels of parkin expression in the 
different cell lines and different levels of ROS. The HeLa and HEK 293 cell lines, which 
constitutively express parkin, showed the most significant shift in molecular weight, 
whereas SH-SY5Y lysates expressing endogenous parkin at lower levels showed a less 
significant shift.  
We next sought to test the effects of adding additional stress inducing chemicals on 
parkin. Spotting assays and fluorescent microscopy were performed with yeast cells 
expressing parkin in the presence of various stress inducing chemicals (Figure 3-5 A). At 
the concentrations used in these experiments, no significant changes were seen in the 
growth rate of parkin expressing yeast cells, but treatment with H2O2 and L-Azetidine-2-
carboxylic acid (AZC) caused parkin-YFP to accumulate into subcellular puncta. Western 
blot analysis of lysates of cells expressing parkin grown in the presence of stress inducing 
chemicals (Figure 3-6) showed no noticeable difference in parkin’s migration patterns, as 
parkin extracted from stress-treated cells showed the same shift in molecular weight in the 
absence of reducing agents as seen in untreated yeast and mammalian cells (Figure 3-4). 
Treatment with two oxidative stress inducing reagents, Antimycin A and peroxynitrite,  
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Figure 3-5. Stress treatment alters parkin localization in yeast. (A) W303 cells used for 
spotting growth assays and BY cells used for fluorescent microscopy were transformed 
with parkin and parkin-YFP, respectively. W303 expressing parkin were spotted onto 
inducing media containing 500 µM AZC, 10 µM peroxynitrite, 100 µM H
2
O
2
, 2 mM DTT, 
25 µM radicicol, or 50 µM antimycin A. BY cells expressing parkin-YFP were grown in 
inducing liquid media for 8 hours containing the above drug concentrations and fluorescent 
images were captured using a Leica TCS SP5 II confocal microscope at 63x magnification. 
The scale bars represents 5 µm. (B) W303 expressing parkin were grown in media 
containing 1 mM, 0.1 mM, or 0.05 mM H
2
O
2
 and incubating at 30°C. OD
600
 measurements 
were taken every 15 minutes and plotted to generate a growth curve. Standard deviations 
did not exceed a maximum OD
600
 = 0.05. At mid-log growth all samples were statistically 
different from the control with a P value ≤ 0.0001 as determined from a One-way ANOVA. 
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Figure 3-5 
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Figure 3-6. Stress treatment does not alter oxidative modification of parkin in yeast. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-6. Stress treatment does not change oxidative modification of parkin in yeast. 
Cell extracts from W303 expressing parkin grown in the presence of 100µM H
2
O
2
,
 
10µM 
peroxynitrite, or 50µM antimycin A were prepared in loading buffer with or without 
reducing agents (1% BME and 100mM DTT). Samples were resolved by SDS-PAGE, 
transferred to nitrocellulose membranes and expression of parkin was detected using 
immunodetection and imaged using infrared conjugated secondary antibodies. 
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appear to cause and increase in overall parkin levels, but the experiment would need to be 
repeated in order to determine if this trend is statistically significant.   
H2O2 was chosen for subsequent experiments based on its relevance to disease 
associated cell damage. Growth curves with increasing concentrations of H2O2 showed that 
up to a concentration of 100 µM, H2O2 had no effect on cell growth in the presence or 
absence of parkin (Figure 3-5 B). Increasing the concentration of H2O2 to 1 mM caused a 
slowed entry in logarithmic growth phase as well as a slower growth rate during 
exponential growth as indicated by the maximum slope of the curve for both control cells 
and cells expressing parkin. Although cell growth is affected by the increased H2O2 
concentration, the difference between wild-type cells and cells expressing parkin did not 
seem to change when compared to untreated cells.  
Next we tested if stress treatment would cause similar changes to parkin 
localization in mammalian cells. HeLa cells transiently transfected with parkin were treated 
with stress inducing chemicals and parkin localization was assessed using 
immunofluorescence microscopy (Figure 3-7 A). In contrast to the results found in yeast, 
HeLa cells treated with stress chemicals showed no change in parkin localization as we 
observed the same diffuse parkin localization seen in untreated cells. Western blots (Figure 
3-7 B) showed that parkin also undergoes a molecular weight shift in the absence of 
reducing agents and this effect seems unchanged by the presence of stress inducing 
chemicals. Overall, there were only minor effects caused by stress treatment that seemed 
mostly exclusive to yeast. The lack of observed effects in HeLa cells could be a result of 
the increased capability of mammalian cells to cope with various types of cellular stress.  
  
69 
 
 
 
Figure 3-7. Parkin is unaffected by stress treatment in HeLa cells. HeLa cells 
transiently transfected with parkin were used to assess the effects of stress treatment on 
parkin in mammalian cells. After transfection, cells were given 24 hours to recover in full 
media before treating for 8 hours with 75 µM H2O2, 10 µM MG132, 10 µM peroxynitrite, 
or 10 mM AZC. Following treatment (A) cells were passaged to 8 chamber microscopy 
slides and prepared for immunofluorescence imaging. Parkin was visualized using an 
AlexaFluor-488 conjugated secondary antibody and nuclei were stained with DAPI. 
Images were captured a Zeiss Axio Vert A1 Inverted fluorescent microscope using a 40x 
objective. Scale bars represent 10 µm. Parkin is stained green and nuclei are stained blue. 
(B) Cells lysates (30 µg total protein) were analyzed by Western blotting detecting parkin 
in the presence or absence of reducing agent in the loading buffer.  
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Figure 3-7. 
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3.5 Subcellular Localization of Parkin Truncations and Point 
Mutations  
Extensive experimentation has been performed to structurally characterize each of 
the functional domains of parkin and to determine how different domains interact and move 
within the entire parkin protein while executing its enzymatic activity (63, 65). Based on 
this knowledge, we generated functional truncation variants of parkin that we used to 
characterize and map changes to specific domains of the protein. Four truncation variants 
were generated and transformed into yeast. These variants include: 1. 141C, which has a 
N-terminal truncation of the first 140 residues that include the autoinhibitory Ubl domain 
and an unstructured linker region of approximately 70 amino acids; this parkin variant has 
increased activity compared to the wild-type protein and can be used to monitor how 
dysregulation of parkin affects misfolding and toxicity; 2. 141-409, which is similar to 
141C with an additional 56 residue C-terminal truncation of the catalytic C-terminal 
Rcat/RING2 domain. This variant is unable to perform the catalytic transfer of ubiquitin 
from E2 to substrate proteins; 3. 321C, which has a 320 residue N-terminal truncation 
leaving only the two most C-terminal domains (Brcat/IRB and Rcat/RING2) intact. This 
variant is capable of ubiquitination activity, albeit with reduced efficiency; and 4. Ubl, 
which only has the most N-terminal 76 residues that make up the ubiquitin-like (Ubl) 
domain; this domain performs an autoinhibitory function within the parkin protein.   
Furthermore, we employed a set of four point mutants selected based on structural 
and functional features of parkin. Two of these point mutants were used previously by 
Wen-Jie et. al (71). C289G and C418R, and have been identified as AR-JP causing 
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mutations. These parkin variants contain amino acid changes of cysteine residues that 
coordinate Zn2+ ions required for proper parkin folding (60). By altering these residues, 
parkin is unable to properly bind Zn2+ ions and loses its structural integrity, and thus has 
an increased propensity to misfold. These mutants were used to compare oxidative stress 
induced misfolding to aggregation caused by pathogenic AR-JP mutants. The other two 
mutations were to S65, the serine residue in parkin’s Ubl domain, which is phosphorylated 
by PINK1 (88). The S65A mutant was used to monitor how parkin aggregation and toxicity 
changes in the absence of PINK1-mediated phosphorylation. The S65E mutant was used 
as a phospho-mimic to determine whether aggregation and toxicity was caused by S65 
phosphorylation.  
We first developed yeast models of all the truncation variants, testing toxicity, 
localization and expression. Spotting assays and growth curves revealed that all of the 
truncation variants caused a mild growth retardation that was identical to that caused by 
wild-type full-length parkin (Figure 3-8 A and B).  Localization studies were performed 
with C-terminally YFP-tagged parkin truncation variants (Figure 3-8 C and D). 
Fluorescent microscopy showed that like parkin, Ubl and 321C were diffusely spread 
throughout the cytosol, but 141C and 141-409 had altered subcellular localization (Figure 
3-8 E). 141C formed small subcellular puncta, similar in size and distribution to those 
caused by AZC or H2O2 treatment on parkin-YFP expressing cells (Figure 3-5 A) with 
some diffuse staining. 141-409 caused more severe changes, forming either several large 
or many small puncta with no diffuse staining occurring in any cells. These findings  
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Figure 3-8. Truncations cause subcellular accumulation of parkin without altering 
growth in yeast. W303 transformed with parkin truncation variants (A/B) or C-terminally 
YFP tagged parkin truncation variants (C/D) were used to perform growth assays. Spotting 
assays (A/C) were performed by growing liquid cultures of W303 to stationary phase in 
non-inducing selective media. Cultures were diluted to OD
600
 = 1.0 and serial diluted 1:5 
before spotting on selective inducing agar media and incubated at 30°C for 2-4 days before 
imaging to assess the effects of parkin truncations with and without C-terminal YFP tags 
compared to wild type parkin. Growth curves (B/D) were performed by growing liquid 
cultures to stationary phase in non-inducing selective media. Cultures were washed twice 
with sterile H
2
O and resuspended in inducing selective media before diluting to OD
600
 = 
0.2 and incubating at 30°C. OD
600
 measurements were taken every 15 minutes and plotted 
to generate a growth curve. Standard deviations did not exceed a maximum OD
600
 = 0.02. 
At mid-log growth all samples were statistically different from the control with a P value 
≤ 0.001 as determined from a One-way ANOVA ● (Black) – Vector; ■ (Green) – Parkin or 
Parkin-YFP; ▲ (Purple) – 141C or 141C-YFP; ▼ (Blue) – 141-409 or 141-409-YFP; ♦ 
(Orange) – 321C or 321C-YFP; ● (Teal) – Ubl or Ubl-YFP. (E) BY transformed with N-
terminally YFP tagged parkin truncation variants were grown in inducing liquid media for 
8 hours and fluorescent images were captured using a Leica TCS SP5 II confocal 
microscope at 63x magnification. The scale bars represents 5µm. 
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Figure 3-8
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Figure 3-9. Parkin 141C truncation is expressed at higher levels than wild type parkin 
in yeast. (A) Schematic representation of parkin and its domains. Thirty µg total protein 
were used for Western blots detecting parkin. Primary antibodies with epitopes specifically 
recognizing various domains were used to detect parkin and the various truncation variants 
and compare relative expression. A RING2 specific antibody was used to detect parkin, 
141C, and 321C (B), a RING 1 specific antibody was used to detect parkin, 141C, and 141-
409 (D), and a Ubl specific antibody was used to detect parkin and Ubl (F). Signal 
intensities were measured and quantified, setting the value of wild-type parkin expression 
to 1. Means were compared using a one-way ANOVA (C and E) or an unpaired T-test (G). 
Two asterisks (**) indicates a statistical difference with a p value ≤ 0.01. . Black – Parkin; 
Green – 141C; Purple – 321C; Blue – 141-409; Orange – Ubl. 
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Figure 3-9 
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suggest that the Rcat/RING2 domain removed in the 141-409 variant plays a role in 
maintaining proper parkin folding and localization.  
We next tested expression levels of the parkin truncation variants in yeast. Because 
it was not possible to compare all variants using the same antibody, three different primary 
anti-parkin antibodies were used to quantify the expression of the different truncation 
variants. In each case, the level of wild-type full length parkin expression was arbitrarily 
set to one, and the relative intensity of the truncation variants was compared to wild-type 
parkin (Figure 3-9). Although the α-Rcat/RING2 1° antibody (Cell Signalling) yielded 
approximately a three-fold stronger signal than the α-RING1 1° antibody (Abcam) for 
wild-type parkin using the same lysates (data not shown), in both cases, nearly three times 
more 141C was expressed than wild-type parkin (Figure 3-9 C and E). The three 
remaining truncation variants were expressed at relatively similar levels to wild-type full-
length parkin (Figure 3-9 C, E, and G). 
We then performed the same set of experiments to test the four parkin point 
mutants. All four point mutants had the same growth phenotypes as wild-type parkin in the 
presence or absence of C-terminal YFP tags, showing only mild growth restriction (Figure 
3-10 A, B, C, and D). Fluorescent microscopy revealed that the C289G and C418R 
mutants formed subcellular aggregates (previously shown in mammalian cells (71)), but 
both S65 mutants showed diffuse cytosolic localization (Figure 3-10 E). The aggregates 
formed by the C289G and C418R mutants resemble those formed by the 141C variant 
(Figure 3-8 E), forming one or more small puncta per cell with some diffuse staining still 
occurring. Analysis of expression levels showed that all four point mutants had similar 
expression levels compared to wild type parkin (Figure 3-11 A and B). Only  
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Figure 3-10. Parkin point mutants are non-toxic but alter parkin localization and 
expression levels in yeast. W303 cells expressing parkin point mutants (A and B) or C-
terminally YFP tagged parkin point mutants (C and D) were used for growth assays. 
Spotting assays (A and C) were performed to assess the effects of parkin truncations with 
and without C-terminal YFP tags compared to wild type parkin. Growth curves (B and D) 
were performed by growing in inducing selective at 30°C. OD
600
 measurements were taken 
every 15 minutes and plotted to generate a growth curve. Standard deviations did not 
exceed a maximum OD
600
 = 0.05. At mid-log growth all samples were statistically different 
from the control with a P value ≤ 0.01 as determined from a One-way ANOVA. Samples 
tested were; ● (Black) Vector, ■ (Green) Parkin/Parkin-YFP, ▲ (Purple) Parkin 
S65A/Parkin S65A-YFP, ▼ (Blue) Parkin S65E/Parkin S65E-YFP, ♦ (Orange) Parkin 
C289G/Parkin C289G-YFP; and ● (Teal) Parkin C418R/Parkin C418R-YFP. (E) BY cells 
expressing C-terminally YFP tagged parkin point mutants were grown in inducing liquid 
media for 8 hours and fluorescent images were captured using a Leica TCS SP5 II confocal 
microscope at 63x magnification. The scale bars represents 5µm.   
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Figure 3-10 
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Figure 3-11. Point mutations change parkin levels in yeast. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-11. Point mutations change parkin levels in yeast. (A)  30µg total protein of 
cell extracts from W303 transformed with parkin or parkin point mutants were resolved by 
SDS-PAGE, transferred to a nitrocellulose membrane and expression was detected using 
immunodetection and imaged using infrared conjugated secondary antibodies. Samples 
were run in triplicate, quantified, and graphed (B) setting the value of wild type parkin 
expression to 1. Means were compared using a one-way ANOVA. An asterisk (*) indicates 
statistical difference with a p value ≤ 0.05. Black – Parkin; Green – Parkin S65A; Purple – 
Parkin S65E; Blue – Parkin C289G; Orange – Parkin C418R.    
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the decreased level of the S65A mutant and the increased amount of the S65E, C289G and 
C418R mutants were statistically significant.  
We next tested the expression of the parkin truncation variants and point mutants 
in mammalian cells to test if any of these results were artefacts caused by parkin expression 
in yeast, as shown for chemical stress treatment of parkin (Figure 3-7). Due to technical 
issues with strong background signals, the 141-409, 321C, and Ubl truncation variants 
could not be detected though immunofluorescence microscopy in transfected HeLa cells. 
Despite extensive testing and protocol adjustments, all four different parkin antibodies 
tested here showed significant background staining in untransfected HeLa cell that express 
no endogenous parkin (Appendix 3). Additionally, only the Rcat/RING2 primary antibody 
was able to detect parkin in Western blots, so the following experiments were performed 
with only the parkin point mutants and the 141C variant. Immunofluorescence microscopy 
staining revealed that 141C, S65A and S65E, like wild type parkin, were cellular diffuse, 
and the C289G and C418R mutants formed subcellular aggregates as previously shown 
(71) (Figure 3-12 A). Western blots of transfected cell lysates showed that, in contrast to 
results in yeast, 141C is expressed at significantly lower levels than parkin (Figure 3-12 B 
and C). Similarly, the S65A point mutant, that had lower expression in yeast, was 
expressed at nearly four-fold higher levels than wild-type parkin in transfected HeLa cells 
(Figure 3-12 D and E). Similarly, the S65E point mutant was expressed at even higher 
levels than S65A, suggesting that modification of the Ubl domain plays a significant role 
in parkin expression and stability in mammalian cells. In contrast, the expression levels of 
the two parkin cysteine mutants were similar to wild-type parkin (Figure 3-12 D and E). 
82 
 
 
 
Figure 3-12. Parkin point mutants and truncations have altered expression and 
cellular localization in Hela cells. HeLa cells transiently transfected with parkin, parkin 
truncation variants, or parkin point mutants were used to assess the effects of parkin 
alterations in mammalian cells. After transfection, cells were given 24 hours to recover in 
full media before further treatment. (A) Transfected Hela cells were passaged to 8 chamber 
microscopy slides and prepared for immunofluorescence imaging. Parkin, 141C, and four 
parkin point mutants were immunodetected with a RING2 specific primary antibody and 
subsequently visualized using an AlexaFluor-488 conjugated secondary antibody. Cell 
nuclei were stained with DAPI. Images were captured a Zeiss Axio Vert A1 Inverted 
fluorescent microscope using a 40x objective. Scale bars represent 10µm. Parkin, 141C, 
and parkin point mutants are stained green, nuclei are stained blue. (B and D) Cells used 
for Western blotting were washed and lysed before resolving 30µg total protein by SDS-
PAGE. Samples were run in triplicate and signal intensities were quantified relative to the 
tubulin loading control and graphed (C and E), setting wild-type parkin levels to 1. Means 
were compared using an unpaired T-test (C) or a one-way ANOVA (E). Two, three, or four 
asterisks (**/***/****) indicates a statistical difference with a p value ≤ 0.01, ≤ 0.001, or 
≤ 0.0001, respectively. Tubulin was used to assess equal loading. . Black – Parkin; Green 
– 141C; Purple – Parkin S65A; Blue – Parkin S65E; Orange – Parkin C289G; Teal – Parkin 
C418R. 
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Figure 3-12
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In summary, modification of key cysteine residues involved in zinc ion 
coordination (C289G and C418) significantly affected parkin solubility in both yeast and 
mammalian cells. Modification of S65 did not seem to affect parkin localization but had 
variable effects on expression in yeast and mammalian cells. 141C caused parkin 
aggregation and increased expression in yeast but had no effect on localization and showed 
reduced expression in HeLa cells.  
3.6 PINK1 Modulates Parkin Localization, Toxicity, and Stability 
With the recent explosion of literature focused on the relationship between parkin 
and PTEN-induced putative kinase 1 (PINK1), we next decided to study the effects of co-
expressing these two proteins in yeast. Most of the parkin/PINK1 related literature focuses 
on how PINK1 activates parkin and the ensuing ubiquitination and turnover of damaged 
mitochondria (mitophagy). In contrast, our study aimed to explore PINK1 as a modifier of 
parkin folding and stability, and thereby determine how the addition of PINK1 affects 
parkin localization, expression, degradation, and toxicity.  
Unlike most proteins, expression of the human form of PINK1 in yeast would not 
allow for proper function of the protein because human PINK1 appears to be degraded 
rapidly in yeast. Many studies suggest that PINK1 is anchored to the mitochondria via an 
N-terminal leader sequence that directs the protein to the mitochondrial membrane after 
translation (77). Unfortunately, this leader sequence is human-specific, and would not 
properly transport PINK1 to the mitochondria in yeast. A modified PINK1 clone containing 
a yeast specific N-terminal outer mitochondrial protein (OMP) leader sequence and a C-
terminal FLAG tag was generously provided to us by our collaborator Dr. Endo (Kyoto 
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Sangyo University). This template was used to clone PINK1 into yeast vectors for 
expression in our model system. Also, the kinase activity of PINK1 was eliminated by 
mutating two key aspartic acid residues to alanine (D3682A and D384A). We used these 
mutations to create a kinase dead (KD) PINK1 mutant by mutagenic PCR and subsequently 
cloned into yeast expression vectors as a control.  
3.6.1  Co-expression of PINK1 and Parkin in Yeast 
These yeast specific PINK1 and KD PINK1 clones were co-expressed with parkin 
and the parkin truncation variants to test for toxicity (Figure 3-13). Interestingly, in yeast, 
PINK1 expression caused a mildly toxic phenotype on its own (Figure 3-13 A lane 2) 
which does not occur with the KD PINK1 mutant (Figure 3-13 E lane 2). When co-
expressed with PINK1, wild-type parkin caused a severe toxic phenotype, almost 
completely inhibiting growth (Figure 3-13 A lane 3). Although parkin and PINK1 on their 
own caused only mild or slightly more severe growth inhibition, respectively, the co-
expression of both had drastically increased (i.e. synergistic) growth inhibition. 
Interestingly, co-expression of PINK1 with the parkin truncation variants still exhibit 
artificial toxicity, even when expressed with variants lacking S65, including 141C, which 
is the site of PINK1 mediated phosphorylation of parkin (Figure 3-13 A and B).  
PINK1 was then co-expressed with parkin-YFP and C-terminally YFP-tagged 
truncation variants (Figure 3-13 C and D) which showed a similar growth phenotype as 
their untagged counterparts with PINK1 and parkin-YFP causing the most significant 
toxicity, and reduced toxicity when PINK1 is co-expressed with 141C-YFP. In all cases, 
the addition of a C-terminal YFP tag slightly reduced the growth defect compared to their  
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Figure 3-13. Co-expression of parkin and PINK1 causes toxicity in yeast. W303 
expressing PINK1-FLAG (A, B, C, and D) or kinase dead (KD) PINK1-FLAG (E and F) 
and parkin truncation variants (A, B, E, and F) or C-terminally YFP tagged parkin 
truncations (C and D) were used to perform growth assays. Spotting assays (A/C/E) were 
performed to assess the effects of parkin truncations with and without C-terminal YFP tags 
compared to wild type parkin in the presence of PINK1 or KD PINK1. Growth curves (B, 
D, and F) were performed by growing in inducing selective media at 30°C. OD
600
 
measurements were taken every 15 minutes and plotted to generate a growth curve. 
Standard deviations did not exceed a maximum OD
600
 = 0.02. At mid-log growth all 
samples were statistically different from the control with a P value ≤ 0.01 as determined 
from a One-way ANOVA  The constructs tested were; ● (Black) Vector, ■ (Green) 
PINK1/KD PINK1, PINK1/KD PINK1 with ▲ (Purple) Parkin/Parkin-YFP, ▼ (Blue) 
141C/141C-YFP, ♦ (Orange) 141-409/141-409-YFP, ● (Teal) 321C/321C-YFP, and ■ 
(Red) Ubl/Ubl-YFP. 
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Figure 3-14. Co-expression of parkin and PINK1 causes yeast cell death. (A) Western 
blot using 30µg total protein of cell extracts from W303 expressing parkin, parkin and 
PINK1-FLAG, or parkin and KD PINK1-FLAG were probed with an anti-parkin antibody. 
PGK1 was used to assess equal loading. (B) SYTOX Green cell death assay was used to 
assess cell death from the co-expression of parkin with wild-type or KD PINK1 based on 
the dye’s inability to enter live cells. After 8 hour of induction, cultures were incubated 
with SYTOX Green dye and emission was measured that was correlate to cell death. Values 
were corrected to culture density. Samples were run in triplicate, quantified, and graphed 
setting a boiled control to 100% cell death. Two, three, or four asterisks (**/***/****) 
indicate a statistical difference with a p value ≤ 0.05, ≤ 0.001, or ≤ 0.0001 respectively. 
Black – Vector; Green – Parkin; Purple – PINK1; Blue – PINK1 + Parkin; Orange – KD 
PINK1; Teal – KD PINK1 + Parkin; ■ Red – Boiled. 
89 
 
 
 
Figure 3 
 
-14 
  
90 
 
 
 
untagged counterparts. Co-expression of parkin and the parkin truncation variants with KD 
PINK1 were all non-toxic (Figure 3-13 E and F), suggesting that this toxic effect is 
dependent on the kinase activity of PINK1. We then ensured that wild-type (WT) and KD 
PINK1 were expressed properly in yeast. Western blots of yeast cell expressing WT or KD 
PINK1 in the absence and presence of parkin showed that PINK1 was stably expressed in 
yeast, but the KD mutant seemed to be expressed at lower levels than WT PINK1 (Figure 
3-14 A).  
To test whether the toxic effects caused by PINK1/parkin co-expression were based 
on growth inhibition or cell death, a SYTOX® Green based assay was used (Figure 3-14 
B). SYTOX® Green is a nuclear stain that is membrane impermeable and can only enter 
dead cells. As shown above (Figure 3-2 A and B and Figure 3-13 A and B), parkin and 
PINK1 independently cause mild growth defects. The SYTOX® assay revealed that this 
defect is actually cell death, each resulting in approximately 75% viability compared to the 
control. The co-expression of the two proteins caused even more cell death showing 
approximately 45% viability compared to the control. Given that parkin and PINK1 
independently cause about 25% cell death each, these results suggest that the amount of 
cell death caused by their co-expression is proportional to the combinatorial effects of the 
two. This contrasts our result seen in Figure 3-13 A and B in which PINK1/parkin toxicity 
appears to be synergistic, almost completely inhibiting growth. These findings would 
suggest that PINK1/parkin co-expression causes cell death while simultaneously inhibiting 
growth of viable yeast cells. As expected, expression of KD PINK1 causes no additional 
cell death compared to the control, but its co-expression with  
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Figure 3-15. PINK1 causes parkin accumulation in yeast. BY cells expressing parkin-
YFP or C-terminally YFP tagged parkin truncations in the absence (As shown above in 
Figure 3-8) and presence of (B) PINK1 or (C) KD PINK1. Cells were grown in inducing 
liquid inducing media for 8 hours and fluorescent images were captured using a Leica TCS 
SP5 II confocal microscope at 63x magnification. The scales bar represent 5µm.   
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parkin eliminated the cell death caused by parkin alone, suggesting that KD PINK1 protects 
yeast from parkin toxicity.  
We next performed fluorescent microscopy to test if PINK1 co-expression caused 
changes to parkin localization (Figure 3-15). The addition of PINK1 caused parkin-YFP 
to form subcellular aggregates and almost completely eliminated any diffuse parkin 
staining from the cytosol. Since 141C-YFP and 141-409-YFP already formed subcellular 
aggregates on their own, co-expression with PINK1 did not have an effect on their 
localization. 321C-YFP localization was also unaffected from the co-expression with 
PINK1 which is not surprising because PINK1 does not interact with or phosphorylate any 
residues within this parkin truncation. However, the co-expression of PINK1 did cause a 
subtle change to Ubl-YFP localization, causing the formation of extremely small 
fluorescent foci in a small number of cells.  
Since PINK1 caused such a significant change in parkin localization, we next tested 
if parkin aggregates caused by the introduction of PINK1 had amyloid-like biophysical 
properties, such as robust insolubility in the presence of potent detergents. To test this, 
semi-denaturing detergent agarose gel electrophoresis (SDD AGE) was used (Figure 3-
16). This technique utilizes mild lysis conditions in attempts to preserve subcellular 
aggregates. Protein samples are run through agarose with low sodium dodecyl sulfate 
(SDS) content, instead of polyacrylamide gel, where large amyloid-like complexes remain 
intact and run through the gel very slowly. This results in a high molecular weight species 
for insoluble, amyloid-like protein aggregates, as seen with the polyQ-expanded huntingtin 
protein (72Q) which was used as a positive control.  
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Figure 3-16. PINK1 induced parkin aggregates are not amyloid-like. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-16. PINK1 induced parkin aggregates are not amyloid-like. 30µg total protein 
of cell extracts from W303 expressing parkin, or parkin and PINK1 were resolved by semi-
denaturing detergent agarose gel electrophoresis (SDD AGE), transferred to nitrocellulose 
membranes via capillary force and expression of parkin was detected using 
immunodetection and imaged using infrared conjugated secondary antibodies. 25Q and 
72Q huntingtin lysates were used as controls to show non amyloid-like and amyloid-like 
aggregation respectively.  
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In contrast, soluble, non-amyloid-like proteins run migrate through the gel as a monomer 
and show a single band at the expected molecular weight, as seen with the non-expanded 
huntingtin protein (25Q) which was used as a negative control.  Despite testing several 
lysis and running conditions, as well as H2O2 treated parkin samples (data not shown), we 
did not detect amyloid-like protein aggregates composed of parkin in cells co-expressing 
parkin and PINK1.  
We next tested how point mutations within parkin would affect PINK1 induced 
growth phenotypes in yeast. Growth assays were performed using WT and KD PINK1 co-
expressed with the four parkin point mutants. All four of the point mutants showed 
significantly reduced toxicity compared to wild-type parkin (Figure 3-17 A and B). The 
results from spotting assays and growth curve assays were somewhat contradictory, as 
spotting assays performed on solid agar media showed strong reduction of toxicity (Figure 
3-17 A), whereas growth curves performed in liquid media showed that the point mutants, 
when co-expressed with PINK1, are still more toxic than PINK1 alone (Figure 3-17 B). 
This discrepancy might be caused by the different growth patterns of yeast in liquid and on 
solid media. Results from spotting assays typically represent a later time point in the yeast 
growth cycle where the point mutants co-expressed with PINK could have caught up to 
cells expressing PINK1 alone. In both cases, wild-type parkin was significantly more toxic 
than all of the point mutants when expressed with PINK1, implying that the interaction of 
PINK1 and parkin is altered by parkin point mutations. Again, co-expression of the point 
mutants with the KD PINK1 abolished all toxicity (Figure 3-17 C and D).  
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Figure 3-17. PINK1/parkin toxicity is rescued by parkin point mutations. W303 cells 
expressing PINK1-FLAG (A and B) or kinase dead (KD) PINK1-FLAG (C and D) and 
parkin point mutants (A, B, C, and D) were used to perform growth assays. Spotting assays 
(A/C) were performed by growing on selective inducing agar media to assess the effects of 
parkin truncations with and without C-terminal YFP tags compared to wild type parkin in 
the presence of PINK1 or KD PINK1. Growth curves (B and D) were performed by 
growing liquid cultures in inducing selective media at 30°C. OD
600
 measurements were 
taken every 15 minutes and plotted to generate a growth curve. Standard deviations did not 
exceed a maximum OD
600
 = 0.02. At mid-log growth all samples were statistically different 
from the control with a P value ≤ 0.05 as determined from a One-way ANOVA. Samples 
tested were; ● (Black) Vector, ■ (Green) PINK1/KD PINK1, PINK1/KD PINK1 with ▲ 
(Purple) Parkin,▼ (Blue) Parkin S65A, ♦ (Orange) Parkin S65E, ● (Teal) Parkin C289G, 
and ■ (Red) Parkin C418R. 
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Figure 3-17. 
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Figure 3-18. PINK1 mildly affects localization of mutant forms of parkin in yeast. BY 
cells expressing parkin-YFP or C-terminally YFP tagged parkin point mutants in the 
absence (As shown above in Figure 3-10) and presence of (B) PINK1 or (C) KD PINK1 
were grown in inducing liquid media for 8 hours and fluorescent images were captured 
using a Leica TCS SP5 II confocal microscope at 63x magnification. The scales bar 
represent 5 µm.  
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Figure 3-19. Parkin levels are decreased upon co-expression with PINK1 in yeast.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-19. Parkin levels are decreased upon co-expression with PINK1 in yeast. (A) 
30µg total protein of cell extracts from W303 expressing parkin or parkin and PINK1 were 
resolved by SDS-PAGE, transferred to nitrocellulose membranes and expression of parkin 
was detected using immunodetection and imaged using infrared conjugated secondary 
antibodies. (B) Parkin signal intensities from n=11 samples were measured and quantified 
relative to the PGK1 loading control and parkin levels in cells not co-expressing PINK1 
was set to 1. Means were compared using an unpaired T-test and two asterisks (**) 
indicates a statistical difference with a p value ≤ 0.001. PGK1 was used to assess equal 
loading. Black – Parkin; Green – PINK1 + Parkin.  
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Florescent microscopy was also performed with cells co-expressing the parkin 
point mutants and WT or KD PINK1 (Figure 3-18). We observed mild changes in the 
localization of parkin S65A and S65E mutants, which formed one to two puncta in a small 
proportion of cells. The drastically reduced effects on parkin localization caused by point 
mutations also suggest the PINK1/parkin interaction is modified by parkin point mutations. 
While testing the effects of co-expressing parkin and PINK1, we noticed that the 
levels of parkin being expressed in the presence of PINK1 seemed to be reduced compared 
to cells expressing parkin alone. Western blots were performed with protein lysates from 
yeast cells expressing parkin and co-expressing parkin and PINK1 using different 
combinations of protease inhibitors, and run in the presence and absence of reducing agents 
(Figure 3-19 A). The levels of parkin in cells co-expressing parkin and PINK1 were 
reduced by almost two and a half fold compared to cells expressing parkin alone (Figure 
3-19 B).  
3.6.2 Co-expression of PINK1 and Parkin in Mammalian Cells 
Since the expression of wild type parkin with PINK1 had the most drastic effects 
in yeast, we decided to focus on this interaction in mammalian cells. HeLa cells transfected 
with parkin, co-transfected with parkin and PINK1, or co-transfected parkin and KD 
PINK1 were analyzed for parkin localization and stability (Figure 3-20). 
Immunofluorescence microscopy revealed that the co-expression of parkin with WT 
PINK1 caused no changes in parkin localization, as parkin staining remained diffuse 
(Figure 3-20 A). This result is consistent with the literature which shows that cells 
endogenously expressing parkin and PINK1 do not show altered parkin localization 
102 
 
 
 
Figure 3-20. Co-expression of PINK1/parkin in HeLa cells. HeLa cells transiently 
transfected with parkin, parkin and PINK1, or parkin and kinase-dead (KD) PINK1 were 
used to assess the affects PINK1 on parkin localization and stability in mammalian cells. 
After transfection, cells were given 24 hours to recover in full media before further 
treatment. (A) Transfected HeLa cells were passaged to 8 chamber microscopy slides and 
prepared for immunofluorescence imaging. Parkin was visualized using an AlexaFluor-488 
conjugated secondary antibody and nuclei were stained with DAPI. Images were captured 
a Zeiss Axio Vert A1 Inverted fluorescent microscope using a 40x objective. Scale bars 
represent 10µm. Parkin is shown in green and nuclei are shown in blue. (B) Cell lysates of 
HeLa transfected with the indicated constructs were used for Western blotting detecting 
parkin and tubulin as a loading control (C) Parkin signal intensities were measured and 
quantified relative to the tubulin loading control and graphed. Parkin levels in non-co-
transfected cells was set to 1. Means were compared using a one-way ANOVA. Black – 
Parkin; Green – PINK1 + Parkin; Purple – KD PINK1 + Parkin.  
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Figure 3-20. 
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unless they are treated with the mitochondrial uncoupling agent CCCP (83) which causes 
the production of excessive amounts of ROS. Western blots were performed with lysates 
from these cells and quantification yet again revealed no changes in response to co-
expression of parkin and PINK1 (Figure 3-20 B and C). 
Our next goal was to test whether PINK1/parkin co-expression caused toxicity in 
mammalian cells. For these experiments, both HeLa and HEK 293 cell lines were used. 
Initially, HeLa cells were transfected with all possible combinations of parkin, wild-type 
PINK1 and KD PINK1. Following the transfection period, cells were given 24 hours to 
recover in full media (10% FBS and 4.5 g/L glucose) before testing cell viability (Figure 
3-21 A). We observed no significant difference in cell viability for any combination of 
proteins. We speculated that the 24 hour recovery period was not long enough for the cells 
to accumulate sufficient amounts of the toxic species potentially caused by co-expressing 
PINK1 and parkin. To test this, HeLa cells were transfected with the same combination of 
proteins, but following the transfection period, cells were given four days to recover in 
either full media or minimal media (1% FBS and 1 g/L glucose) (Figure 3-21 B). 
Incubating cells in minimal media reduces their division rate and could allow for more 
accumulation of a toxic species.  
Yet again, the co-expression of PINK1 and parkin was not detrimental to cell 
viability, but in fact, had the highest cell viability in both the full and minimal media 
recovery conditions. This would suggest that the co-expression of PINK1 and parkin 
actually plays a protective role in mammalian cells. Lastly, HEK 293 cells stably  
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Figure 3-21. PINK1 and parkin co-expression in mammalian cells is non-toxic. (A) 
HeLa cells transiently transfected with all permutations of parkin, PINK1, kinase dead 
(KD) PINK1, and GFP as a control were given 24 hours to recover in full media (4.5 g/L 
glucose and 10% FBS) before analyzing cell viability using an ATP based luminescence 
assay. (B) HeLa cells transfected in an identical manner as in A were given four days to 
recover in either full media or minimal media (1 g/L glucose and 1% FBS) before analyzing 
cell viability using an ATP based luminescence assay. (C) HEK 293 cells stably expressing 
FLAG-parkin were transfected with vectors for PINK1 or KD PINK1 expression and given 
four days to recover in either full media or minimal media before analyzing cell viability 
using an ATP based luminescence assay. For all data sets samples were run in triplicate, 
quantified and graphed. Means were compared using a one-way ANOVA. One, two, three, 
or four asterisks (*/**/***/****) indicates a statistical difference with a p value ≤ 0.05, ≤ 
0.01, ≤ 0.001, or ≤ 0.0001 respectively. Black – No DNA; Green – GFP; Purple – Parkin; 
Blue – PINK1; Orange – PINK1 + Parkin; Teal – KD PINK1; Red – KD PINK1 + Parkin. 
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expressing FLAG-parkin were used to test how cells that are constantly expressing parkin 
are affected by the introduction of PINK1. Again cells were transfected to combine parkin 
expression with wild-type or KD PINK1 and allowed to recover for four days in full or 
minimal media (Figure 3-21 C). Again, cells expressing parkin and PINK1 were equally 
as viable as cells co-expressing parkin and KD PINK1, suggesting that the co-expression 
of parkin and PINK1 does not exhibit the same toxicity in mammalian cells as it does in 
yeast. These results suggest that the changes in parkin localization and stability caused by 
PINK1 are yeast-specific and could be due to their inability to cope with phospho-parkin 
as they do not inherently express orthologues of either of these two proteins. 
3.7 Parkin Proteolysis and Degradation in Yeast 
Throughout our investigations, we noticed that Western blots of parkin expressing 
yeast lysates showed multiple highly reproducible bands of a lower molecular weight than 
the expected 52 kDa size of the full-length protein. These additional banding patterns also 
seemed to be specific depending on the epitope of the 1° antibody used (Figure 3-22 B). 
When using the α-Ubl antibody (Figure 3-22 B panel 3) or the α-Rcat/RING2 antibody 
(Figure 3-22 B panel 1), which correspond to the most N and C-terminal domains of 
parkin, respectively, multiple bands were visualized between the range of 50 and 10 kDa 
with an additional band of high intensity running close to the dye front at around 5-10 kDa. 
Alternatively, using an α-RING1 antibody (Figure 3-22 B panel 2), which is specific to a 
domain near the middle of parkin, showed fewer low molecular weight bands, and instead, 
showed two to three bands greater than 25 kDa. Given that these bands were clearly  
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Figure 3-22. Parkin is degraded into distinct proteolytic fragments in vivo. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-22. Parkin is degraded into distinct proteolytic fragments in vivo. (A) 
Schematic representation of parkin and its domains. (B) Thirty µg total protein of cell 
extracts from wild type W303 and W303 expressing parkin were analyzed by Western-
blotting using three different primary antibodies with epitopes specific for distinct regions 
of parkin. (C) To assess if proteolytic cleavage products were being produced during or 
after cell lysis an alternate technique was used to prepare cell lysates. One W303 culture 
expressing parkin was equally split and lysed using two different techniques. The left lane 
used the standard glass bead lysis technique where cell are lysed in the presence of multiple 
different protease inhibitor. The right panel was lysed by boiling in a NaOH based lysis 
buffer and loading directly to the gel following neutralization, which does not allow post-
lysis proteolysis. After lysis samples were resolved by SDS-PAGE and imaged in an 
identical manner as described in B.   
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parkin specific as they did not appear in wild type yeast cells, we believe that parkin is 
naturally undergoing proteolytic cleavage in vivo. To eliminate the possibility that this 
cleavage was occurring after lysis of the yeast cells, a NaOH based lysis technique was 
used, where cells were boiled in a NaOH based buffer, which would immediately denature 
all proteins and deactivate all proteases. After boiling, the samples were pH-neutralized 
and loaded directly into acrylamide gels, where they were resolved by SDS-PAGE next to 
a lysate that was prepared by glass bead lysis with protease inhibitors in the buffer (Figure 
3-22 C). Western blots of these samples showed nearly identical size bands at 
approximately 30, 25 and 10 kDa in both lysates, suggesting that this proteolytic cleavage 
is occurring pre-lysis.  
Next we tested if parkin was degraded in yeast cells by the 26S proteasome. 
Because yeast efficiently export many small molecules, including the proteasome inhibitor 
MG132, a yeast strain with deletions of the genes encoding PDR1 and PDR3, cell 
membrane transport proteins, were used to allow effective proteasome inhibition by 
MG132. Δpdr1,3 yeast cells transformed with parkin were grown in inducing liquid media 
for ten hours to allow for parkin accumulation. Then expression of the galactose inducible 
GAL1 parkin promoter was quenched with the addition of glucose to a final concentration 
of 2%. Simultaneously, samples were treated with either 50 µM MG132 to inhibit 26S 
proteasome dependent degradation or an equivalent volume of dimethyl sulfoxide (DMSO) 
as a control. Aliquots of the cultures were taken every four hours for twelve hours. Western 
blots were performed with these lysates and parkin levels were quantified relative to PGK1, 
which is a highly abundant stable protein in yeast. After setting the values of parkin at time  
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Figure 3-23. Inhibiting the 26S proteasome increases parkin stability in yeast. (A) 
After 8 hours of induction in selective media W303 Δpdr1,3 cells expressing parkin were 
washed twice in sterile water and resuspended in non-inducing selective media (to prevent 
further parkin expression) with either 50 µM MG132 or an equivalent volume of DMSO 
added. Aliquots of the cultures were taken every four hours for twelve hours. (C) Cultured 
HEK 293 cells stably expressing FLAG-parkin and (D) SH-SY5Y cells expressing 
endogenous parkin were treated with cycloheximide (Cx) and DMSO or 10 µM MG132. 
Similar to the technique described in panel A, samples were harvested at various time 
points and frozen until all time points had been collected. (B/C/D) samples were lysed and 
30 µg of total protein was resolved by Western blotting for parkin (B) Samples were run in 
triplicate and parkin levels were quantified and normalized relative to the PGK1 loading 
control. (C and D) Sample were run in triplicate and parkin levels were quantified without 
normalization to a loading control. (B, C, and D) Parkin levels were independently set to 1 
at time zero for the DMSO and MG132 treated samples. Means of the same time points 
were compared using a two-way ANOVA. Three or four asterisks (***/****) represent 
statistically significant differences with a p value ≤ 0.001 or ≤ 0.0001 respectively. Black 
– DMSO treated; Green – MG132 treated. 
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Figure 3-23. 
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0 to 100%, the relative parkin intensities showed a decrease in overall parkin over the 
course of 12 hour for both the MG132 and DMSO treated controls, with significantly less 
degradation in the MG132 treated samples (Figure 3-23 A and B). After twelve hours 
about 30% of the original parkin remained in control cells whereas MG132 treated cells 
retained nearly double the amount of parkin. In these experiments only the predominant 
band representing the full length protein was quantified, although samples did exhibit lower 
molecular weight bands as described in Figure 3-22 as well as high molecular weight 
smears that could represent poly-ubiquitinated parkin (data not shown). These data suggest 
that in yeast grown under normal conditions, parkin undergoes significant proteasome-
dependent degradation. 
Similar experiments were performed with HEK 293 cells stably expressing FLAG-
parkin and SH-SY5Y cells expressing endogenous parkin. In these systems expression of 
all proteins was quenched using cycloheximide and samples were again treated with either 
MG132 or DMSO as a control (Figure 3-23 C and D). Cells were followed for either 16 
or 20 hours before lysis and Western blotting. The results showed no statistical difference 
between MG132-treated or untreated samples in either cell line. 
We next tested the effect on proteasome inhibition on parkin degradation without 
inhibiting protein expression. HeLa cells transfected with parkin-expressing vectors were 
treated to test the effects of decreased protein degradation. Following treatment with 10 
µM MG132 for 8 hours, proteins were extracted, and parkin stability was analyzed by 
Western blotting. We noticed an increase in parkin levels in MG132 treated cells compared 
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to untreated controls (Figure 3-24 A and B). This result indicates that transfected parkin 
is degraded by the 26S proteasome in HeLa cells.  
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Figure 3-24. Parkin stability is mildly increased by MG132 in Hela cells. 
 
 
 
 
 
 
 
 
 
Figure 3-24. Parkin stability is mildly increased by MG132 in Hela cells. Cell lysates 
of HeLa cells transfected with parkin were analyzed by Western blotting (A) to detect 
parkin. (B) Steady state levels of parkin were compared to cells treated with MG132 and 
parkin levels were quantified relative to the tubulin loading control. Parkin levels in 
untreated cells was set to 1. Means were compared using an unpaired T-test and an asterisk 
(*) indicates a statistical difference with a p value ≤ 0.05. Tubulin was used to assess equal 
loading. Black – untreated; Green – MG132 treated.  
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Chapter Four: Discussion 
4.1 Introduction – Parkin in PD 
The E3 ubiquitin ligase parkin is essential for maintaining neuronal health in the 
substantia nigra and the dysfunction of parkin has been associated with familial and 
sporadic forms of PD (139). Parkin prevents the accumulation of damaged cellular 
proteins, particularly mitochondrial proteins, thus regulating the homeostasis of 
mitochondria, and consequently diminishing oxidative stress caused by ROS (140). 
PINK1, a serine/threonine kinase, has been implicated as a key regulator of parkin through 
two interrelated mechanisms: PINK1-mediated phosphorylation of parkin and PINK1-
mediated phosphorylation of ubiquitin, which activates parkin (77, 78). In addition to 
insufficient phosphorylation of parkin by PINK1, damage to parkin by oxidative stress, 
loss of function mutations, and gain of function mutations resulting in parkin misfolding 
have also been associated with parkin dysfunction in PD (114, 139, 141, 142). Yet the 
cellular and molecular mechanisms by which parkin damage and misfolding contribute to 
PD remain poorly understood.  
The overall goal of this thesis was to decipher how parkin regulation by 
PINK1, parkin misfolding and subsequent stress on the cellular protein quality 
control machinery, and oxidative damage to parkin contribute to parkin 
dysregulation and dysfunction in PD. 
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4.2 Summary of Findings and Significance 
4.2.1 Sequence Analysis 
Analysis of parkin’s amino acid sequence demonstrated that the structurally and 
functionally determined catalytic triad consisting of C431, H433, and E444 located in 
parkin’s Rcat/RING2 domain (112) is highly conserved across multiple different 
evolutionary distant species (Figure 3-1). Importantly, this analysis also revealed an 
unusually high level of conserved cysteine residues throughout the entire parkin protein 
with the exception of the N-terminal Ubl domain that contains only one cysteine. Thirty 
five of human parkin’s 465 total amino acid residues are cysteines, giving it an overall 
cysteine content of 7.52%, which is nearly three times higher than the average for other 
human proteins (2.26% according to (7)). Structural studies have determined that 28 of 
these cysteine residues are required for coordination of eight Zn2+ ions in four distinct 
parkin domains (59). Accordingly, Zn2+ coordination does not account for all 31 of the 
conserved cysteines within parkin.  
Cysteine residues are inherently sensitive to oxidative and nitrogenous 
modifications, and they can be essential for sensing and regulating levels of stress-inducing 
chemicals in the cell.  For example, the Kelch-like ECH-associated protein 1 (Keap1) is an 
oxidative stress sensing protein that regulates the transcription factor Nuclear factor 
(erythroid-derived 2)-like 2 (Nrf2, (143)). Under normal cellular conditions Keap1 
facilitates ubiquitination of Nrf2 in the cytosol, thus inducing rapid degradation of Nrf2. 
This prevents Nrf2 from entering the nucleus where it is transcriptionally active (143). 
Under condition of oxidative stress, C151 of Keap1 is oxidatively modified, causing a 
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conformational shift that releases Nrf2 and allows it to enter the nucleus and promote 
transcription of antioxidant genes.   
Increased oxidative stress is a hallmark of PD (144, 145) and is closely associated 
with cellular damage. Additionally, oxidative stress induced by CCCP-mediated 
uncoupling of the electron transport chain causes a change in parkin localization, recruiting 
it to the mitochondria to activate its role in mitophagy (76, 78, 81). Also, Chung et al. have 
shown that parkin can be S-nitrosylated by nitric oxide (NO) and that this modification 
reduces its activity (146). In a similar manner, parkin could be modified in response to 
increased levels of oxidative stress, diminishing its E3 activity. A decrease in parkin 
activity could result in an increased load on the protein quality control machinery and 
activate one of many protective cellular stress responses programs.  
In essence, parkin could act as a cellular sensor to detect and preemptively respond 
to oxidative stress and activate an anti-oxidant response. However, no previous studies 
have directly addressed oxidative damage to parkin and its ensuing misfolding. This would 
present a previously unknown function of parkin in stress homeostasis and in PD. 
4.2.2 Parkin Yeast Model  
Following successful examples of PD yeast models in the literature (99–109), we 
established a parkin yeast model, which we used as an experimental platform for further 
experimentation (Figure 3-2). In our model, parkin was diffusely localized throughout the 
yeast cytosol as previously observed in mammalian cells, including human neurons (113, 
114, 147). We also showed that parkin is stably expressed and that it only slightly decreased 
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the growth rate of yeast. This effect can be attributed specifically to expression of parkin 
since expression of a similar sized protein in yeast does not inhibit growth (Appendix 5).    
4.2.3 Genetic Interactions of Parkin  
Using our parkin yeast model, we performed a small scale genetic screen with 17 
yeast deletion strains deficient in genes required for oxidative stress management and 
protein quality control to unravel genetic interactions with parkin (Figure 3-3). In this 
screen one gene deletion (SGT2) was identified that significantly altered parkin 
localization and two gene deletions (YAP1 and BTN2) were identified that significantly 
reduced growth of yeast cells expressing parkin.  Notably, only one gene deletion (SOD2) 
altered both parkin localization and reduced the growth of cells expressing parkin 
simultaneously.  
Deletion of SOD2, encoding the mitochondrial superoxide dismutase, which 
prevents the accumulation of superoxide radicals, does not have a growth phenotype under 
regular conditions. Yet the expression of parkin caused a significant reduction in the 
growth rate of SOD2 deleted yeast. SOD2 deletion also altered parkin localization, causing 
small subcellular inclusions of parkin in addition to the diffuse localization pattern 
observed in wild-type cells. This result supports our idea that parkin acts as an oxidative 
stress sensor. The yeast SOD2 deletion strain accumulates excessive amounts of ROS 
(148), which may oxidatively damage parkin, result in parkin misfolding, and alter parkin’s 
subcellular localization, thus inhibiting growth.  
In order to confirm that these changes are indeed a result of increased levels of 
ROS, future experiments would need to test for increased levels of ROS and compare these 
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results to wild-type cells and cells exposed to chemically-induced oxidative stress. If parkin 
were properly functioning in wild-type yeast cells to degrade damaged proteins, the 
increase in ROS may modify parkin causing its aggregation, thereby inhibiting its 
protective function. This decrease in protective parkin activity could cause an increased 
burden on the protein quality control machinery, leading to growth inhibition.  
Alternatively, the rise in ROS levels may not damage parkin itself. Instead, ROS 
may modify and damage other cellular proteins, increasing the number of proteins that 
require processing and degradation. The juxtaneuclear quality-control compartment 
(JUNQ) and perivacuolar insoluble protein deposit (IPOD) were first described by 
Kaganovich et. al in yeast as intracellular compartments that sequester misfolded cytosolic 
proteins (33). This research showed that when ubiquitinated, soluble misfolded proteins 
are directed to JUNQ, which contains a high concentration of proteasomes. JUNQ has been 
described as a site where misfolded proteins are sequestered when proteasome activity is 
impaired, often in response to cellular stress including heat shock. Following recovery from 
stress conditions, proteins sequestered to JUNQ can either be refolded via molecular 
chaperones or degraded by the proteasome. In contrast, proteins that were not ubiquitinated 
were directed to IPOD which is speculated to permanently sequester toxic amyloid-like 
proteins, thus preventing their toxic interaction with cytosolic proteins. 
 In the SOD2 deletion strain, parkin may be recruited to areas with increased need 
for UPS activity, like JUNQ, which would account for our observation of subcellular 
puncta with some remaining diffuse signal. In this scenario, an increased burden on the 
protein quality control machinery could also prevent normal growth by directing more 
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resources towards eliminating damaged proteins. Whether parkin or other cellular proteins 
are damaged by ROS in the SOD2 deletion strain, our data suggest that parkin responds to 
increased ROS in the cell. The relationship between SOD2 and parkin has not been 
thoroughly characterized in the literature but our findings present an enticing basis to 
further study this genetic interaction.    
Deletion of YAP1, and deletion of BTN2 both caused a decrease in growth rate of 
yeast cell expressing parkin compared to wild-type cells, yet neither deletion caused a 
change in parkin localization. Yap1 encodes a transcription factor required for oxidative 
stress tolerance (117) and BTN2 encodes a v-SNARE binding protein that facilities protein 
retrieval from the late endosome to the Golgi and contributes to prion curling (118). 
Decreased growth in the YAP1 deletion strain closely relates to the effects of the SOD2 
deletion strain, in that an inadequate cellular response to oxidative stress causes parkin-
related growth defects. This further supports the notion that oxidative stress is a major 
contributor to parkin modification.  
Our data for the BTN2 deletion, however, suggests a role of parkin associated with 
inadequate protein quality control beyond oxidative stress. Yeast deficient in BTN2 show 
increased propensity to accumulate prions (149), and have altered protein trafficking and 
localization. Therefore parkin toxicity in the BTN2 deletion strain could imply that parkin’s 
E3 activity is required to degrade accumulating prion proteins. Here, an increased burden 
on the protein quality control machinery caused by increased UPS activity of parkin could 
induce cellular stress and inhibit growth.  
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This may seem counter-intuitive as it is also plausible that parkin expression in 
these cells would eliminate prion accumulation, thus playing a protective role. The 
accumulation of potentially toxic proteins, such as prions, into benign aggregates has been 
suggested to prevent additional damage to the cell (33). It is possible that parkin 
ubiquitinates the sequestered prions and releases them into the cell, causing toxicity and 
inhibiting growth. This could be tested by assessing parkin ubiquitination activity on prion 
or prion-like proteins in the absence of BTN2 in future experiments. 
Finally, deletion of SGT2, encoding a cytoplasmic HSP90 co-chaperone required 
to mediate post-translational insertion of tail-anchored proteins into the ER membrane 
(119), altered parkin localization. In this strain, we observed the formation of large puncta 
in addition to diffuse cytosolic parkin staining. Without SGT2, yeast cells may accumulate 
unprocessed proteins in the cytosol that normally require processing and insertion into the 
ER membrane. The observed change in parkin localization suggests that parkin is recruited 
to areas of the cell with an increased need for protein degradation, including JUNQ as 
described above, and may play a protective role to eliminate damaged or misfolded proteins 
and prevent cell damage. Notably, SGT2 deletion strains do not exhibit decreased growth 
in the absence of parkin, even though they have impaired insertion of tail-anchored proteins 
into the ER membrane. Apparently, the cellular protein quality control machinery 
adequately processes these mislocalized proteins and prevent growth defects. The 
expression of parkin in this strain may act as an additional support for UPS-mediated 
degradation of mislocalized proteins and therefore alters parkin localization without 
causing toxicity.  
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Figure 4-1. Parkin genetic interaction network. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-1. Parkin genetic interaction network. Network of genetic interactions of 
parkin showing two degrees of separation. Genetic interactions with parkin identified in 
this thesis are shown in blue and previously established genetic associations with 
interactors of parkin are shown in yellow.  
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To test this concept, we would need to examine parkin expression in a SGT2 
deletion strain that has additional gene deletions of yeast E3 ligases or other genes involved 
in protein turnover and UPS. If parkin expression in these cells rescues growth defects 
caused by the buildup of misfolded proteins, it will support our claim that parkin is essential 
for protein folding homeostasis.    
 Overall, our pilot screen identified interesting and rather unexpected genetic 
interactions with parkin that implicate a role for parkin in both oxidative stress management 
and protein quality control as shown in Figure 4-1. Importantly, this provides a strong 
rationale to proceed with large scale genetic screens using deletion and over-expression 
libraries encompassing the entire yeast genome. This will further elucidate the parkin 
interaction network and identify previously unknown roles for parkin and potential 
therapeutic targets for treating PD. This is supported by previous findings from large scale 
genetic screens that identified toxic modifiers of mutant Htt and α-synuclein in yeast (150). 
4.2.4 Oxidative Damage to Parkin 
We next assessed the state of parkin oxidation. When performing Western blots on 
cellular protein lysates, the convention is to use reducing conditions (151). Although this 
often improves the quality and analyses of results, artificially reducing proteins eliminates 
oxidative modifications to proteins (151). In Figure 3-4, we compared protein lysates of 
yeast and mammalian cells prepared in reducing and non-reducing conditions by Western 
blot. We found that, under non-reducing conditions, parkin migrates in SDS-PAGE at a 
faster rate and produces a less defined signal. This suggests the presence of intramolecular 
disulfide formation between any of the 35 cysteine residues within parkin.  
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Furthermore, we observed a large shift in the apparent molecular weight of parkin 
expressed in HeLa and HEK293, and to a lesser extent in SH-SY5Y cells (Figure 3-4 B). 
In these experiments, unmodified SH-SY5Y cells were used to analyze endogenous levels 
of parkin, whereas HeLa and HEK293 cells used constitutively expressed transfected 
parkin at higher levels, as indicated by the strong signal intensity. Excess parkin 
accumulation caused by constitutive over-expression in HeLa and HEK293 cells may not 
be turned over as efficiently as lower levels of endogenous parkin in SH-SY5Y. As a result, 
excess parkin may be subjected to increased oxidative damage, thus increasing the number 
of disulfides formed and enhancing the shift in molecular weight seen in non-reducing 
Western blots for HeLa and HEK293 cells. 
To further test the effects of parkin oxidation, we performed experiments in yeast 
with the addition of stress inducing chemicals to mimic the conditions potentially found in 
aging and PD patient cells (Figures 3-5, 3-6 and 3-7). We found that treatment with H2O2 
and AZC elicited drastic changes in parkin localization causing the formation of multiple 
small puncta throughout cells. Treatment with these chemicals thus resembled aberrant 
parkin localization as observed in our pilot yeast deletion screen (Figure 3-4). H2O2 
treatment is reminiscent of the oxidative stress in the SOD2 deletion strain as both caused 
the accumulation of parkin. Furthermore, impaired protein folding by AZC treatment and 
the ensuing induction of the heat shock response (152) mimic the effects of SGT2 deletion 
which lead to increased levels of damaged or misfolded proteins which also affects parkin 
localization.  
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Both AZC and H2O2 altered parkin localization, which suggests that different types 
of cellular stress conditions affect the cellular localization and accumulation of parkin. 
Also, treatment with H2O2 and AZC generally causes the accumulation and mislocalization 
of damaged and misfolded proteins, which may recruit a significant proportion of parkin. 
Alternatively, stress treatment could cause damage to parkin itself, leading to its 
sequestration for processing by molecular chaperones or the protein degradation 
machinery. However, Western blot analysis did not reveal any significant change in parkin 
migration patterns in the presence of H2O2 and other stress inducing chemicals (Figure 3-
6), which does not clarify whether parkin is directly modified as a result of chemical stress. 
Further experiments will be required to decipher whether these chemicals are indeed 
modifying parkin itself or whether they indirectly affect parkin localization in yeast. The 
use of antibodies that specifically recognize oxidatively modified cysteine residues could 
clarify if parkin directly undergoes oxidative modification.   
Growth curve assays in the presence of increasing concentrations H2O2 in yeast 
were used to elucidate a role of parkin under high levels of oxidative stress (Figure 3-5 B). 
Only at a concentration of 1 mM did the addition H2O2 have an effect on cell growth. At 
this concentration, H2O2 caused a delayed entry in logarithmic growth phase and caused 
slower growth during exponential growth phase. Although cell growth was affected by the 
increased H2O2 concentration, the difference between wild-type cells and cells expressing 
parkin was unaffected compared to untreated cells, suggesting that parkin is neither playing 
a protective nor a detrimental role in the presence of H2O2 in yeast. 
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We performed similar experiments in HeLa cells where H2O2, AZC, and other 
stress inducing chemicals were added before assessing parkin localization by 
immunofluorescence microscopy and parkin modification via Western blot (Figure 3-7). 
None of these stress treatments showed changes in parkin localization or migration 
compared to untreated cells. Although they are derived from human cells, the rapid rate of 
division of HeLa cells may act to effectively dilute toxic misfolded proteins induced by 
chemical stress, thus preventing changes to parkin localization or oxidative modification.  
4.2.5 Parkin Mutants and Truncations Alter Parkin Localization 
We used several truncation variants of parkin and specific parkin point mutants 
(Figure 1-6) to study the effect of parkin misfolding and map these effects to specific 
parkin domains. When expressed in wild-type yeast cells, none of the parkin variants or 
point mutants had any effect on cell growth. Furthermore, expression of the parkin S65A 
and S65E mutants as well as the 321C parkin variant did not alter parkin localization. 
Several parkin variants did, however, cause drastic changes in parkin localization and 
stability (Figures 3-8, 3-9, 3-10, and 3-11).  
The AR-JP causing C289G and C418R mutants affecting residues required for Zn2+ 
coordination caused parkin to accumulate into subcellular foci (Figure 3-10) as shown 
previously (71). This change in parkin localization was similar to changes observed upon 
treatment with AZC and H2O2, and the SOD2 and SGT2 gene deletions from our pilot 
screen, where parkin formed multiple small inclusions while additionally maintaining 
some diffuse cytosolic localization. Expressing the overactive 141C mutant (Figure 3-8) 
also showed a similar localization pattern. The C289G and C418R mutants are structurally 
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unstable and misfold and thus may form aggregates. However, our Western blot analysis 
revealed that these mutants were expressed at the same level as wild-type parkin, which 
would suggest that they are not being degraded more than wild-type parkin. These mutants 
might simply relocate to specific subcellular locations, such as IPOD or JUNQ, to prevent 
their interference with normal cellular functions as discussed in section 4.2.3. 
 In contrast, the 141-409 mutant caused a more drastic change to parkin 
localization. Truncation of both the Ubl and Rcat/RING2 domains eliminated all diffused 
cytosolic parkin, and instead, caused parkin to form either two to three larger, or multiple 
smaller puncta. Evidently, the regulation of parkin by the Ubl domain and linker alters its 
localization as shown with the 141C variant.  The additional truncation of the Rcat/RING2 
domain in the 141-409 parkin variant, however, seems to further decrease parkin stability. 
This effect may be caused by the loss of the two structurally required Zn2+ ions found in 
the Rcat/RING2 domain, or destabilization of the entire C-terminus of parkin since 
Rcat/RING2 is adjacent to the RING0 domain when properly folded  (63).  
Our experiments did not directly test the solubility of these parkin aggregates. 
Future work should therefore include experiments that directly assess the solubility of 
parkin and its mutants, which could determine whether parkin mutations and truncations 
form insoluble protein aggregates or if they simply change parkin localization. These 
experiments will include Triton X-100 based solubility assays that can differentiate 
between soluble and insoluble fractions of cell lysates (153). 
 We selected only the 141C variant and the four point mutants for our experiments 
in HeLa cells (Figure 3-12). Localization studies showed that neither S65A nor S65E 
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parkin mutants altered parkin localization, but the AR-JP causing C289G and C418R 
mutants formed subcellular inclusions while maintaining some diffuse cytosolic 
localization. Western blots showed similar expression levels of the cysteine mutants 
compared to wild-type parkin. This supports our previous claim that these mutants are 
being sequestered to JUNQ-like compartments, and are not degraded as discussed in 
section 4.2.3.  
In contrast to the results seen in yeast, the N-terminal truncation of the Ubl domain 
and linker region in the 141C variant did not alter parkin localization in HeLa cells. Also, 
experiments testing the stability of 141C in mammalian cells similarly did not resemble 
our result in yeast. In Hela cells, 141C is expressed at approximately 50% of the level of 
wild-type parkin (Figure 3-12 B and C), whereas in yeast, 141C is expressed at nearly 
three times higher levels than wild-type parkin (Figure 3-9 B, C, D and E). Human cells 
endogenously express parkin, and likely contain pathways that require parkin activity. 
However, 141C is not normally expressed in mammalian cells and may therefore not be 
recognized and subsequently degraded. Alternatively, yeast cells do not endogenously 
express parkin or 141C, suggesting that they may be processed differently in yeast than in 
mammalian calls which could account for the difference in stability observed in these 
experiments. The discrepancies between our yeast and mammalian systems are further 
discussed below in section 4.3.1. 
4.2.6 PINK1 Modulates Parkin Localization and Toxicity  
The regulation of parkin by PINK1 has emerged as an important concept in parkin 
activation. Our next experiments addressed the PINK1-parkin interaction using our yeast 
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and mammalian cell models and we further characterized this interaction with parkin point 
mutants and parkin truncation variants.  
4.2.6.1 Co-expression of PINK1 and Parkin Truncation Variants Cause Toxicity in Yeast   
When expressed alone in yeast, human PINK1, containing a yeast-specific 
mitochondrial targeting sequence, exhibited a slightly more pronounced growth defect than 
that seen when expressing parkin alone (Figure 3-13 A and B). In contrast, the co-
expression of PINK1 and wild-type parkin caused a severe growth inhibition. Experiments 
with a kinase dead mutant form of PINK1 showed that this effect is dependent on the kinase 
activity of PINK1. Of all variants used in this study, only the wild-type parkin and the two 
cysteine mutants contain intact S65 and thus can be phosphorylated by PINK1. It was 
therefore unexpected to find that the co-expression of PINK1 with 141C also exhibited a 
severe growth inhibition that was only slightly less toxic than the co-expression of PINK1 
and wild-type parkin.  
Our results suggest that the toxicity caused by the co-expression of PINK1 and 
parkin can at least partially be attributed to PINK1-mediated parkin phosphorylation. Yet 
the toxicity observed from co-expression of PINK1 cannot be attributed to phosphorylation 
of 141C, since it lacks the PINK1 phosphorylation site located in parkin’s Ubl domain. 
Here, PINK1 may interact with and phosphorylate other proteins, which could be 
particularly toxic in yeast cells expressing 141C. 
PINK1 has previously been shown to phosphorylate not only parkin (81, 142), but 
also mitochondrial proteins including TOM20 and mitofusin (86, 87) and, importantly, 
ubiquitin. Additionally, it has been postulated that phospho-ubiquitin strongly contributes 
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to parkin activation (154). Given that the 141C variant that lacks the auto-inhibitory Ubl 
domain, phosphorylation of ubiquitin in yeast by PINK1 may act to even further activate 
141C. This may result in UPS overloading and cellular stress. Figure 4-2 presents a model 
for PINK1 activity that involves phosphorylation of ubiquitin, mitochondrial, and 
cytoplasmic proteins causing increased activity of the 141C variant leading to increased 
UPS activity and degradation of essential cellular proteins. This can explain the observed 
growth inhibition that occurred independently of PINK1-mediated phosphorylation of 
parkin. 
When co-expressing all of our parkin variants with PINK1, wild-type parkin, 141C 
and the independently expressed Ubl domain all exhibited PINK1-dependent changes in 
localization (Figure 3-15 B). Since PINK1 can phosphorylate ubiquitin and considering 
the structural similarity between the Ubl domain and ubiquitin, PINK1 may phosphorylate 
S65 of parkin’s Ubl domain, even when it is detached from the rest of parkin. The Ubl 
domain might thus mimic phospho-ubiquitin and its function in the UPS.  Only a fraction 
of the Ubl appears to be affected by PINK1 because the majority of the Ubl remains 
diffusely localized and small bright foci are formed in a small proportion of cells. 
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Figure 4-2. Model of PINK1-mediated increase of parkin ubiquitination activity in 
yeast causing toxicity. A) Under normal conditions, parkin or 141C is located in the 
cytosol and exhibits standard levels of ubiquitination activity. B) Following the 
introduction of PINK1 1) ubiquitin, 2) cytosolic proteins, or 3) mitochondrial proteins are 
phosphorylated by PINK1. 4) In response to 1, 2, or 3, parkin or 141C becomes overactive, 
which leads to 5) uncontrolled ubiquitination and 6) degradation of essential cellular 
proteins causing toxicity. 7) Alternatively, an increase in parkin activity increases parkin 
auto-ubiquitination leading to its degradation.  
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To test if parkin’s Ubl domain can at least partially function as ubiquitin future 
experiments could use yeast strains expressing Ubl in place of the standard ubiquitin fusion 
genes and test their viability. Yeast cells contain four genes encoding ubiquitin, and yeast 
cells remain viable when up to three of these genes are deleted. By deleting these ubiquitin 
fusion genes while simultaneously expressing parkin’s Ubl domain, we would be able to 
test cell viability and determine whether the Ubl domain can function in place of ubiquitin 
in yeast cells.     
When independently expressed in yeast, the 141C parkin variant exhibited an 
altered localization compared to wild-type parkin as we have previously discussed in 
section 4.2.5. However, when we co-expressed 141C with PINK1, the formation of 
subcellular 141C puncta was exacerbated, causing a decrease in the amount of diffusely 
localized protein. This finding supports our model presented in Figure 4-2 where PINK1 
increases the activity of the already overactive 141C variant of parkin indirectly by 
phosphorylating ubiquitin or other cellular proteins.   
Most parkin variants used here maintained some level of diffuse localization when 
expressed in yeast. The co-expression of PINK1, however, eliminated all diffuse wild-type 
parkin from the cytosol and formed similar puncta as seen with the 141-409 variant. In 
combination with the results from our growth assays, this could suggest that in the presence 
of PINK1, parkin is activated, as documented by several groups (142, 154–156). Yet parkin 
may also undergo a conformational change that causes its misfolding into a species that is 
toxic to the cell. Further testing would be required to determine the composition and 
structure of the parkin inclusions caused by its interaction with PINK1. 
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In addition, PINK1 expression could create phospho-ubiquitin in yeast. This could 
explain the toxicity associated with PINK1 expression, as yeast may not normally express 
a kinase that efficiently phosphorylates ubiquitin. Therefore phospho-ubiquitin may disturb 
UPS function and cause toxicity. In any case, the co-expression of parkin with PINK1 adds 
complexity to this scenario.  
We did not assess the presence of phospho-parkin or phospho-ubiquitin in our yeast 
model, but future work could clarify the cause of these significant changes in parkin 
localization and toxicity. Experiments to test the presence of phospho-parkin or phospho-
ubiquitin using phospho-specific antibodies in localization studies and Western blot could 
establish that PINK1 acts to phosphorylate parkin or ubiquitin in yeast. Co-
immunoprecipitation of parkin substrates while inhibiting protein degradation with 
proteasome inhibitor would be followed by Western blot analysis probing for ubiquitin and 
phospho-ubiquitin in the presence and absence of PINK1. These experiments would 
indicate if parkin activity is increased in the presence of PINK1, if phospho-ubiquitin is 
created by PINK1, and if phospho-ubiquitin is incorporated into poly-ubiquitin chains built 
on parkin substrates. 
Growth assays testing PINK1 co-expression with parkin-YFP supports our notion 
that PINK1 induces parkin misfolding. When co-expressing C-terminally YFP tagged 
wild-type parkin and parkin variants with PINK1, we observed similar toxicity as with 
untagged parkin and parkin variants co-expressed with PINK1. In all cases, the expression 
of YFP fusion forms of parkin reduced growth inhibition compared to untagged forms of 
the protein. Fluorescent protein fusions have been shown to increase the solubility of 
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normally insoluble proteins (157, 158) thus reducing the toxicity associated with protein 
misfolding. Our results suggest that PINK1 causes parkin to misfold and form a toxic 
insoluble species and subsequently the YFP fusion solubilizes parkin and reduces its 
toxicity.  
We also tested if parkin formed amyloid-like aggregates in yeast using SDD-AGE 
(Figure 3-16), yet our experiments showed that parkin does not form amyloid-like 
conformers. This does not, however, disprove that parkin misfolds and forms soluble 
aggregates. Future experiments will include sedimentation assays to assess if parkin 
changes its three-dimensional conformation or misfolds when co-expressed with PINK1, 
when mutated, or when exposed to stress conditions. 
4.2.6.2 Toxicity Associated with Co-expression of PINK1 and Parkin is Reduced by 
Parkin Point Mutations in Yeast 
As discussed above, the co-expression of PINK1 with parkin induced severe growth 
inhibition in yeast. However, when co-expressing our four parkin point mutants with 
PINK1, we observed a significant decrease in PINK1-parkin dependent toxicity that only 
slightly differed depending on the parkin mutant being expressed (Figure 3-17).  
The expression of all four point mutants caused similarly reduced levels of toxicity. 
However, the parkin S65E mutant, which to some extent mimics PINK1 phosphorylated 
parkin, caused a more severe growth defect than the other parkin point mutants, including 
the S65A mutant which cannot be phosphorylated by PINK1. This finding again may 
indicate that PINK1 alters parkin activity indirectly by phosphorylation of other cellular 
proteins including ubiquitin, which only additional experiments can clarify. 
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The increased toxicity caused by the phospho-mimic S65E parkin suggests that 
PINK1-mediated phosphorylation of parkin also contributes to parkin regulation. The use 
of aspartic and glutamic acid residues to mimic phosphorylation of proteins is a widely 
used technique but many studies have suggested that these substitutions can only partially 
recapitulate effects caused by phosphorylation (154, 159). The addition of a negatively 
charged residue mimics the effects of phosphate addition to a protein, but phosphate groups 
have a significantly a different shape than the carboxyl group of aspartic or glutamic acid 
residues. Additionally, phosphates carry two negative charges compared to the single 
negative charge on an acidic residue. These differences between phosphates and phospho-
mimics may explain the decreased toxicity caused by the expression of the S65E parkin 
mutant compared to PINK1 co-expression with wild-type parkin.    
The co-expression of the C289G and C418R parkin mutants with PINK1 also 
reduced toxicity compared to wild-type parkin. Although these parkin mutants still contain 
the S65 site of PINK1-directled phosphorylation and can be phosphorylated, they are 
structurally unstable (71). The misfolding of these parkin mutants caused by the loss of 
structurally required Zn2+ ions may cause a conformational shift that renders S65 partially 
inaccessible to PINK1 and prevent their phosphorylation. Alternatively, the structural 
instability of C289G and C418R may expose the Ubl domain to more efficient PINK-
mediated phosphorylation. In any case, C289G and C418R are loss of function mutations 
(57), suggesting that PINK1-mediated phosphorylation of these mutants or other cellular 
proteins do not have the capacity to affect their already compromised functional state. 
Phosphorylation of parkin and C289G and C418R, may induce parkin misfolding, which 
is toxic to yeast cells. This would account for the toxicity observed in these experiments 
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co-expressing PINK1 with C289G and C418R parkin. Additionally, this would explain part 
of the toxicity caused by co-expression of PINK1 with wild-type parkin as discussed in 
section 4.2.6.1.  
Co-expression of PINK1 (Figure 3-18) with C289G and C418R resulted in 
unaltered localization patterns. S65 parkin mutants exhibited slightly altered localization 
upon co-expression with PINK1, where both S65A and S65E parkin formed one or two 
small puncta in a small proportion of cells. Since neither of these S65 parkin mutants can 
be phosphorylated by PINK1, this suggests that the change in localization is due to the 
phosphorylation of ubiquitin to activate these parkin mutants and alter their localization.  
4.2.6.3 PINK1 Co-expression with Parkin in HeLa Cells Increases Viability 
Following these findings in yeast we performed similar localization and viability 
experiments in mammalian cells co-expressing wild-type parkin and PINK1. Neither 
toxicity associated with co-expression of PINK1 and parkin, nor changes in parkin 
localization were observed in HeLa cells. Viability assays showed an increase in cell 
viability by approximately 25% (Figure 3-21 B). These findings support the model 
currently accepted in the literature that parkin and its regulation by PINK1 are protective 
(88, 160, 161). As discussed in sections 4.2.5. and 4.3.1., the absence of endogenously 
expressed PINK1 and parkin and subsequent lack of processing or function in yeast may 
account for the discrepancies between our yeast and mammalian models.  
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4.2.7 Parkin Turnover and Degradation 
In some of our experiments, we showed that parkin undergoes oxidative 
modification in vivo. Additionally, our results suggested that parkin undergoes proteolytic 
degradation (Figure 3-22 B). We also determined that parkin is degraded in yeast via 
degradation by the UPS (Figure 3-23). We propose that parkin misfolding under normal 
conditions and, by extension, conditions of oxidative stress, affect parkin activity, stability, 
and misfolding.  
We also showed that when co-expressed with PINK1, parkin is less stable than 
when expressed alone in yeast (Figure 3-19). Similar experiments found that parkin 
stability was increased in HeLa cells following inhibition of the proteasome, albeit to a 
small extent. This suggests that parkin also undergoes proteasome-dependent degradation 
in mammalian cell but at a slower rate than in yeast. Future experiments could include 
testing the degradation and relative stability of the parkin point mutants and truncation 
variants used in this study to determine if AR-JP causing mutations can lead to altered 
parkin stability and potentially map which domains of parkin are essential for maintaining 
stability.    
Ultimately, more work is required to further clarify the involvement of the protein 
quality control machinery in parkin degradation, and if this contributes to PD pathogenesis. 
Nevertheless, these results give an interesting basis for studying parkin post-translational 
processing and degradation and its effects on protein function and longevity. 
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4.3 Experimental Limitations 
A thorough discussion of technical problems and limitations can be found in Appendix 1. 
4.3 Modelling Parkinson’s Disease in Yeast – Opportunities and Limitations 
Studying human proteins and diseases in model organisms is a commonly used 
strategy in biomedical research, but there are inherent limitations with every model system. 
During our investigation, we discovered several interesting results regarding parkin 
misfolding, altered localization, toxicity, degradation, and oxidative modification in our 
yeast model. Notably, most of these findings did not replicate in mammalian cells. Unlike 
human cells, yeast cells do not endogenously express parkin, PINK1, or related orthologues 
of either protein. This allowed us to monitor the effects of co-expressing these proteins in 
yeast using it as a simple living test tube. Our approach to studying parkin and PINK1 in 
yeast relied mainly on analyzing phenotypic changes caused by the expression of one or 
both of these proteins; these phenotypic analyses included changes in growth rate, protein 
localization, and levels of protein expression.  
One limitation of using yeast to study these proteins is that it is difficult to assess 
the functional state of parkin or PINK1 in vivo using these methods of analysis. It is 
possible that parkin expressed in yeast has altered function compared to parkin expressed 
in human cells. For example, parkin could have increased or decreased activity, or even be 
completely inactive. This could be due to differences is in the subcellular environment of 
yeast cells, which may render parkin unable to recognize substrates for ubiquitination. 
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Alternatively, yeast E2s may not interact with parkin, rendering it unable to carry out 
ubiquitination and protein degradation.  
It is also possible that the introduction of a non-native E3 to yeast disrupts normal 
cellular protein quality control and causes adverse effects. This circumstance seems 
unlikely, as expression of parkin alone did not noticeably affect yeast in any of our 
experiments. This could, however, occur upon co-expression of parkin with PINK which 
caused drastic changes to parkin toxicity, localization, stability, and potentially, activity.  
Nevertheless, without a bona fide parkin substrate, it is nearly impossible to definitively 
determine if parkin activity is altered in yeast.  
Similarly, it is difficult to assess the phosphorylation activity of PINK1 in yeast. In 
attempts to ensure normal PINK1 localization, a modified mitochondrial targeting 
sequence was used in our experiments to direct PINK1 to yeast mitochondria. Most 
evidence suggests that PINK1 predominantly acts to phosphorylate parkin or ubiquitin (88, 
142, 154, 155). PINK1 has also been shown to phosphorylate mitochondrial proteins such 
as TOM20 and mitofusin (86, 87). As discussed above, the foreign environment of yeast 
could expose PINK1 to different substrates and yeast mitochondrial proteins may not be 
recognized by PINK1, preventing their phosphorylation. All these scenarios may 
contribute to the toxic effects caused by the co-expression of PINK1 and parkin in yeast, 
which do not directly translate to human cells.  
Additionally, results from our yeast model may not have been replicated in 
mammalian system due to poor transfection efficiency. When optimizing transfection 
protocols, a GFP expressing plasmid was used to determine transfection efficiency, which 
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was calculated to be 68.7% based on fluorescence. However, when examining cells 
transfected with parkin in the presence or absence of PINK1, immunofluorescence showed 
an estimated 20-25% of cells expressing transfected parkin. Based on this low transfection 
efficiency, the lack of change to parkin localization and toxicity in the presence of PINK1 
could be due to an insufficient proportion of cells expressing the transfected proteins. As a 
result, any phenotypic changes potentially occurring would have been masked by the large 
majority of untransfected cells. 
Generally, the discrepancy observed between yeast and mammalian cells suggests 
that our results may not directly address how dysfunction of parkin and PINK1 cause cell 
death in human brain cells in PD. Nevertheless, our findings lead to a better understanding 
of the interactions of parkin and PINK1 and cellular processing of parkin. In future, it 
would be advantageous to expand other conditions established in our yeast model into 
mammalian cells, using the truncation variants and point mutants in attempts to 
characterize and map the PINK1/parkin related effects and perform structure-function 
analyses to assess misfolding altered the activity of PINK1 or parkin.   
4.4 Future Directions 
We have outlined several experiments above that will be completed in the future to 
address questions directly raised from our results. These experiments include: 1) 
characterizing the genetic interaction of parkin and SOD2, 2) assessing the ability of parkin 
to ubiquitinate prions or prion-like proteins, 3) expression of parkin in an SGT2 deletion 
strain containing additional deletions of yeast E3s to determine if parkin acts to assist 
normal yeast UPS, 4) perform large scale genetic screens with the entire yeast deletion and 
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overexpression libraries to elucidate previously undescribed genetic interactions of parkin 
and potentially, cellular functions, 5) test for direct oxidative modification of parkin, 6) 
determine the solubility and conformation of parkin puncta caused by mutations, 
truncations, oxidative stress, or co-expression with PINK1, 7) determine is parkin’s Ubl 
domain can function in place of ubiquitin in yeast, 8) perform assays to test the activity of 
PINK1 and parkin in yeast to determine their functional status, 9) test for the presence of 
phospho-ubiquitin in yeast and determine if is incorporated into K63 poly-ubiquitin chains 
build on substrates of the UPS, and 10) pulse-chase experiments to assess the degradation 
of parkin in mammalian cells.   
Looking beyond, expanding research on parkin oxidation, misfolding, and 
degradation into other model systems could be extremely advantageous for understanding 
these effects in humans. C. elegans has been used previously to study PD, in particular 
parkin (54–57), and their eight defined dopaminergic neurons present a simplistic system 
to study parkin activity in PD-relevant neuronal cell types. Fruit fly (D. melanogaster) 
models have also proven to be useful for studying PD given that there are several fruit fly 
models of PD genes, including parkin (166–170), and that the relationship of PINK1 and 
parkin was first studied in fruit flies (171). Rodent models may also be useful to study 
parkin degradation and altered localization in a complex brain system that can be used to 
study and compare different brain regions that have different levels of neuronal cell death 
in PD patients. Ultimately, studying these aspects of parkin regulation and modification in 
post mortem PD patient brain samples will help to determine if findings from these models 
translate into humans and can be attributed to parkin-mediated PD. 
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4.5 Significance 
The implication of parkin in both familial and idiopathic PD and the limited 
understanding of the mechanisms underlying parkin dysfunction in PD present a strong 
rationale for continued research on parkin oxidation, misfolding, and degradation. This 
thesis repeatedly provides evidence that oxidative stress, regulation by PINK1, protein 
misfolding, UPS-mediated degradation, and the protein quality control machinery work in 
tandem to regulate both parkin function and dysfunction. Future research based upon our 
findings and using our yeast model will further determine the underlying genetic, cellular, 
and molecular mechanisms by which parkin contributes to PD and may also establish 
parkin misfolding as a promising therapeutic target for PD treatment.   
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Appendices  
Appendix 1. Discussion of technical limitations. 
Immunofluorescence Microscopy 
The use of immunofluorescence microscopy to visualize subcellular localization of 
proteins is powerful tool that eliminates the need to genetically modify the cells or cellular 
proteins with fluorescent protein fusions. One limitation of immunofluorescence 
microscopy is the availability of specific and effective antibodies required for proper 
protein recognition. Parkin is a widely studied protein and there are several commercially 
available antibodies recognizing different epitopes within parkin. In this study, four 
different parkin antibodies were used that mapped to three different domains of the protein.  
HeLa cells were chosen to transfect wild-type human parkin as the literature 
suggests that they do not express any endogenous parkin. Untransfected HeLa cells were 
used to test the specificity of these four parkin antibodies. These experiments showed that 
all four of these parkin antibodies resulted in significant background staining. (Appendix 
3). While the RING1 and Rcat/RING2 specific antibodies caused diffuse staining 
throughout the cytosol of HeLa cells with varying degrees of intensity, the Ubl specific 
antibody caused strong staining in the nucleus and weaker staining in the cytosol. It is 
possible that the Ubl specific antibody, given the structural similarities of the Ubl domain 
to ubiquitin, could be binding to ubiquitin or the ubiquitin-like protein SUMO in HeLa 
cells which would account for the strong nuclear and weaker cytosolic staining (172). 
Alternatively, HeLa cells might express parkin-like proteins or proteins with structurally 
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similar epitopes to parkin, which may include other E3s. This would result in non-specific 
binding of parkin antibodies in fixed HeLa cells. This speculation is supported by the fact 
that Western blots performed with these antibodies did not elicit non-specific staining, 
suggesting that these antibodies are not suitable for immunofluorescence microscopy. 
Several attempts were made to decrease or eliminate non-specific signals. These 
strategies included increasing blocking periods, increasing concentrations of BSA in the 
blocking solution, adding goat serum to blocking solutions to prevent non-specific binding 
of the secondary goat-derived antibodies, and decreasing primary and secondary antibody 
incubation times. Despite all these efforts, the non-specific staining persisted even when 
using all of the techniques described above in combination. This could bring into question 
the specificity of these antibodies when probing for non-denatured proteins. Due to time 
constrains, we were unable to rectify this problem and immunofluorescent images were 
taken of cells expressing parkin at high enough levels to overcome the background staining. 
To address this problem in the future, our protocol would need to be further optimized. 
Additionally, the use of other commercially available parkin antibodies or a home-made 
parkin antibody would be tested to determine if this issue was due to the specific antibodies 
used in this study. 
Parkin Protein Fusions 
The use of fluorescent fusions or peptide epitope tags is an invaluable technique 
that enables simple and easy identification of protein localization. Protein fusions can be 
cloned onto proteins onto either the N- or C-terminus. 
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Fluorescent protein fusions are used to visualize proteins in living cells. A concern 
regarding using recombinant proteins with fluorescent fusions is the effects the fluorescent 
fusion has on protein folding and stability. GFP is significantly larger than most peptide 
epitope tags as it is a 238 amino acid protein and must adopt a proper three dimensional 
fold in order to function. The beta barrel fold of GFP is also an extremely stable 
conformation and can remain in cells for extensive periods of time after translation, even 
if it is cleaved from a recombinant protein. The addition of stable fluorescent fusions like 
GFP can also affect the stability of recombinant proteins. For these reasons the use of 
fluorescent fusion proteins can raise concerns regarding the validity of results acquired 
using these recombinant proteins when assessing protein function, folding and stability. 
These concerns are particularly important when studying parkin. Structural studies 
have shown that the C-terminal residue of parkin is buried within the hydrophobic core of 
the Rcat/RING2 domain (60, 112) and the addition of large protein fusions at the C-
terminal end of the protein may likely disrupt the fold of the Rcat/RING2 domain that is 
required for parkin’s E3 ligase function. For this reason, many groups have chosen N-
terminal fluorescent fusions when studying parkin localization in order prevent misfolding 
and subsequent loss of function of the C-terminal domain. However, recently structural 
findings have shown that the N-terminal Ubl domain of parkin is highly mobile and plays 
a major role in regulating parkin activity (63) rendering N-terminal fusions problematic 
regarding effects on parkin function.   
For these reasons, in this study, we used unmodified parkin wherever possible to 
avoid concerns regarding effects of protein fusions. All of our growth experiments were 
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performed using both wild-type parkin and parkin-YFP which showed no difference in 
growth with the exception of co-expression of PINK1 and parkin discussed in section 
4.2.6.1. Although immunofluorescence can be done in yeast, due to time constrains of this 
project, we chose to use fluorescently fused parkin, parkin point mutants, and parkin 
truncation variants for localization studies in yeast. In our experiments, we observed drastic 
changes in parkin localization caused by various parkin point mutations, truncations and 
PINK1 co-expression. Notably, when assessing parkin localization using parkin point 
mutants and truncation variants with C-terminal YFP fusions, our results were always 
compared to a C-terminally YFP fused wild-type parkin as a control to ensure all changes 
were due to changes to parkin itself or co-expression with PINK1. However, we cannot 
definitively rule out that the fluorescent tags did not have an effect on parkin localization, 
and may have stabilized mutant or truncated forms of the protein. To validate these results, 
immunofluorescence would need to be performed to assess if point mutants, truncations, 
and PINK1 co-expression have the same effects on untagged parkin.  
Inhibiting Protein Degradation in Mammalian Cells 
Before treating yeast cells with the proteasome inhibitor MG132 to test parkin 
degradation and stability we first had to quench parkin expression. In yeast, this was 
achieved by engineering parkin expression constructs under control of the galactose-
inducible GAL1 promoter. Thus, by switching yeast cells to a glucose based media, parkin 
transcription was attenuated. In mammalian cells however, inhibiting transcription of 
parkin using cycloheximide also prevents translation of other cellular proteins. Therefore, 
experiments testing parkin stability in mammalian cells probably did not yield the same 
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results as those performed in yeast, which are likely due to alterations to many cellular 
processes and potential cell death following prolonged exposure to cycloheximide. It is 
also possible that the treatment with cycloheximide alters general cellular protein 
expression so severely that the protein degradation machinery is stressed to a point that it 
can no longer facilitate the same rate of parkin degradation that would occur under normal 
conditions. This concern could be addressed by performing pulse chase experiments using 
radio-labelled atoms that would eliminate the need to inhibit protein production while still 
allowing the assessment of parkin degradation. 
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Appendix 2. Comprehensive parkin sequence alignment. 
SP|O60260|PRKN2_HUMAN          -------------------------------------MIVFVRFNSSHGFPVEVDSDTSI 23 
TR|Q7KTX7|Q7KTX7_DROME         -----MSFIFKFIATFVRKMLELLQFGGKT---LTHTLSIYVKTNTGKTLTVNLEPQWDI 52 
SP|Q9WVS6|PRKN2_MOUSE          -------------------------------------MIVFVRFNSSYGFPVEVDSDTSI 23 
SP|Q9JK66|PRKN2_RAT            -------------------------------------MIVFVRFNSSYGFPVEVDSDTSI 23 
TR|F1NWU0|F1NWU0_CHICK         -------------------------------------MIVFVRFNSSHGFPVELGLDASI 23 
TR|H2QU08|H2QU08_PANTR         -------------------------------------MIVFVRFNSSHGFPVEVDSDTSI 23 
TR|F6U1L3|F6U1L3_MACMU         --------------------------------------SVFVRFNSSHGFPVEVDSDTSI 22 
TR|I3N341|I3N341_ICTTR         ---------------------------------------VFVRFNSSHGFPVEVDSDTSI 21 
TR|U3KCF7|U3KCF7_FICAL         ---------------------------------------VFVRFNSSHGFPVEVGLDSSI 21 
TR|Q561U2|Q561U2_DANRE         -------------------------------------MIVFVRFNSSHGFPVELEQGASV 23 
TR|W4YQE2|W4YQE2_STRPU         -------------------------------------------------MTVHINPSQNG 11 
TR|Q7Q591|Q7Q591_ANOGA         -----MFDLFGFIRQLIGSMLAIFSFGKKK---LSNSLSVYVKTNTGNTLAVDLEPHMDI 52 
TR|C3Z502|C3Z502_BRAFL         ----------------------------------MSTFQVMVRFNSNHSFLVTVHTSWTI 26 
TR|H3D789|H3D789_TETNG         -------------------------------------VPVIVRYNLGPEVVVEVQEEATV 23 
TR|M3ZNV3|M3ZNV3_XIPMA         -------------------------------------AAVFVRFNRGPGVAMELSAAARV 23 
TR|A0A087XI83|A0A087XI83_POEFO -------------------------------------VAVFVRFNRGPGVAVELSAAAHV 23 
TR|A0A0A9XSY6|A0A0A9XSY6_LYGHE ------MFLFDFFWSLWESLVHIMTFSRNP---QNNKLSIHVKSNTGNSVDVDLDPQWDI 51 
TR|E0VIU9|E0VIU9_PEDHC         ------MSILEWFWNILCGMAQYLTFSKNL--TNDNLVNIYVKSNVGGTISVNLDPKSDI 52 
TR|T1H7C6|T1H7C6_MEGSC         -----MEFIFEFFRSFLNAMLALLSFGKKT---VKNTLNINVKTNDQ-VLNIELQKSRNL 51 
TR|L7M1N2|L7M1N2_9ACAR         -MAGALRSFLDALALFLWRRLAFLSFRLRQPETPMNEITINVRFSADLVIPLRLERDATA 59 
TR|V5GZV6|V5GZV6_IXORI         MAASFLRWLLYVLASTFQRPLAFLRRGWPPPHVAMDEVTINVQFSTNLAISVTVKRDCTV 60 
TR|V5IIZ0|V5IIZ0_IXORI         MAASFLRWLLYVLASTFQRPLAFLRRGWPPPHVAMDEVTINVQFSTNLAISVTVKRDCTV 60 
TR|H0ZGE3|H0ZGE3_TAEGU         ---------------------------------------VFVRFNSSHGFPVEVGSDSSI 21 
TR|Q1WDP3|Q1WDP3_PIG           -------------------------------------MIVFVRFNSSHGFPVEVDSDTSI 23 
TR|H0X3U6|H0X3U6_OTOGA         ---------------------------------------VFVRFNSSHGFPVEVDSDTSI 21 
TR|I3JJF6|I3JJF6_ORENI         -------------------------------------FLPFLQFNLGPGVPVELQEEASV 23 
TR|B8YGJ6|B8YGJ6_MACFA         -------------------------------------MIVFVRFNSSHGFPVEVDSDTSI 23 
TR|Q5J4W3|Q5J4W3_TAKRU         -------------------------------------MIVFVRYNLGPEVVVELQEEATV 23 
TR|U3FQA1|U3FQA1_CALJA         -------------------------------------MLVFVRFNSSHGFPVEVDSDTSI 23 
TR|G3N0R1|G3N0R1_BOVIN         -------------------------------------MKVFVRFNSNHGFPVEVDSDTSI 23 
TR|Q17DC3|Q17DC3_AEDAE         -----MFDIVNFFKNLIYNMLAIFSFGRKK---LSNTLSIYVKTNTGNTLSVDLEPHMDI 52 
TR|G3PFJ2|G3PFJ2_GASAC         -------------------------------------MIIYVRYNLGPCVPVELQEEASV 23 
TR|E2BWM9|E2BWM9_HARSA         ------------------------------------------------------------ 
TR|A0A067RG71|A0A067RG71_ZOONE -----MSFIINFIRKILQTMLQLVSVGKRT---ISNSLNVYIKTNTGCTLSVDLDPKWYI 52 
TR|A0A0L0CIZ3|A0A0L0CIZ3_LUCCU -----MSFLINLIKAFIDKMLALLSFGSKT---ITNTLSIYVKTNTGRTLSVNLEPKWDI 52 
TR|A0A0F7Z269|A0A0F7Z269_CROAD -------------------------------------MIVFVRFNSSHGFPVEVDSDTSI 23 
TR|A0A0B2UTN0|A0A0B2UTN0_TOXCA -------------------M-QLLVSVRNR------SQKHYAHLDRSMNLHIDVPSEGTI 34 
TR|Q9XUS3|Q9XUS3_CAEEL         ---------------MSDEI-SILIQDRKT------G--------QRRNLTLNINITGNI 30 
165 
 
 
 
                                                                                            
 
SP|O60260|PRKN2_HUMAN          FQLKEVVAKRQGVPADQLRVIFAGKELRNDWTVQNCDLDQQSIVHIVQRPWRKGQEMNAT 83 
TR|Q7KTX7|Q7KTX7_DROME         KNVKELVAPQLGLQPDDLKIIFAGKELSDATTIEQCDLGQQSVLHAIRLRPPVQR----- 107 
SP|Q9WVS6|PRKN2_MOUSE          LQLKEVVAKRQGVPADQLRVIFAGKELPNHLTVQNCDLEQQSIVHIVQRPRRRSHETNAS 83 
SP|Q9JK66|PRKN2_RAT            FQLKEVVAKRQGVPADQLRVIFAGKELQNHLTVQNCDLEQQSIVHIVQRPQRKSHETNAS 83 
TR|F1NWU0|F1NWU0_CHICK         LQLKEAVAQRQGVPADQLRVIFAGRELSNDLTLQNCDLVQQSIVHIVQNLQKNSD-KDET 82 
TR|H2QU08|H2QU08_PANTR         FQLKEVVAKRQGVPADQLRVIFAGKELRNDWTVQHCDLDQQSIVHIVQRPWRKGQEMNAT 83 
TR|F6U1L3|F6U1L3_MACMU         FQLKEVVAKRQGVPTDQLRVIFAGKELRNDWTVQNCDLDQQSIVHIVQRPRRKGQEMNAT 82 
TR|I3N341|I3N341_ICTTR         FQLKEVVAKRQGVPAGQLRVIFAGKELQNDLTVQNCDLEQQSIVHIVQRPRR-GPEADAP 80 
TR|U3KCF7|U3KCF7_FICAL         LQLKEAVAQRQGVPADQLRVIFAGRELSNDLTLQNCDLAQQSIVHIVQSPQ-NSQNKEKT 80 
TR|Q561U2|Q561U2_DANRE         SELKEAVGRLQGVQSDQLRVIFAGRELCNESTLQGCDLPEQSTVHVVLPPSTSAHRSELI 83 
TR|W4YQE2|W4YQE2_STRPU         GELRSEVARLSGQSPADIRLVFAGKLIDDVQIMEDLRICENTMIHAVPAQRIQCHSDGPK 71 
TR|Q7Q591|Q7Q591_ANOGA         KDVKEMVAPRLGLEPQELKIIFAGRELSDTTTISECDLGQQSIIHVVKSRPTAITTPQKR 112 
TR|C3Z502|C3Z502_BRAFL         ARFKQEVGRTQGVPSGQIHILFAGRDLSDSLRIEDCQLGQQTVIHAISGLPQLSVDA--- 83 
TR|H3D789|H3D789_TETNG         AELKEVVARQQGVQPERLRVLFAGRELKSTSTLQDCDLPEQSTVHVLVPPPAASSSKVHL 83 
TR|M3ZNV3|M3ZNV3_XIPMA         AELKEIVASQQGVPAQELRVLFAGRELQSSASLQGCDLPEHSTVHVVLPPPGSLHLPPPQ 83 
TR|A0A087XI83|A0A087XI83_POEFO AELKEIVGRQQGVPAQALRVLFAGRELQSSDSLQGCDLPDQSTVHVVLPPPGSIHLLPL- 82 
TR|A0A0A9XSY6|A0A0A9XSY6_LYGHE GTLKEAIAPKIGLPADDMEIILAGKSLDDSTTIADCDLGEQSVLHAVKSHGQRQRRSRPL 111 
TR|E0VIU9|E0VIU9_PEDHC         KNVKELVAPKLGLEPDDVKIIFAGKELLDSTVIEVLDFFS-DILHAVKVNKKI------- 104 
TR|T1H7C6|T1H7C6_MEGSC         KK----SLLLLGITVEEIKIIFAGKELTDSTTIAECDLGNMSFLHAIKPRRNVQGQG--- 104 
TR|L7M1N2|L7M1N2_9ACAR         KDVKERLAEQLSLPVQEIRIIFAGKELLDHIAIKDYNVEEQTTVHAVRSANDGA-----Y 114 
TR|V5GZV6|V5GZV6_IXORI         KAMKERLASQLDVPVQELRVIFAGKELRDDAYFKDCNIEEYTTVHAVRSAACATPGAEPV 120 
TR|V5IIZ0|V5IIZ0_IXORI         KAMKERLASQLDVPVQELRVIFAGKELRDDAYFKDCNIEEYTTVHAVRSAACATPGAEPV 120 
TR|H0ZGE3|H0ZGE3_TAEGU         LQLKEAVAQRQGVPADQLRVIFAGRELSNDLTLQNCDLAQQSIVHIVESPQKNSQDKEKT 81 
TR|Q1WDP3|Q1WDP3_PIG           FQLKEVVAKRQGVPADQLRVIFAGKELRNDLTVQRCDLDQQSIVHVVLRPQRNGQERGVA 83 
TR|H0X3U6|H0X3U6_OTOGA         FQLKEVVAKRQGVPADQLRVIFAGKELRNDWTVQNCDLDQQSIVHIVQKPWRKGHEMAAT 81 
TR|I3JJF6|I3JJF6_ORENI         AQLKEVVGSQQGVRPERLRVLFAGRELQSTATLQGSDLPEQSTVHVVLPPSGASSFQQLM 83 
TR|B8YGJ6|B8YGJ6_MACFA         FQLKEVVAKRQGVPTDQLRVIFAGKELRNDWTVQNCDLDQQSIVHIVQRPRRKGQEMNAT 83 
TR|Q5J4W3|Q5J4W3_TAKRU         AELKEVVGQQQGVQPDLLRVLFAGRELKSTSTLQGCDLPEQSTVHIIVPSPASSSYKTLL 83 
TR|U3FQA1|U3FQA1_CALJA         FQLKEVVAKRQGVPADQLRVIFAGKELRNDWTVQNCDLDQQSIVHIVQRPWRKGQESNAT 83 
TR|G3N0R1|G3N0R1_BOVIN         FQLKEVVARRQGVPADQLCVIFAGKELRNDWTVQSCDLDQQSIVHIVLRPRRKGPE---- 79 
TR|Q17DC3|Q17DC3_AEDAE         KDVKEIVAPQLGLAPGELKIIFAGKELSDTITISECDLGQQSIIHAVKARTIPKKVN--- 109 
TR|G3PFJ2|G3PFJ2_GASAC         ADLQQLVGSQQGVHAELLRVLFAGRELKSSFTLQGCDLPEQSTVHVVLPKSAPTPGHLLL 83 
TR|E2BWM9|E2BWM9_HARSA         ----------MGMAAEDIKIIFAGKELHNSIVIEECDLGQQSTLHAVRNPHKKLKNQC-- 48 
TR|A0A067RG71|A0A067RG71_ZOONE KDVKELVAPRLGLSPEEVKIIFAGKELHDSIVIEECDLGQQSILHAVRSHASHRKKP--- 109 
TR|A0A0L0CIZ3|A0A0L0CIZ3_LUCCU KNVKEIVAPQLGLQPEEVKIIFAGKELSDATTIEECDLGQQSILHAIQARPVQQR----- 107 
TR|A0A0F7Z269|A0A0F7Z269_CROAD FQLKEAVAKRQGVPADQLHVIFAGKELRNDLTLKNCDLPQQSIVHIVQNRQKSENENPR- 82 
TR|A0A0B2UTN0|A0A0B2UTN0_TOXCA SDVIEVLARRIKVSPNSFKIILCGKVLGGATSLHSLLLGPQTSLAAVVVDVSASDDKSAN 94 
TR|Q9XUS3|Q9XUS3_CAEEL         EDLTKDVEKLTEIPSDELEVVFCGKKLSKSTIMRDLSLTPATQIMLLRPKFNSHN-ENGA 89 
                                                . :::.*: :     .    .     :  :              
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SP|O60260|PRKN2_HUMAN          GGDDPRNAAGGCEREPQSLTRVDLSSSVLPGDSVGLAVILHTDSRKDSPP---------- 133 
TR|Q7KTX7|Q7KTX7_DROME         ---QKI---QSATLEEEEPSLSDEASKPLNETLLDLQLESEER-L--------------- 145 
SP|Q9WVS6|PRKN2_MOUSE          GGDEPQSTSEGSIWESRSLTRVDLSSHTLPVDSVGLAVILDTDSKRDSEA---------- 133 
SP|Q9JK66|PRKN2_RAT            GGDKPQSTPEGSIWEPRSLTRVDLSSHILPADSVGLAVILDTDSKSDSEA---------- 133 
TR|F1NWU0|F1NWU0_CHICK         EDNHAGGILKTLERVPESLTRIDLSSSILPSLSAGLAVILDTKEPNISPP---------- 132 
TR|H2QU08|H2QU08_PANTR         GGDDPRNAAGGCEREPQSLTRVDLSSSVLPGDSVGLAVILHTDSRKDSPP---------- 133 
TR|F6U1L3|F6U1L3_MACMU         GGDNARNTAGGCEREPQSLTRVDLSSSVLPGDSVGLAVILHTDSRNDSPP---------- 132 
TR|I3N341|I3N341_ICTTR         GGDEPRTVLGGPEREPRSLTRVDLSSSVLPADSVGLAVVLDTGSRRDSTA---------- 130 
TR|U3KCF7|U3KCF7_FICAL         EDSCIGGVPKTLKREPESLTRIDLSTSILPSVSAGLAVILDPGKNSVSLP---------- 130 
TR|Q561U2|Q561U2_DANRE         Q-------QRRLGSGMESLTRLDLSSSRQTTASEGLAVILETEASRREDT---------- 126 
TR|W4YQE2|W4YQE2_STRPU         ------T-IKDEGVKPQPVH------------VLMESRIIDEDQRSPET----------- 101 
TR|Q7Q591|Q7Q591_ANOGA         QAKPAL---NATISEEPSPEEQQQHNKPLSETMSELTVLDERN----------------- 152 
TR|C3Z502|C3Z502_BRAFL         ---------RSSAAAPRSLSDVQLNVRP-------------------------------- 102 
TR|H3D789|H3D789_TETNG         L---QEHQARGEEEDHDSLTRLDLSSSRLTTTTSGLAVILERNGLGGVGATAGGGEAG-- 138 
TR|M3ZNV3|M3ZNV3_XIPMA         E-----H----LAASVTRLTRLDLSSSRLAAVATAAVQTT---------VLEGGGGDED- 124 
TR|A0A087XI83|A0A087XI83_POEFO ------------AARGTRLTRLDLSSSRLAVLEG-----------------GRGGGDED- 112 
TR|A0A0A9XSY6|A0A0A9XSY6_LYGHE ---NQI---MSDLVEE---------NDALPATVSEIDEN-HDT-VQ-------------- 140 
TR|E0VIU9|E0VIU9_PEDHC         --------------------KNVIPDKPLCETLEELHQLNDQK-NV-------------- 129 
TR|T1H7C6|T1H7C6_MEGSC         -----I---------STLTKKEDQPSKPLCETLPDLKLVNM------------------- 131 
TR|L7M1N2|L7M1N2_9ACAR         M-------------------DAEVQC-PLGEGII--TSQ--------------------- 131 
TR|V5GZV6|V5GZV6_IXORI         V-------------------SAEMCCAPLGGSLAKGTRG--------------------- 140 
TR|V5IIZ0|V5IIZ0_IXORI         V-------------------SAEMCCAPLGGSLAKA--Q--------------------- 138 
TR|H0ZGE3|H0ZGE3_TAEGU         EYSCVGGVPKALKREPESLTRIDLSTSILPSVSAGLAVILDPGKNSVSLP---------- 131 
TR|Q1WDP3|Q1WDP3_PIG           AGHR----PGRAGREPASLTRVDLSGSVLPGDAVGLAVILQDDSADGAAP---------- 129 
TR|H0X3U6|H0X3U6_OTOGA         GGDGPRSTTGGPGREPQSLTRVDLSSSLLPADSVGLAVILDTESRSDPPR---------- 131 
TR|I3JJF6|I3JJF6_ORENI         Q-----E----H-RAEGSLTRLDLSSSRLPASSE-----------------GGGGGAEG- 115 
TR|B8YGJ6|B8YGJ6_MACFA         GGDNARNTAGGCEREPQSLTRVDLSSSVLPGDSVGLAVILHTDSRNDSPP---------- 133 
TR|Q5J4W3|Q5J4W3_TAKRU         L---PEHLSQGEEENHDSLTRLDLSASRLPTTSSTLGVILERNDSEGVGATAGGGGAEAA 140 
TR|U3FQA1|U3FQA1_CALJA         GGDNPRNAAGGCEREPQSLTRVDLSSSVLPGDSVGLAVILHTESRDDSPP---------- 133 
TR|G3N0R1|G3N0R1_BOVIN         -GHSPRPAWGRSDREPESLTRVDLSSSMLPADSVGLAVILQDGEESGASS---------- 128 
TR|Q17DC3|Q17DC3_AEDAE         NGKTLL---ESPISEETL--EESTSTKPLCETLTDLQMTEVNE----------------- 147 
TR|G3PFJ2|G3PFJ2_GASAC         L---RERLAGGGQEEGNSLARLDISSSRFPCTPPGLDGS------------NGGGG-EGA 127 
TR|E2BWM9|E2BWM9_HARSA         -ASSSI---EE--YKSESSDLNESGSKPMNETLTDLSLDSSDQ-H--------------- 86 
TR|A0A067RG71|A0A067RG71_ZOONE -----------------GSESPSEGSKPLNETLMDLQLSDHER-RS-------------- 137 
TR|A0A0L0CIZ3|A0A0L0CIZ3_LUCCU ---KRL---YSTVAEE-EP-SEEQPSKPLCETLVDLQLLSEER-S--------------- 143 
TR|A0A0F7Z269|A0A0F7Z269_CROAD ------LLLSSNGREPTSLTRVDLSTNLLPSDSLGLAVILDNRIPI-------------- 122 
TR|A0A0B2UTN0|A0A0B2UTN0_TOXCA A----------------------------------------------------------- 95 
TR|Q9XUS3|Q9XUS3_CAEEL         T----------------------------------------------------------- 90 
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SP|O60260|PRKN2_HUMAN          ---------------AGSPAGRSIYNSFYVYCKGPCQ-----------RVQPGKLRVQCS 167 
TR|Q7KTX7|Q7KTX7_DROME         --------------NITDEERVRAKAHFFVHCS-QCD-----------KLCNGKLRVRCA 179 
SP|Q9WVS6|PRKN2_MOUSE          ---------------ARGP-VKPTYNSFFIYCKGPCH-----------KVQPGKLRVQCG 166 
SP|Q9JK66|PRKN2_RAT            ---------------ARGPEAKPTYHSFFVYCKGPCH-----------KVQPGKLRVQCG 167 
TR|F1NWU0|F1NWU0_CHICK         ---------------SEK-SGAASYNSFYVFCKNFCQ-----------AVKPGKLRVRCN 165 
TR|H2QU08|H2QU08_PANTR         ---------------AGSPAGRSIYNSFYVYCKGPCQ-----------RVQPGKLRVQCS 167 
TR|F6U1L3|F6U1L3_MACMU         ---------------AGSPADRPIYNSFYVYCKGPCQ-----------RVQPGKLRVQCS 166 
TR|I3N341|I3N341_ICTTR         ---------------ARGP-GRPTYNSFYVYCKGPCQ-----------GVQPGKLRVRCG 163 
TR|U3KCF7|U3KCF7_FICAL         ---------------SEKSAGAASYNSFYVFCKNFCQ-----------AVKPGKLRVRCS 164 
TR|Q561U2|Q561U2_DANRE         ---------------A-GHTGAKAHSSFYVFCKTVCK-----------AIQPGKLRVRCK 159 
TR|W4YQE2|W4YQE2_STRPU         ---------------PDVDLASSLHPSFYVYCKSHCR-----------SVQPGKLRVCCQ 135 
TR|Q7Q591|Q7Q591_ANOGA         --------------GDQSIPIGRTKAHFFVYCS-QCE-----------KVCTGKLRVRCG 186 
TR|C3Z502|C3Z502_BRAFL         ---------------EGADTAAGSLPSYFVFCKRPCK-----------AVRPGKLRVRCG 136 
TR|H3D789|H3D789_TETNG         NDGATPESGGEVQAAGVKGHSVHPRSTFFVYCKS-CK-----------SIQPGKLRVRCR 186 
TR|M3ZNV3|M3ZNV3_XIPMA         ------QR--T---EQQAAAPKGVCSTFFVYCKR-CS-----------SIQSGKLRVRCR 161 
TR|A0A087XI83|A0A087XI83_POEFO ------QR--T---EQQAAAPKG---TFFVYCKR-CS-----------SIQSGKLRVRCR 146 
TR|A0A0A9XSY6|A0A0A9XSY6_LYGHE ----------PSPADSDGKPQKPQQAHFYVYCA-TCMTNNLGNPTLPLKPKEGKLRVRCS 189 
TR|E0VIU9|E0VIU9_PEDHC         ----------ESIEESNLKNEGKNKAHFFIYCANPCK-----------KINTGKLRVCCS 168 
TR|T1H7C6|T1H7C6_MEGSC         -----------------------RKAHFFVYC--QCK-----------KLCKGKLRVRCF 155 
TR|L7M1N2|L7M1N2_9ACAR         ----------LTEEEHLARKTEADKALFFVYCKQPCD-----------RVLPGKLRVCCA 170 
TR|V5GZV6|V5GZV6_IXORI         ----------YTEEERLASTAEVDKTLFFVYCKSPCG-----------RVEPGKLRVRCA 179 
TR|V5IIZ0|V5IIZ0_IXORI         ----------LTEEERLASTAEVDKTLFFVYCKSPCG-----------RVEPGKLRVRCA 177 
TR|H0ZGE3|H0ZGE3_TAEGU         ---------------SEKSAGAASYNSFYVFCKNFCQ-----------AVKPGKLRVRCS 165 
TR|Q1WDP3|Q1WDP3_PIG           ---------------AGRPADRPTNKSFYVYCKGPCQ-----------RVQPGKLRVRCS 163 
TR|H0X3U6|H0X3U6_OTOGA         ---------------AAGPAGRPVYNSFYVYCKGPCH-----------RVQPGKLRVQCN 165 
TR|I3JJF6|I3JJF6_ORENI         ------ES--LEEVQAVAHSSVRACSTFFVFCKS-CC-----------SIEPGKLRARCQ 155 
TR|B8YGJ6|B8YGJ6_MACFA         ---------------AGSPADRPIYNSFYVYCKGPCQ-----------RVQPGKLRVQCS 167 
TR|Q5J4W3|Q5J4W3_TAKRU         LGGDSADDRAVLQSAGAKDHSVRPRSTFFVYCKS-CK-----------LVQPGKLRVRCR 188 
TR|U3FQA1|U3FQA1_CALJA         ---------------AGSAAGRPVYNSFYVYCKGPCQ-----------KVQPGKLRVQCG 167 
TR|G3N0R1|G3N0R1_BOVIN         ---------------ARRPAGRPTYNSFYVYCKGPCQ-----------GVQPGKLRVRCS 162 
TR|Q17DC3|Q17DC3_AEDAE         --------------KPGSPARERRKAHFFVYCS-QCE-----------KVCTGKLRVRCG 181 
TR|G3PFJ2|G3PFJ2_GASAC         EGG----DREQVQAASLKVLCVRTCSTFFVYCKR-CK-----------SIQPGKLRVCCS 171 
TR|E2BWM9|E2BWM9_HARSA         --------------NLSTEEQQDNRAHFYIYCPGPCK-----------IVTAGKLRVKCA 121 
TR|A0A067RG71|A0A067RG71_ZOONE --------------VRTDEDRERKRAHFYVYCAWPCK-----------EMKLGKLRVRCA 172 
TR|A0A0L0CIZ3|A0A0L0CIZ3_LUCCU --------------NIPEENRERSKAHFYVHCS-QCN-----------KLCKGKLRVRCS 177 
TR|A0A0F7Z269|A0A0F7Z269_CROAD ----------------PPNNSEVKYSSFYVFCKSFCQ-----------AVKPGKLRVRCK 155 
TR|A0A0B2UTN0|A0A0B2UTN0_TOXCA --------------SSSIDSNRTDVPSFHVFCKG-CN-----------SLAKGKLRVYCA 129 
TR|Q9XUS3|Q9XUS3_CAEEL         --------------TAKITTDSSILGSFYVWCKN-CD-----------DVKRGKLRVYCQ 124 
                                                          :.: *   *                ****. *  
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SP|O60260|PRKN2_HUMAN          TCRQATLTLTQGPSCWDDVLIPNRMSGECQSPHC----------PGTSA-EFFFKCGAHP 216 
TR|Q7KTX7|Q7KTX7_DROME         LCKGGAFTVHRDPECWDDVLKSRRIPGHCESLEVACV--DNAAGDPPFA-EFFFKCAEHV 236 
SP|Q9WVS6|PRKN2_MOUSE          TCKQATLTLAQGPSCWDDVLIPNRMSGECQSPDC----------PGTRA-EFFFKCGAHP 215 
SP|Q9JK66|PRKN2_RAT            TCRQATLTLAQGPSCWDDVLIPNRMSGECQSPDC----------PGTRA-EFFFKCGAHP 216 
TR|F1NWU0|F1NWU0_CHICK         ECKQGTLTLARGPSCWDDVLIPNRITGVCQSPDC----------SGNVA-EFYFKCGAHP 214 
TR|H2QU08|H2QU08_PANTR         TCGQATLTLTQGPSCWDDVLIPNRMSGECQSPHC----------PGTSA-EFFFKCGAHP 216 
TR|F6U1L3|F6U1L3_MACMU         TCRQATLTLTQGPSCWDDVLIPNRMSGECQSPHC----------PGTTAVRFFLRCGEHG 216 
TR|I3N341|I3N341_ICTTR         TCRQATLTLAQGPSCWDDVLIPNRMSGKCQSPGC----------PGTRA-EFFFKCGAHP 212 
TR|U3KCF7|U3KCF7_FICAL         VCKQGTLTLARGPSCWDDVLIPNRIGGVCQSRGC----------TGNVA-EFYFKCGAHP 213 
TR|Q561U2|Q561U2_DANRE         DCKQGTLTLSRGPSCWDDVLLPNRIHGVCQSQGC----------NGRLA-EFYLKCASHP 208 
TR|W4YQE2|W4YQE2_STRPU         TCKDNAFIVKEDPVCWDDVILSNRISGSCFVPGC----------QGQKA-EFFFKCSSHA 184 
TR|Q7Q591|Q7Q591_ANOGA         ICGSGAFTVHRDPTCWDDVLKRKRITGHCENYEVPCV--ENDEGEPPFT-EFYFKCSEHS 243 
TR|C3Z502|C3Z502_BRAFL         TCRQTTLTLSRDPNCWEDVLVPGKIQGRCLSRGC----------PGTVA-EFYFKCADHH 185 
TR|H3D789|H3D789_TETNG         SCRQTTLTLSRGPSCWDDVLLRNRLHGVCHSDGC----------HGTEA-EFYMKCARHP 235 
TR|M3ZNV3|M3ZNV3_XIPMA         RCRQMTLTLCRGPSCWDDVLLPGRIHGVCQFEGC----------HGNEA-EFYMKCASHP 210 
TR|A0A087XI83|A0A087XI83_POEFO RCRQMALTLSRGPSCWDDVLLPGRIHGVCQFEGC----------HGNEA-EFYMKCASHP 195 
TR|A0A0A9XSY6|A0A0A9XSY6_LYGHE SCKSGAIQLDSDPASWSDVLERTRITGDCQEQGCS-------DGPVAWA-EFYFKCAEHV 241 
TR|E0VIU9|E0VIU9_PEDHC         ECKHGAFTVDTDPQSWADVLDKNKITGVCNNVG----------CEGLYA-KFYFKCASHP 217 
TR|T1H7C6|T1H7C6_MEGSC         KCKSGAFTVYKDPECWDDVLKPQRIHGLCEGNEESPC--TGNDNGLPYA-EFYFKCAEHS 212 
TR|L7M1N2|L7M1N2_9ACAR         SCGEGSFILQKDPSCWKDVLEPGRLLGQCQICH-----------QVRAA-RFFFKCTG-- 216 
TR|V5GZV6|V5GZV6_IXORI         TCGQGCFLLDREPSCWPDVLERGRLGGRCEQEG----------CGGRLA-DFFFKCASSN 228 
TR|V5IIZ0|V5IIZ0_IXORI         TCGQGCFLLDREPSCWPDVLERGRLGGRCEQEG----------CGGRLA-DFFFKCASSN 226 
TR|H0ZGE3|H0ZGE3_TAEGU         VCKQGTLTLARGPSCWDDVLIPNRIGGVCQSQGC----------NGNVA-EFYFKCGAHP 214 
TR|Q1WDP3|Q1WDP3_PIG           TCQQATLTLTQGPSCWDDVLIPNRMSGECQSPNC----------PGTTA-EFFFKCGAHP 212 
TR|H0X3U6|H0X3U6_OTOGA         TCKQATLTLAQGPSCWEDVLIPNRMSGECQSPNC----------PGTTA-EFFFKCGAHP 214 
TR|I3JJF6|I3JJF6_ORENI         SCKQTTLTLSRGPSCWDDVLLPGRIHGICQSEGC----------QGNEA-EFYMKCASHP 204 
TR|B8YGJ6|B8YGJ6_MACFA         TCRQATLTLTQGPSCWDDVLIPNRMSGECQSPHC----------PGTTA-EFFFKCGAHP 216 
TR|Q5J4W3|Q5J4W3_TAKRU         SCRQATLTLSRGPSCWDDVLLQSRVHGVCHSDGC----------HGTEA-EFYMKCASHP 237 
TR|U3FQA1|U3FQA1_CALJA         TCRQATLTLTQGPSCWDDVLIPNRMSGECQSPNC----------PGTSA-EFFFKCGAHP 216 
TR|G3N0R1|G3N0R1_BOVIN         TCQQATLTLAQGPSCWEDVLIPNRMSGECQSPNC----------PGTRA-EFFFKCGAHP 211 
TR|Q17DC3|Q17DC3_AEDAE         ICKSGAFTVHRDPACWDDVLKKKRITGHCENYEIPCV--ENELGDPPFT-EFYFKCSEHS 238 
TR|G3PFJ2|G3PFJ2_GASAC         SCRETTFTLSRGPSCWDDVLLPGRVHGFCQSDAC----------VGNEA-EFYMKCASHP 220 
TR|E2BWM9|E2BWM9_HARSA         KCNSGAVTVDRDPQCWSDILEPNRITVHCENDFCPASSLSEEEFQVTYA-HFYFKCTRHV 180 
TR|A0A067RG71|A0A067RG71_ZOONE SCRSGAFTVDRDPQCWDDVLEGRRITGDCQNDS---C--IGSDDGPKFA-EFYFKCFEHT 226 
TR|A0A0L0CIZ3|A0A0L0CIZ3_LUCCU LCKGGAFTVHRDPECWDDVLKSRRIRGHCESLEIACV--DNDIGDPPFA-EFYFKCAEHI 234 
TR|A0A0F7Z269|A0A0F7Z269_CROAD TCKQGTLTLARDPSCWEDVLIPNSILGVCHYQNC----------SGEIA-EFYFKCGAHP 204 
TR|A0A0B2UTN0|A0A0B2UTN0_TOXCA RCLSSSVVLKRDPEKWSDVLSSRAINAECEDCE-----------EETFA-KFCFKCVICD 177 
TR|Q9XUS3|Q9XUS3_CAEEL         KCSSTSVLVKSEPQNWSDVLKSKRIPAVCEECCT----------PGLFA-EFKFKCLACN 173 
                                *    . :   *  * *::    :   *                   :  * ::*     
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SP|O60260|PRKN2_HUMAN          T--SDKE-TSVALHLIATNSRNITCITCTDVRSPVLVFQCNSRHVICLDCFHLYCVTRLN 273 
TR|Q7KTX7|Q7KTX7_DROME         S-GGEKD-FAAPLNLIKNNIKNVPCLACTDVSDTVLVFPCASQHVTCIDCFRHYCRSRLG 294 
SP|Q9WVS6|PRKN2_MOUSE          T--SDKD-TSVALNLITSNRRSIPCIACTDVRSPVLVFQCNHRHVICLDCFHLYCVTRLN 272 
SP|Q9JK66|PRKN2_RAT            T--SDKD-TSVALNLITNNSRSIPCIACTDVRNPVLVFQCNHRHVICLDCFHLYCVTRLN 273 
TR|F1NWU0|F1NWU0_CHICK         T--TDSE-TSVALNLVTTNSRGITCITCTDIRSPVLVFQCMHRHVICLDCFHLYCVTMLN 271 
TR|H2QU08|H2QU08_PANTR         T--SDKE-TSVALHLIATNSRNITCITCTDVRSPVLVFQCNSRHVICLDCFHLYCVTRLN 273 
TR|F6U1L3|F6U1L3_MACMU         A--EDKS-LGHGLHLLPTKLRNVRNIFLSLCRSPVLVFQCNSRHVICLDCFHLYCVTRLN 273 
TR|I3N341|I3N341_ICTTR         T--SDKE-TSVALNLITTNSRDISCITCTDTRSPVLVFQCTHRHVICLDCFHLYCVTRLN 269 
TR|U3KCF7|U3KCF7_FICAL         T--ADSE-TSVALNLVTTNSRCITCITCTDIRSPVLVFQCVHRHVICLDCFHLYCVTMLN 270 
TR|Q561U2|Q561U2_DANRE         T--CDND-TSVALDLIMPNTRRVPCIACTDIMTPVLVFQCAERHVICLECFHLYCVSRLN 265 
TR|W4YQE2|W4YQE2_STRPU         S--SVND-QFTVLPLVKTNTRRVICITCADILTSVLVFPCSASHVMCLDCFRQYCRLCLD 241 
TR|Q7Q591|Q7Q591_ANOGA         S-GGEKD-FAAPLSLIKTNHKNIPCIACTDTSETILVFPCVAGHVSCLDCFRQYCVTRLL 301 
TR|C3Z502|C3Z502_BRAFL         T--SEDD-TSVALPLVKSNTQSVDCLGCTDVRTPVMVFECADGHVMCLDCFARYCVTKLN 242 
TR|H3D789|H3D789_TETNG         T--SDSD-HSVALDLIMTNSRDVPCIACADVVDVVLVFQCLERHVICLECFRHYCQVRVN 292 
TR|M3ZNV3|M3ZNV3_XIPMA         T--SEDD-VSVALDLVLSNTRSVPCIGCTDIRDVVLVFQCSDRHVICLDCFQRYCQTRLN 267 
TR|A0A087XI83|A0A087XI83_POEFO T--SEDD-VSVALDLVLSNTRGVPCIGCTDIRDVVLVFQCSDRHVICLDCFQRYCQTRLN 252 
TR|A0A0A9XSY6|A0A0A9XSY6_LYGHE P-KSENESEAVPLYLIRANSRSTPCLACMDIMDTVIVFSCA--HTICLDCFNDYITSKIR 298 
TR|E0VIU9|E0VIU9_PEDHC         S-QGEND-TAVPLNLIKRNHKKIPCLACTDICDPVLVFSCDNRHVTCLECFKNYCGSRLK 275 
TR|T1H7C6|T1H7C6_MEGSC         L-GMEDD-FAAPLKLIRINEQNVPCLACMDVSETILVFPCELRHVTCLDCFLQYCRSRLL 270 
TR|L7M1N2|L7M1N2_9ACAR         KIGSHDDQVPIVLQLIRYNYLQVPCLACLDVSRLVLVFKCA--HVICLDCFRAYCRSRLD 274 
TR|V5GZV6|V5GZV6_IXORI         RLEGHDQRGSTVLPLVRCNFLGVPCLSCTDVSRIVLVFPCTSSHVICLECFGTYCRSRLD 288 
TR|V5IIZ0|V5IIZ0_IXORI         RLEGHDQRGSTVLPLVRCNFLGVPCLSCTDVSRIVLVFPCTSSHVICLECFGTYCRSRLD 286 
TR|H0ZGE3|H0ZGE3_TAEGU         T--TDSE-TSVALNLVTTNSRCITCITCTDIRSPVLVFQCVHRHVICLDCFHLYCVTMLN 271 
TR|Q1WDP3|Q1WDP3_PIG           T--SDKE-TSVALNLITTNSRDITCITCTDIRSPILVFQCNCRHVICLDCFHLYCVTRLN 269 
TR|H0X3U6|H0X3U6_OTOGA         T--SNKD-TSVALNLITTNSRDISCITCTDVRSPVLVFQCNYRHVICLDCFHLYCVTRLN 271 
TR|I3JJF6|I3JJF6_ORENI         T--SDDD-FSVALDLIMTNTRGVPCIACTDVMGVVLVFQCLERHVICLDCFQRYCQTRLN 261 
TR|B8YGJ6|B8YGJ6_MACFA         T--SDKE-TSVALHLIATNSRNITCITCTDVRSPVLVFQCNSRHVICLDCFHLYCVTRLN 273 
TR|Q5J4W3|Q5J4W3_TAKRU         T--SDND-HSVALDLIMTNSRDVPCIACTDVMDVVLVFECLERHVICLECFRHYCQVRLN 294 
TR|U3FQA1|U3FQA1_CALJA         T--SDKE-TSIALHLIATNSRNITCITCTDVRSPVLVFQCNSRHVICLDCFHLYCVTRLN 273 
TR|G3N0R1|G3N0R1_BOVIN         T--SDKE-TSVALNLITTNSRDISCITCTDIRSPVLVFQCTHRHVICLDCFHLYCVTRLN 268 
TR|Q17DC3|Q17DC3_AEDAE         S-GGEKD-FAAPLNLIKTNHKDIPCIACTDTSDTVLVFPCEAGHVTCLDCFRQYCVSRLL 296 
TR|G3PFJ2|G3PFJ2_GASAC         T--PEDE-VSVALDLIMTNSREVPCMACSDTTELVLVFQCAERHVICLHCFHRYCQTRLN 277 
TR|E2BWM9|E2BWM9_HARSA         S-LGEDD-KVIPLYLIRANLRNVPCLACTDVRETVLVFPCEAHHVTCLDCFCEYCIVRLQ 238 
TR|A0A067RG71|A0A067RG71_ZOONE S-QGEDD-QAVPLYLIKSNVRDVPCLACTDVSDPVLVFPCDLAHVTCLECFRAYCVARLR 284 
TR|A0A0L0CIZ3|A0A0L0CIZ3_LUCCU S-GGEKD-FAAPLNLIKINIKDIPCLACTDVSDTVLVFPCESKHVTCIECFLHYCRSRLM 292 
TR|A0A0F7Z269|A0A0F7Z269_CROAD T--SDSE-TSVPLNLITTNTRYISCITCTDVRSPVLVFPCIHHHVICLDCFHLYCVTMLN 261 
TR|A0A0B2UTN0|A0A0B2UTN0_TOXCA E-------VAVPLTHVRGYRGEGECSICGETALR-AVVDVGCHHETCVDCFTAYMETAFT 229 
TR|Q9XUS3|Q9XUS3_CAEEL         D-------PAAALTHVRGNWQMTECCVCDGK-EK-VIFDLGCNHITCQFCFRDYLLSQLE 224 
                                           *  :                    :.     *  *  **  *    .  
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SP|O60260|PRKN2_HUMAN          DRQFVHDP-QLGYSLPCVAGCPNSLIKELHHFRILGEEQYNRYQQYGAEECV-LQMGGVL 331 
TR|Q7KTX7|Q7KTX7_DROME         ERQFMPHP-DFGYTLPCPAGCEHSFIEEIHHFKLLTREEYDRYQRFATEEYV-LQAGGVL 352 
SP|Q9WVS6|PRKN2_MOUSE          DRQFVHDA-QLGYSLPCVAGCPNSLIKELHHFRILGEEQYTRYQQYGAEECV-LQMGGVL 330 
SP|Q9JK66|PRKN2_RAT            DRQFVHDA-QLGYSLPCVAGCPNSLIKELHHFRILGEEQYNRYQQYGAEECV-LQMGGVL 331 
TR|F1NWU0|F1NWU0_CHICK         DRQFIYDP-DLGYSLPCVAGCPDSLIKEVHHFRILGEEQYNRYQRYGAEECV-LQMGGLL 329 
TR|H2QU08|H2QU08_PANTR         DRQFVHDP-QLGYSLPCVAGCPNSLIKELHHFRILGEEQYNRYQQYGAEECV-LQMGGVL 331 
TR|F6U1L3|F6U1L3_MACMU         DRQFVHDP-QLGYSLPCVAGCPNSLIKELHHFRILGEEQYNRYQQYGAEECV-LQMGGVL 331 
TR|I3N341|I3N341_ICTTR         DRQFLHDP-QLGYSLPCVAGEQGEERFE-LHFRLLGQLQYNRYQQYGAEECV-LQMGGVL 326 
TR|U3KCF7|U3KCF7_FICAL         DRQFIHDP-ELGYSLPCVAGCPDSLIKELHHFRILGEEQYGRYQRYGAEECV-LQMGGVL 328 
TR|Q561U2|Q561U2_DANRE         ERQFTQET-LLGYSLPCAAGCPDSLIKEVHHFRVLGEEQYERYQRYAAEECV-LQMGGVL 323 
TR|W4YQE2|W4YQE2_STRPU         ERRFIQSP-ELGYTLPCPAGCEDSLIKDTHHFLVLGKEQYARYKRFGTEEYL-LSEGGVL 299 
TR|Q7Q591|Q7Q591_ANOGA         ERQFVEHP-TGGYTLQCPAGCDNSFIEDVHHFKLLNKEQYERYQRFATEEFV-LKNGGVL 359 
TR|C3Z502|C3Z502_BRAFL         DRQFVQHA-SLGYTLPCPGGCDNSLIKEVHHFRMLGDEQYDRYQRFGAEECV-LQMGGVL 300 
TR|H3D789|H3D789_TETNG         ERQFVYDA-AIGYSLPCAAGCTNSLIKEVHHFRILGENQYERYLQYGAEECL-LRNGGLM 350 
TR|M3ZNV3|M3ZNV3_XIPMA         ERQFIYDA-VIGYSLPCAAGCENSLIRELHHFRILGDNQYGRYQQYGAEECL-LTAGGVL 325 
TR|A0A087XI83|A0A087XI83_POEFO ERQFIYDA-VIGYSLPCAAGCENSLIRELHHFRILGDDQYGRYLQYGAEEFL-LTAGGVL 310 
TR|A0A0A9XSY6|A0A0A9XSY6_LYGHE ERKFVLDD-DVGYSLLCPVGCEGSLITEIHHFRLLAPHLYNMYQQFATEDFV-LKSGGVL 356 
TR|E0VIU9|E0VIU9_PEDHC         DRQFLSHP-DFGYTLPCPAGCSNSFIEEVHHFRLLTDAQYEQYHRFATEEFI-LQAGGVL 333 
TR|T1H7C6|T1H7C6_MEGSC         ERQFMPHP-DIGYTLQCPTGCPDSFIDEIHHFKLLTPEEYDRYQMYATEEYV-LQAGGVL 328 
TR|L7M1N2|L7M1N2_9ACAR         ERAFVQHP-TLGWTLPCPVGCADSLIEESHHFYLLGSEQYQRYQRFAAEEWV-LQAGGVL 332 
TR|V5GZV6|V5GZV6_IXORI         ERGFVQHP-QLGSTLPCPVGCDDSFIQETHHFCLLGPEQYQRYQRFAAEEFV-LQAGGVL 346 
TR|V5IIZ0|V5IIZ0_IXORI         ERGFVQHP-QLGSTLPCPVGCDDSFIQETHHFCLLGPEQYQRYQRFAAEEFV-LQAGGVL 344 
TR|H0ZGE3|H0ZGE3_TAEGU         DRQFIHDP-ELGYSLSCVAGCPDSLIKELHHFRILGEEQYNRYQHYGAEECV-LQMGGVL 329 
TR|Q1WDP3|Q1WDP3_PIG           DRQFVHDP-QLGYSLPCVAGCPNSLIKELHHFRILGEEQYNRYQQYGAEECV-LQMGGVL 327 
TR|H0X3U6|H0X3U6_OTOGA         DRQFVHDP-QLGYTLPCVAGCPNSLIKELHHFRILGEEQYSRYQQYGAEECV-LQMGGVL 329 
TR|I3JJF6|I3JJF6_ORENI         DRQFVYHP-VIGYSLPCAVGCDDSLIKEVHHFRILGDEQYGRYLQYGAEECL-LITGGMM 319 
TR|B8YGJ6|B8YGJ6_MACFA         DRQFVHDP-QLGYSLPCVAGCPNSLIKELHHFRILGEEQYNRYQQYGAEECV-LQMGGVL 331 
TR|Q5J4W3|Q5J4W3_TAKRU         ERQFVYDP-DVGYSLPCAAGCINSLIKEVHHFRILGEHQYDRYLQYGAEECL-LRSGGLM 352 
TR|U3FQA1|U3FQA1_CALJA         DRQFVHDP-QLGYSLPCVAGCPNSLIKELHHFRILGEEQYNRYQHYAAEECV-LQMGGVL 331 
TR|G3N0R1|G3N0R1_BOVIN         DRQFVHDP-QLGYSLPCVAGCPNSLIKELHHFRILGEEQYNRYQQYGAEECV-LQLGGVL 326 
TR|Q17DC3|Q17DC3_AEDAE         ERQFLEHP-SGGYTLQCPVGCESSYIEDVHHFKLLSKEQYERYQRFATEEFV-LRNGGVL 354 
TR|G3PFJ2|G3PFJ2_GASAC         DRRFFSHP-VIGYSLPCAAGCADSLIKELHHFRILGDDQYGRYQKYGAEECL-LMNGGLM 335 
TR|E2BWM9|E2BWM9_HARSA         ERQFQFDSVEGYYTLPCPAGCPDSFISEVHHFHLLNAELYNKYQRFGTEEYV-LRSGGFL 297 
TR|A0A067RG71|A0A067RG71_ZOONE DRQFWSHP-EHGYTLPCPAGCKDSLITEVHHFRLLTPAQYAQYQRFATEEYV-LQAGGVF 342 
TR|A0A0L0CIZ3|A0A0L0CIZ3_LUCCU ERQFMPHP-DIGYTLACPAGCENSFIEEIHHFKLLTREEYERYQRFATEEYV-LQAGGVL 350 
TR|A0A0F7Z269|A0A0F7Z269_CROAD NRQFVHDP-IFGYSLSCVASCPDSLIKELHHFRILGEEQYNRYQSYGAEEYV-LQMGGVL 319 
TR|A0A0B2UTN0|A0A0B2UTN0_TOXCA QQQFFIRP-PYGYTLSCPVYGCRGCVTDVHLFYLLGKQRYSNYQTQATEKFVSLENEGIF 288 
TR|Q9XUS3|Q9XUS3_CAEEL         RFGFVNQP-PHGFTIFCPYPGCNRVVQDVHHFHIMGQTSYSEYQRKATERLIAVDDKGVT 283 
                                  *         :: *          :   * ::    *  *   .:*  : :   *.  
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SP|O60260|PRKN2_HUMAN          CPRPGCGAGLLP----------EPD--QRKVTCEGG-NGLGCGFAFCRECKEAYHEGECS 378 
TR|Q7KTX7|Q7KTX7_DROME         CPQPGCGMGLLV----------EPD--CRKVTCQ-----NGCGYVFCRNCLQGYHIGECL 395 
SP|Q9WVS6|PRKN2_MOUSE          CPRPGCGAGLLP----------EQG--QRKVTCEGG-NGLGCGFVFCRDCKEAYHEGDCD 377 
SP|Q9JK66|PRKN2_RAT            CPRPGCGAGLLP----------EQG--QKKVTCEGG-NGLGCGFVFCRDCKEAYHEGECD 378 
TR|F1NWU0|F1NWU0_CHICK         CPTPSCGAGLLP----------EPE--VRKIVCEPG-NGIGCGFVFCRECKEEYHEGECS 376 
TR|H2QU08|H2QU08_PANTR         CPRPGCGAGLLP----------EPD--QRKVTCEGG-NGLGCGFAFCRECKEAYHEGECS 378 
TR|F6U1L3|F6U1L3_MACMU         CPRPGCGAGLLP----------ESD--QRKVTCEGG-NGLGCGFAFCRECKEAYHEGECS 378 
TR|I3N341|I3N341_ICTTR         CPRPGCGAGLLP----------EAG--QRKVTCEAG-NGLGCGFVFCRDCKEEHHEGSCS 373 
TR|U3KCF7|U3KCF7_FICAL         CPSPGCGAGLLP----------EPG--LRRIVCEPG-NGIGCGSVFCRECKEEFHEGECN 375 
TR|Q561U2|Q561U2_DANRE         CPAPGCGAGLLP----------PDE--ERRVCCEPGNNGLGCGFVFCRDCKEEFHEGPCR 371 
TR|W4YQE2|W4YQE2_STRPU         CPSPGCGAGILP----------ESD-GESRVECLQE-EGFGCGFVFCRNCHEAYHEGECG 347 
TR|Q7Q591|Q7Q591_ANOGA         CPQPGCGMGLLV----------DPE--CRRIQCQ-----NGCGYVFCRSCLQGYHIGECF 402 
TR|C3Z502|C3Z502_BRAFL         CPGRGCGVGLLP----------EGS--SNMVECVRQ-AGSGCGFVFCKLCKEAYHNGPCG 347 
TR|H3D789|H3D789_TETNG         CPSPGCGAGLVP----------PDG--ARRVECDRQ---VGCGFVFCRNCREGYHEGVCP 395 
TR|M3ZNV3|M3ZNV3_XIPMA         CPSPGCGAGLLP----------PEG--SRKVECDRR--LLGCGFVFCRDCREGFHEGPCE 371 
TR|A0A087XI83|A0A087XI83_POEFO CPSPGCGAGLLP----------PEG--SRRVECDRR---LGCGFVFCRDCREGFHEGPCE 355 
TR|A0A0A9XSY6|A0A0A9XSY6_LYGHE CPHPNCGMGIYP----------DDD--CDAVRC-------TCGYVFCKKCLQGNHIGDCD 397 
TR|E0VIU9|E0VIU9_PEDHC         CPQPGCGQGILI----------DQN--CNRVQC-------SCGYVFCGKCLEGFHLGECL 374 
TR|T1H7C6|T1H7C6_MEGSC         CPRPDCGMGLLI----------EPD--CKKVVCQ-----NGCGFVFCRDCLQGYHIGECN 371 
TR|L7M1N2|L7M1N2_9ACAR         CPRPGCGQGLLP----------EPG--CDRVKCD-----RGCGFVFCRLCLQGHHLGPCT 375 
TR|V5GZV6|V5GZV6_IXORI         CPQPGCGQGILV----------DLG--CTRVTCEAA--TQGCGFVFCRLCLQGHHLGPCI 392 
TR|V5IIZ0|V5IIZ0_IXORI         CPQPGCGQGILV----------DLG--CTRVTCEAA--TQGCGFVFCRLCLQGHHLGPCI 390 
TR|H0ZGE3|H0ZGE3_TAEGU         CPTPGCGAGLLP----------EPD--LRRIVCEPG-NGIGCGSVFCRECKEEFHEGECN 376 
TR|Q1WDP3|Q1WDP3_PIG           CPRPGCGAGLLP----------EPG--QRKVTCEGG-NSLGCGLVFCRDCKESYHEGECS 374 
TR|H0X3U6|H0X3U6_OTOGA         CPRPGCGAGLLP----------EPG--QRRVACERD-SGLGCGFVFCRECKEADHDGECS 376 
TR|I3JJF6|I3JJF6_ORENI         CPSPGCGAGLVP----------PDG--SRKVECDRR---LGCGFVFCRLCRGEYHEGPCQ 364 
TR|B8YGJ6|B8YGJ6_MACFA         CPRPGCGAGLLP----------ESD--QRKVTCEGG-NGLGCGFAFCRECKEAYHEGECS 378 
TR|Q5J4W3|Q5J4W3_TAKRU         CPSPGCGAGLVP----------PDD--SRRVECDRQ---IGCGFVFCRICREGYHEGGCL 397 
TR|U3FQA1|U3FQA1_CALJA         CPRPGCGAGLLP----------EPD--QRKVTCEGG-NGLGCGFAFCRECKEAYHEGECS 378 
TR|G3N0R1|G3N0R1_BOVIN         CPGPGCGAGLLP----------EPG--QRKVSCEPG-HGLGCGFVFCRDCKEPYHEGDCG 373 
TR|Q17DC3|Q17DC3_AEDAE         CPQPGCGMGLLV----------DPE--CKRVQCQ-----NGCGFVFCRNCLQGYHIGECL 397 
TR|G3PFJ2|G3PFJ2_GASAC         CPSPGCGAGLIP----------PDD--SRRVTCDRH---LGCGFVFCKCCREGYHEGACL 380 
TR|E2BWM9|E2BWM9_HARSA         CPMPDCGMGIIPPTIEEQAEKDDDQ--RRRIQCI-----GGCGYVFCRLCLQGYHTGKCE 350 
TR|A0A067RG71|A0A067RG71_ZOONE CPQPGCGMGIIA----------EPE--CRRITCT-----NGCGFVFCRQCLQGYHLGECV 385 
TR|A0A0L0CIZ3|A0A0L0CIZ3_LUCCU CPQPGCGMGLLV----------EPD--CKKVTCQ-----NGCGYVFCRNCLQGYHLGDCL 393 
TR|A0A0F7Z269|A0A0F7Z269_CROAD CPTPGCGAGLLP----------ESE--MRKIVCEPR-NGLGCGFVFCRECKEEYHEGECH 366 
TR|A0A0B2UTN0|A0A0B2UTN0_TOXCA CPYSGCGAAFLW----------EQDVTSPKVLCP------ECHRLFCGVCRREHCVC--- 329 
TR|Q9XUS3|Q9XUS3_CAEEL         CPNVSCGQSFFW----------EPYDDDGRSQCP------DCFFSFCRKCFERNCVC--- 324 
                               **   ** .:                      *        *   **  *           
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SP|O60260|PRKN2_HUMAN          AVFEAS---GTTT-QAYRVDERAAEQARWEA-AS-KETIKKTTKPCPRCHVPVEKNGGCM 432 
TR|Q7KTX7|Q7KTX7_DROME         PEGTGA---SATNSCEYTVDPNRAAEARWDE-AS-NVTIKVSTKPCPKCRTPTERDGGCM 450 
SP|Q9WVS6|PRKN2_MOUSE          SLLEPS---GATS-QAYRVDKRAAEQARWEE-AS-KETIKKTTKPCPRCNVPIEKNGGCM 431 
SP|Q9JK66|PRKN2_RAT            SMFEAS---GATS-QAYRVDQRAAEQARWEE-AS-KETIKKTTKPCPRCNVPIEKNGGCM 432 
TR|F1NWU0|F1NWU0_CHICK         SFLSTQ---GAVAQKGYVVDENAAMQARWEE-AS-KETIKKTTKPCPNCHIPVEKNGGCM 431 
TR|H2QU08|H2QU08_PANTR         ALFEAS---GTTT-QAYRVDERAAEQARWEA-AS-KETIKKTTKPCPRCHVPVEKNGGCM 432 
TR|F6U1L3|F6U1L3_MACMU         ALFEAS---GTTT-QAYRVDERAAEQARWEE-AS-KETIKKTTKPCPRCHVPVEKNGGCM 432 
TR|I3N341|I3N341_ICTTR         TLLEAS---AAAK-QAYRVDERAAEHARWEE-AS-KETIKRTTKPCPHCGVPVEKNGGCM 427 
TR|U3KCF7|U3KCF7_FICAL         SLLSPQ---GAVA-QGYAVDEHAAMQARWEE-AS-RETIKKTTKPCPNCNIPVEKNGGCM 429 
TR|Q561U2|Q561U2_DANRE         HTTSTA---SAGALQGYVVDEEAALRARWEQ-AS-QETITKTTHPCPKCQVPVEKNGGCM 426 
TR|W4YQE2|W4YQE2_STRPU         QRIEEP---HGPRGSGSEVDMERERRARWESEES-KRTIGETSKPCPNCKVPVERNGGCM 403 
TR|Q7Q591|Q7Q591_ANOGA         ETPTPS---TPGNEQGYAIDPLRASEARWDE-AT-KIAIKVTTKPCPQCRTATERDGGCM 457 
TR|C3Z502|C3Z502_BRAFL         QTAPQP---SAPA-NNYRVDRDRARRARWER-RT-AATIERTTKACPGCKVRTEKNDGCM 401 
TR|H3D789|H3D789_TETNG         TTQSQT---TAEASQDFVVDEEATLRARWDQ-AS-LLLLQESTKPCPKCSVPVERNGGCM 450 
TR|M3ZNV3|M3ZNV3_XIPMA         GPAAPP---PADACQGFVVEDEASQRGRWDR-AS-LQLILESTRRCPRCLVPVERNGGCM 426 
TR|A0A087XI83|A0A087XI83_POEFO GPAAPP---PGDACQGFVVGDEASQRGRWDL-AS-LQLIQESTRRCPRCLVPVERNGGCM 410 
TR|A0A0A9XSY6|A0A0A9XSY6_LYGHE NAVDIL----TGLSPTYTIDPSRAAQSKWDE-AS-HRSIRAGTKPCPKCRTATERAGGCM 451 
TR|E0VIU9|E0VIU9_PEDHC         NPTDVP---FLSQNCDYPLDPEKLEKARWDE-AS-STVIKVLTKPCPKCRTSTERAGGCM 429 
TR|T1H7C6|T1H7C6_MEGSC         PEVNQI---DTTRSCEYSVNPNNAAEARWED-VSTAVTIKVSTKPCPKCRTPTERDGGCM 427 
TR|L7M1N2|L7M1N2_9ACAR         SSREAGEERAAGPRF------LAAQGSSWDE-AS-RLTVQATTKPCPKCRTPTERSGGCM 427 
TR|V5GZV6|V5GZV6_IXORI         RDEEDEASAALGSVWAYPVDEAQARGSRWDE-AS-RLTVRSTTKPCPMCRTPTERDGGCM 450 
TR|V5IIZ0|V5IIZ0_IXORI         RDEEDEASAALGSVWAYPVDEAQARGSRWDE-AS-RLTVRSTTKPCPMCRTPTERDGGCM 448 
TR|H0ZGE3|H0ZGE3_TAEGU         SLLSPP---GAMA-QGYVVDEHAAMQARWEE-AS-RETIKKTTKPCPNCNIPVEKNGGCM 430 
TR|Q1WDP3|Q1WDP3_PIG           ALFEAS---AAVA-QAYRVDQKAAEQARWEE-AS-KETIRKTTKPCPRCHVPVEKNGGCM 428 
TR|H0X3U6|H0X3U6_OTOGA         ALFEAS---GTVA-QAYRVDERAAEQARWEE-AS-KETIKQTTKPCPRCHVPVEKNGGCM 430 
TR|I3JJF6|I3JJF6_ORENI         AVTAPP---TGEAAQGFVVGEEASLRGRWER-AS-LLVIAELTRRCPTCSVPVERNGGCM 419 
TR|B8YGJ6|B8YGJ6_MACFA         ALFEAS---GTTT-QAYRVDERAAEQARWEE-AS-KETIKKTTKPCPRCHVPVEKNGGCM 432 
TR|Q5J4W3|Q5J4W3_TAKRU         ATQSQT---TAEGSQDFVVDEGASLRGRWDR-AS-LLLLQESTKPCPKCSAPVERNGGCM 452 
TR|U3FQA1|U3FQA1_CALJA         ALSEAS---GTIP-QAYRVDERAAEQARWEE-AS-KETIKKTTKPCPRCHVPVEKNGGCM 432 
TR|G3N0R1|G3N0R1_BOVIN         AVIEAS---GTVT-QAYRVNEKAAEQARWEE-AS-KETIKKTTKPCPRCHVPVEKNGESG 427 
TR|Q17DC3|Q17DC3_AEDAE         ETPQPN---A-GAAPNYTIDPLRASEARWDE-AS-KIAIKVTTKPCPQCRTATERDGGCM 451 
TR|G3PFJ2|G3PFJ2_GASAC         TEQAPP---IAESSQGFVVEEEASVKGRWDQ-AS-LLLLQETTKRCPQCSVPVERDGGCM 435 
TR|E2BWM9|E2BWM9_HARSA         FQPLGAST-DVSSLRNYSVDPLRAKDAKWDE-AS-RKTIQVSTKPCPLCRTPTERDGGCM 407 
TR|A0A067RG71|A0A067RG71_ZOONE HEGDGSGTSASTGDCQYNVDPGRAAQARWDE-AT-KVAIKVTTKPCPKCRTPTERAGGCM 443 
TR|A0A0L0CIZ3|A0A0L0CIZ3_LUCCU PENGTG---NTTGSCEYAVDPNRAAEARWDE-AS-NVTIKVSTKPCPKCRTPTERDGGCM 448 
TR|A0A0F7Z269|A0A0F7Z269_CROAD SFFKCP---GATAQMGFEIDEHAAVRARWEG-AS-KETIKRTTKPCPKCHVPVEKDGGCM 421 
TR|A0A0B2UTN0|A0A0B2UTN0_TOXCA -EEND---------------------------AT-ELTIKTTCHSCPTCGVPTERNGGCA 360 
TR|Q9XUS3|Q9XUS3_CAEEL         -QSED-------------------------D-LT-RTTIDATTRRCPKCHVATERNGGCA 356 
                                                                :    :    : ** *    *:   .  
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SP|O60260|PRKN2_HUMAN          HMKCPQPQCRLEWCWNCGCEWNRVCMGDHWFDV--------------------------- 465 
TR|Q7KTX7|Q7KTX7_DROME         HMVCTRAGCGFEWCWVCQTEWTRDCMGAHWFG---------------------------- 482 
SP|Q9WVS6|PRKN2_MOUSE          HMKCPQPQCKLEWCWNCGCEWNRACMGDHWFDV--------------------------- 464 
SP|Q9JK66|PRKN2_RAT            HMKCPQPQCKLEWCWNCGCEWNRACMGDHWFDV--------------------------- 465 
TR|F1NWU0|F1NWU0_CHICK         HMKCPRPQCRFEWCWNCGLEWNRTCMGNHWFD---------------------------- 463 
TR|H2QU08|H2QU08_PANTR         HMKCPQPQCRLEWCWNCGCEWNRVCMGDHWFDV--------------------------- 465 
TR|F6U1L3|F6U1L3_MACMU         HMKCPQPQCRLEWCWNCGCEWNRVCMGDHWFDV--------------------------- 465 
TR|I3N341|I3N341_ICTTR         HMKCPQPQCRLEWCWNCGCEWNRTCMGDHWFDV--------------------------- 460 
TR|U3KCF7|U3KCF7_FICAL         HMKCPRPQCRFEWCWNCGLEWNRTCMGDHWFD---------------------------- 461 
TR|Q561U2|Q561U2_DANRE         HMVCPRPQCKFEWCWLCRVEWNRDCMGNHWFE---------------------------- 458 
TR|W4YQE2|W4YQE2_STRPU         HMICSRTQCKYEWCWICGIEWNMGCLEDHWFGAGFLL----------------------- 440 
TR|Q7Q591|Q7Q591_ANOGA         HMVCTRSGCGFEWCWVCQTPWTRDCMAAHWFG---------------------------- 489 
TR|C3Z502|C3Z502_BRAFL         HMTCP--RCGFHWCWLCEREWGRNCQDRHWFGEGR------------------------- 434 
TR|H3D789|H3D789_TETNG         HMQCP--LCKAEWCWLCGVFWNRECMGDHWFG---------------------------- 480 
TR|M3ZNV3|M3ZNV3_XIPMA         HMQCT--QCRAEWCWLCGAPWNRECMGNHWFG---------------------------- 456 
TR|A0A087XI83|A0A087XI83_POEFO HMQCT--QCRAEWCWLCGAPWNRECMGNHWFG---------------------------- 440 
TR|A0A0A9XSY6|A0A0A9XSY6_LYGHE HMVCTR--CNFEWCWVCQISWTRSCMGSHWFG---------------------------- 481 
TR|E0VIU9|E0VIU9_PEDHC         HMICTRANCGFHWCWVCQGPWERDCMASHWFG---------------------------- 461 
TR|T1H7C6|T1H7C6_MEGSC         HMVCTRSGCDFEWCWICQTEWTRDCMGAHWFG---------------------------- 459 
TR|L7M1N2|L7M1N2_9ACAR         HMVCSRSQCGFQWCWLCQDEWTRQCMGAHWFG---------------------------- 459 
TR|V5GZV6|V5GZV6_IXORI         HMICSRSQCGFQWCWLCQTEWSRNCMGAHWFG---------------------------- 482 
TR|V5IIZ0|V5IIZ0_IXORI         HMICSRSQCGFQWCWLCQTEWSRNCMGAHWFG---------------------------- 480 
TR|H0ZGE3|H0ZGE3_TAEGU         HMKCPHPQCRFEWCWNCGLEWNRTCMGDHWFE---------------------------- 462 
TR|Q1WDP3|Q1WDP3_PIG           HMKCPQPQCQLEWCWNCGWEWNRDCMGDHWFDV--------------------------- 461 
TR|H0X3U6|H0X3U6_OTOGA         HMKCPQPQCRLEWCWNCGCEWNRVCMGDHWFDV--------------------------- 463 
TR|I3JJF6|I3JJF6_ORENI         HMHCP--LCKAEWCWLCGVPWNRECMGNHWFGL--------------------------- 450 
TR|B8YGJ6|B8YGJ6_MACFA         HMKCPQPQCRLEWCWNCGCEWNRVCMGDHWFDV--------------------------- 465 
TR|Q5J4W3|Q5J4W3_TAKRU         HMLCP--LCKAEWCWLCGVFWNRECMGDHWFG---------------------------- 482 
TR|U3FQA1|U3FQA1_CALJA         HMKCPQPQCRLEWCWNCGCEWNRVCMGDHWFDV--------------------------- 465 
TR|G3N0R1|G3N0R1_BOVIN         LTEE----------RGCGGLSS---EGGREVGIYKGFLAGELSAGALGPSGQGLNLSTHV 474 
TR|Q17DC3|Q17DC3_AEDAE         HMVCTRSGCGFEWCWVCQTPWTRDCMAAHWFG---------------------------- 483 
TR|G3PFJ2|G3PFJ2_GASAC         HMQCP--LCRAEWCWLCGVSWNTDCMGNHWFG---------------------------- 465 
TR|E2BWM9|E2BWM9_HARSA         HMVCMRAGCGYHWCWVCQMQWTRECMANHWFG---------------------------- 439 
TR|A0A067RG71|A0A067RG71_ZOONE HMVCTRPQCNFHWCWVCQTEWSRDCMGSHWFG---------------------------- 475 
TR|A0A0L0CIZ3|A0A0L0CIZ3_LUCCU HMVCTRAGCGFEWCWVCQTEWTRDCMGAHWFG---------------------------- 480 
TR|A0A0F7Z269|A0A0F7Z269_CROAD HMKCPQSQCKFEWCWKCSLEWNRTCMGDHWFD---------------------------- 453 
TR|A0A0B2UTN0|A0A0B2UTN0_TOXCA HMHCA--HCGTHWCFICVKPWTEECQWDHWFD---------------------------- 390 
TR|Q9XUS3|Q9XUS3_CAEEL         HIHCT--SCGMDWCFKCKTEWKEECQWDHWFN---------------------------- 386 
                                               *           : .                              
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SP|O60260|PRKN2_HUMAN          -------------- 
TR|Q7KTX7|Q7KTX7_DROME         -------------- 
SP|Q9WVS6|PRKN2_MOUSE          -------------- 
SP|Q9JK66|PRKN2_RAT            -------------- 
TR|F1NWU0|F1NWU0_CHICK         -------------- 
TR|H2QU08|H2QU08_PANTR         -------------- 
TR|F6U1L3|F6U1L3_MACMU         -------------- 
TR|I3N341|I3N341_ICTTR         -------------- 
TR|U3KCF7|U3KCF7_FICAL         -------------- 
TR|Q561U2|Q561U2_DANRE         -------------- 
TR|W4YQE2|W4YQE2_STRPU         -------------- 
TR|Q7Q591|Q7Q591_ANOGA         -------------- 
TR|C3Z502|C3Z502_BRAFL         -------------- 
TR|H3D789|H3D789_TETNG         -------------- 
TR|M3ZNV3|M3ZNV3_XIPMA         -------------- 
TR|A0A087XI83|A0A087XI83_POEFO -------------- 
TR|A0A0A9XSY6|A0A0A9XSY6_LYGHE -------------- 
TR|E0VIU9|E0VIU9_PEDHC         -------------- 
TR|T1H7C6|T1H7C6_MEGSC         -------------- 
TR|L7M1N2|L7M1N2_9ACAR         -------------- 
TR|V5GZV6|V5GZV6_IXORI         -------------- 
TR|V5IIZ0|V5IIZ0_IXORI         -------------- 
TR|H0ZGE3|H0ZGE3_TAEGU         -------------- 
TR|Q1WDP3|Q1WDP3_PIG           -------------- 
TR|H0X3U6|H0X3U6_OTOGA         -------------- 
TR|I3JJF6|I3JJF6_ORENI         -------------- 
TR|B8YGJ6|B8YGJ6_MACFA         -------------- 
TR|Q5J4W3|Q5J4W3_TAKRU         -------------- 
TR|U3FQA1|U3FQA1_CALJA         -------------- 
TR|G3N0R1|G3N0R1_BOVIN         KLLNLLNRKSSSVK 488 
TR|Q17DC3|Q17DC3_AEDAE         -------------- 
TR|G3PFJ2|G3PFJ2_GASAC         -------------- 
TR|E2BWM9|E2BWM9_HARSA         -------------- 
TR|A0A067RG71|A0A067RG71_ZOONE -------------- 
TR|A0A0L0CIZ3|A0A0L0CIZ3_LUCCU -------------- 
TR|A0A0F7Z269|A0A0F7Z269_CROAD -------------- 
TR|A0A0B2UTN0|A0A0B2UTN0_TOXCA -------------- 
TR|Q9XUS3|Q9XUS3_CAEEL         -------------- 
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Appendix 3. Non-specific immunofluorescence signal in HeLa cells with parkin 
antibodies. Untransfected HeLa cells were fixed and used for immunofluorescence with 
A) a Cell Signaling parkin antibody B) an Abcam parkin antibody C) a Novus parkin 
antibody or D) a Santa Cruz parkin antibody.   
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Appendix 4. Supplementary figure data. 
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Appendix 5. Growth curve of non-toxic protein expression in yeast. 
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